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Thyroid hormones (THs) are important for fetoplacental development. Human 
intrauterine growth restriction (IUGR) is associated with malplacentation and reduced 
fetal circulating concentration of THs. The expression of the plasma membrane TH 
transporters MCT8, MCT10, LAT1, LAT2, OATP1A2 and OATP4A1 was characterised 
in human placental biopsies across gestation. The protein expression of MCT8 was 
increased in samples from severe IUGR compared with normal pregnancies. In vitro, tri-
iodothyronine (T3) decreased survival and increased apoptosis of IUGR compared with 
normal cytotrophoblasts, which was associated with increased MCT8 expression. In 
normal cytotrophoblasts, MCT8 upregulation decreased survival, whilst MCT8 silencing 
increased survival independently of T3. In the extravillous trophoblast-like cell line, 
SGHPL-4, T3 resulted in a significant increase in cell invasion when MCT8 was 
upregulated. Contrary to cytotrophoblasts, silencing MCT8 decreased apoptosis in 
SGHPL-4s independently of T3. In mice, fetal to placental weight ratio was decreased in 
male MCT8-null compared with wild-type embryos. These findings support the 
hypothesis that THs have an important role in fetoplacental development and that IUGR is 
associated with changes in TH transport and responsiveness of the placenta. Furthermore, 
they highlight the importance of MCT8, which impacts on placental cells via both T3-
dependent and independent mechanisms. 
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1.1 The human placenta 
The placenta connects the developing fetus to the maternal circulation and 
facilitates the exchange of substances between the mother and the fetus. This includes the 
supply of oxygen and nutrients from the maternal circulation and the disposal of fetal 
waste. Fetal growth is thus dependent on transplacental transport. There are different 
placental types found in different mammalian species and they are classified according to 
the shape of the placenta and the number of layers that separate the maternal and the fetal 
circulations. In humans, the placenta is discoid and the placental villi are in direct contact 
with the maternal blood. The human placenta is therefore classified as discoid, 
haemochorial placenta. The human placenta is attached to the maternal uterine wall and in 
particular to the endometrium, the lining of the uterus that is transformed into the decidua 
following changes occurring during the menstrual cycle and with pregnancy. 
1.1.1 Human placental development 
1.1.1.1 Trophoblast differentiation and function 
Fertilisation of the mature oocyte occurs in the ampulla region of the oviduct. 
Following fertilisation, the oocyte undergoes cleavage and compaction, whilst it is 
travelling towards the uterus. This leads to the formation of the morula, which consists of 
a group of internal and a group of external cells. The internal cells generate the inner cell 
mass, which will give rise to the embryo. The external cells give rise to the trophectoderm 
that will differentiate into trophoblast cells that form the placenta. The formation of the 
trophectoderm is the first differentiation event in mammalian development. The morula 
undergoes a process termed cavitation during which the trophoblast cells secrete fluid into 
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the morula leading to the formation of a blastocoel. The blastocoel expands and the inner 
cell mass is positioned on one side leading to the formation of the blastocyst. Once the 
blastocyst reached the uterus, it attaches to the maternal endometrium (Gilbert, 2006). The 
implantation of the blastocyst into the maternal endometrium is the result of interactions 
between the maternal cells of the endometrium and the trophoblast cells and can only 
occur in a restricted period of time that in humans is believed to span days 20-24 of the 
menstrual cycle (Lunghi et al., 2007). 
The human placenta consists of anchoring chorionic villi that are attached to the 
uterus and floating chorionic villi (Figure 1-1). Cytotrophoblast cells (CTs) are the 
proliferative cell type of the placenta that gives rise to other placental cell types (Lunghi 
et al., 2007). In floating villi, some CTs differentiate to post-mitotic cells that fuse 
together to form a multinucleated syncytiotrophoblast (ST) layer (Huppertz and Kingdom, 
2004). Following blastocyst implantation, mononuclear CTs break through the ST layer 
and they form chorionic villi that are attached to the maternal uterine wall (Huppertz and 
Peeters, 2005). At these sites, CTs aggregate forming CT columns and some differentiate 
into extravillous trophoblast cells (EVTs), post-proliferative cells with an invasive 
phenotype. EVTs invade the maternal endometrium and they can follow either the 
interstitial or the endovascular invasion route. Interstitial invasion involves the migration 
of EVTs through the decidua and the endometrium. Scattered giant cells that appear to 
form from the fusion of extravillous trophoblasts are found in the decidua and in the 
myometrium throughout gestation. Some interstitial EVTs reach the walls of the maternal 
spiral arteries and destroy the smooth muscle cells that are replaced by fibrinoid material. 
Endovascular EVTs invade the lumen of the arteries where they initially form arterial 
plugs and they prevent maternal blood from reaching the intervillous space until post-
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menstrual week 12 (Huppertz and Peeters, 2005, Malassine et al., 2003). Therefore, the 
early stages of fetal and placental development occur in a low oxygen environment. After 
week 12, endovascular EVTs migrate to the vessel walls where they replace the 
endothelial cells and thus, maternal spiral arteries are transformed to dilated, low-
resistance vessels that facilitate unobstructed blood flow from the maternal circulation to 
the placenta (Craven et al., 2000, Pijnenborg et al., 1983). 
The ST layer of the chorionic villi is the physical barrier that controls the uptake of 
substances from the maternal circulation and their efflux to the stromal core where they 
can reach the fetal capillaries (Jurisicova et al., 2005). Small lipophilic substances can 
diffuse through the ST plasma membrane and cross the ST layer down their concentration 
gradient, however the transport of larger or hydrophilic molecules such as amino acids 
needs to be facilitated by transporter proteins at the apical and basal side of the ST. In 
addition, the ST has an endocrine function and is responsible for the synthesis of 
hormones and growth factors and their secretion to the maternal and/or the fetal 
circulation. The factors that are secreted by the ST include human chorionic 
gonadotrophin (hCG), human placental lactogen (hPL), placental growth hormone (PGH), 
oestrogen and progesterone and they are important for both the adaptation of the maternal 
metabolism to pregnancy and for fetal growth (Malassine et al., 2003). The ST layer is 
continuously renewed as adjacent CTs fuse with the ST and aged ST nuclei and small 
amounts of cytoplasm are packed into syncytial knots, vesicles surrounded by membrane 
that are released into the maternal circulation (Huppertz et al., 2006, Huppertz and 
Kingdom, 2004, Jurisicova et al., 2005). 
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1.1.1.2 Regulation of ST formation 
The human ST regulates both transplacental transport and the secretion of 
hormones and growth factors into the maternal and fetal circulations. Trophoblast 
turnover from the proliferative CT cells to the post-mitotic ST cell layer and extrusion of 
aged ST nuclei to the maternal circulation as syncytial knots ensures the renewal of the 
ST layer. The fusion of CTs to the ST layer involves the initial stages of the apoptotic 
Figure 1-1: Trophoblast differentiation pathways. In floating villi 
cytotrophoblasts fuse with the syncytiotrophoblast layer and aged 
syncytiotrophoblast nuclei are extruded into the maternal circulation as 
syncytial knots. In anchoring villi proliferating cytotrophoblasts form cell 
columns and some of them differentiate to extravillous trophoblasts that 
migrate to the maternal decidua. Extravillous trophoblasts follow one of two 
differentiation routes. Interstitial extravillous trophoblasts invade the 
maternal decidua and endometrium whilst endovascular extravillous 
trophoblasts invade the maternal spiral arteries. Figure from (Huppertz et al., 
2006).  
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cascade, whilst the extrusion of aged nuclei to the maternal circulation involves the 
execution stages of the apoptotic cascade (Huppertz and Kingdom, 2004). It has been 
shown that the initiator caspase 8 is active in CTs (Huppertz et al., 1999) and is required 
for cell fusion, since blockage of caspase 8 expression or activity reduced trophoblast 
fusion in villous explant cultures (Black et al., 2004). On the other hand, the effector 
caspases 3 and 6 that are part of the final execution stages of apoptosis are not active in 
CTs (Huppertz et al., 1999). Initiator caspases degrade cytoskeletal proteins, such as 
fodrin, and they are involved in the externalisation of phosphatidylserine, a negatively 
charged amino phospholipid (Huppertz and Kingdom, 2004). The degradation of 
cytoskeletal elements and the re-arrangement of charges in the plasma membrane 
facilitate the re-organisation of the cell membrane that is necessary for cell fusion 
(Huppertz and Kingdom, 2004). Effector caspase activity is detected in specific sites of 
the ST layer at tips of villi, where aged, apoptotic nuclei accumulate and are packed in 
syncytial knots and extruded into the maternal circulation. The packaging of this apoptotic 
material in membrane-sealed structures ensures that there is no inflammatory response 
when it is released into the maternal circulation and the syncytial knots are engulfed by 
macrophages in the capillary bed of the maternal lung (Huppertz and Kingdom, 2004). 
The mechanisms that block the transition from the initiator to the execution stages of 
apoptosis in the differentiating CT and restrict its activation to defined areas within the ST 
are not completely understood. It is thought that anti-apoptotic molecules, such as 
members of the Bcl-2 family, actin-regulatory proteins, such as gelsolin and inhibitory 
proteins, such as the X-linked inhibitors of apoptosis protein (XIAP) and flice-like 
inhibiting protein (FLIP) contribute to the regulation of the final stages of apoptosis via 
inhibiting the activity of effector and/or initiator caspases (Huppertz and Kingdom, 2004). 
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The regulation of the apoptotic pathways within trophoblast cells is thus tightly linked to 
the formation and maintenance of the ST layer. 
In addition to the apoptotic cascade, more pathways are thought to be involved in 
the differentiation of the proliferating CT leading to its fusion with the ST layer and 
research is currently ongoing to better define the mechanisms that are regulating this 
differentiation process. It has been shown that oxygen levels and the concentration of 
molecules, such as cyclic adenosine monophosphate (cAMP) and vascular endothelial 
growth factor (VEGF), regulate the expression levels of different transcription factors that 
have been associated with the fate of CT cells by either blocking mitosis and promoting 
cell fusion (GCM1, AP-2 and Sp) or maintaining proliferation and inhibiting fusion 
(Hash-2 and HIF-1) (Lunghi et al., 2007). Cell-cell communication facilitates the 
diffusion of such molecules and it has been shown that connexins (Cx), gap junction 
proteins that form transmembrane channels and facilitate intercellular communication by 
allowing the diffusion of ions and small molecules such as cAMP, cyclic guanosine 
monophosphate (cGMP), inositol triphosphate and calcium ions, play a role in the 
regulation of trophoblast differentiation (Malassine and Cronier, 2005). Cx43 protein is 
localised between CTs and between STs and adjacent CTs indicating that it may be 
important for ST formation (Cronier et al., 2002). Furthermore, in vitro studies have 
shown that blockage of Cx43 in primary cultures of trophoblast cells via treatment with 
heptanol, a non-specific junctional uncoupler that blocks all connexin channels (Cronier et 
al., 2003), or via silencing of Cx43 expression using small interfering RNA (Frendo et al., 
2003) reduced the formation of syncytia, indicating that Cx43 is required for 
syncytialisation. There is also evidence that syncytins, envelope proteins derived from 
human endogenous retroviruses, are important in ST formation (Chen et al., 2008a, Mi et 
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al., 2000, Muir et al., 2004, Rote et al., 2004). Silencing of syncytin-1 or syncytin-2 
expression impaired the fusion of primary CTs in vitro (Vargas et al., 2009). However, 
the pathways that are involved in the regulation of CT fusion by syncytins are not well 
understood yet. In addition, evidence has emerged that CD98, a membrane protein that 
dimerises with the light chains of amino acid transporters thus forming functional amino 
acid transporters, has also a role in cell fusion. In experiments with the choriocarcinoma 
cell line, BeWo, the protein expression of CD98 increased following stimulation of cell 
fusion by treatment with forskolin (Kudo and Boyd, 2004). Furthermore, knockdown of 
CD98 expression decreased both the number of fused BeWo cells and hCG secretion, thus 
suggesting a role for CD98 in trophoblast fusion (Kudo and Boyd, 2004). The 
mechanisms that mediate the role of CD98 in the fusion of BeWo cells are not completely 
understood. CD98 has multiple glycosylation sites and glycosylation appears to be 
necessary for CD98-induced cell fusion (Dalton et al., 2007). Furthermore, CD98 is 
associated with galectin 3, a receptor for ligands such as lactose, as shown by co-
immunoprecipitation assays and by co-localisation of CD98 and galectin 3 at the plasma 
membrane as well as in the cytoplasm and nucleus. The importance of the interaction 
between CD98 and galectin 3 for cell fusion is indicated by the decreased fusion of BeWo 
cells following disruption of galectin 3 and CD98 binding (Dalton et al., 2007). As 
research on the mechanisms that are involved in CT fusion continues, more molecules that 
are involved in the differentiation pathways determining the fate of CTs are likely to be 
identified. 
1.1.1.3 Regulation of EVT invasion 
The differentiation of trophoblasts along the invasive phenotype and invasion into 
the maternal endometrium and transformation of the maternal spiral arteries is necessary 
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to facilitate the unobstructed flow of blood from the maternal circulation. Inadequate 
transformation of maternal spiral arteries has been associated with pregnancy 
complications such as intrauterine growth restriction (IUGR) and pre-eclampsia, whilst 
excessive EVT invasion is seen in molar pregnancies and choriocarcinomas (Lunghi et 
al., 2007). Normal placentation is dependent upon optimal regulation of EVT invasion 
both spatially (decidua and the maternal endometrium, the inner third of myometrium) 
and temporally (early pregnancy) (Figure 1-2). 
The initial stages of decidualisation of the maternal endometrium and 
transformation of the maternal spiral arteries are thought to occur in the late secretory 
phase of the menstrual cycle and are trophoblast-independent (Brosens et al., 2002, 
Huppertz and Peeters, 2005, Lunghi et al., 2007). These initial changes are regulated by 
the secretion of oestrogen and progesterone during the menstrual cycle that impact upon 
endometrial stromal cells and uterine immune cells, such as macrophages and uterine 
natural killer cells (uNK), resulting in altered steroid metabolism, remodelling of the 
extracellular matrix and cytoskeleton and altered expression of intracellular enzymes, 
growth factors, cytokines and their receptors (Brosens et al., 2002). Intercellular 
signalling between smooth muscle cells and endothelial cells of the maternal spiral 
arteries result in the initial events of spiral artery remodelling that include intimal 
swelling, perturbation of arterial walls and disorganised vascular muscle cells and result 
to lumen dilation (Brosens et al., 2002, Huppertz and Peeters, 2005). The remodelling of 
the maternal spiral arteries and the decidualisation of the myometrium are necessary for 
implantation and placentation and they regulate subsequent trophoblast invasion. 
EVT invasion is required for further remodelling of maternal spiral arteries. Cells 
in CT columns that are in direct contact with the basal membrane of the villous maintain 
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their proliferative capacity whilst cells in distal areas of the CT columns differentiate to 
post-proliferative cells with an invasive phenotype (Huppertz and Peeters, 2005). It is 
thought that intercellular communication plays a role in determining differentiation of 
these cells and it has been found that proliferative cells in CT columns express the gap 
junctional protein Cx40 (Malassine and Cronier, 2005). Cx40 can not form functional 
channels with most other connexins, therefore it is hypothesised that Cx40-expressing 
cells in CT columns can not communicate with Cx43-expressing cells that differentiate 
into ST. EVTs that invade the maternal decidua have lost Cx40 expression, whilst EVT 
aggregates in the decidua co-express Cx40, Cx32 and Cx43. It is therefore hypothesised 
that Cx40 expression may promote cell proliferation, whilst loss of Cx40 expression may 
result in lack of cell communication and differentiation along the invasive pathway 
(Malassine and Cronier, 2005). Further research is necessary in order to identify the 
messenger molecules that are exchanged between Cx40-positive cells and favour cell 
proliferation. 
Interstitial EVT invasion into the maternal myometrium is governed by 
interactions between EVTs and cells of the maternal decidua. Maternal cells secrete 
growth factors and cytokines that promote (e.g. VEGF) or inhibit (e.g. TGF-β) EVT 
invasion (Lunghi et al., 2007). Furthermore, EVTs express cell surface molecules, such as 
the MHC class I molecules HLA-C, HLA-E and HLA-G that are ligands for killer 
immunoglobulin receptors present in uNK cells. Interactions between EVTs and uNKs 
regulate the expression of adhesion molecules, such as α5β1 and α1β1 integrins and VE 
cadherin, and the secretion of the degradative enzymes, matrix metalloproteinases, by 
EVTs, thus promoting EVT invasion (Lunghi et al., 2007). Some interstitial EVTs 
migrate deep in the maternal endometrium and they eventually aggregate and fuse to form 
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giant cells. EVT fusion is promoted by TGF-β that is produced in the uterine decidua and 
such a mechanism might prevent excess invasion by interstitial EVTs (Brosens et al., 
2002). TGF-β is activated by plasmin, a protein that is generated by EVTs during invasion 
suggesting that there is the potential for autoregulation of interstitial EVT invasion 
(Brosens et al., 2002). 
Other EVTs follow the endovascular invasion route and invade the lumen of the 
spiral arteries where they initially create arterial plugs. After week 12 of pregnancy the 
plugs start to dislocate allowing blood flow from the maternal circulation and 
endovascular EVTs migrate in a retrograde direction within spiral arteries (Huppertz and 
Peeters, 2005, Pijnenborg et al., 2006). The motility and migration of EVTs within spiral 
arteries is thought to be regulated by the increased oxygen level and the flow stress due to 
the blood stream that induce changes such as the expression of adhesion molecules like β1 
integrin by endovascular EVTs (Pijnenborg et al., 2006). Endovascular EVTs express 
hemoxygenase that facilitates the production of carbon monoxide, a vasodilator that 
causes further dilation of the arterial wall (Lunghi et al., 2007). Furthermore, 
endovascular EVTs secrete matrix metalloproteinases that can degrade the subendothelial 
basement membranes of the vessel walls (Pijnenborg et al., 2006). Spiral artery 
remodelling is completed by the reduction in the elastic fibres of the arterial walls and the 
replacement of smooth muscle cells by endovascular EVTs (Huppertz and Peeters, 2005). 
These changes result in a three-fold increase in the lumen diameter and reduced 
contractility of spiral arteries and facilitate constant unobstructed blood flow from the 
maternal circulation to the placental intervillous space (Huppertz and Peeters, 2005). 
The differentiation of trophoblast cells along the invasive phenotype and their 
subdifferentiation towards the interstitial or the endovascular route is governed by 
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complex mechanisms that involve intercellular communication, growth factor and 
cytokine signalling and matrix metalloproteinase activity (Huppertz and Peeters, 2005, 
Lunghi et al., 2007, Pijnenborg et al., 2006). It is postulated that changes in oxygen level 
that are induced by changes in spiral arteries affect cell differentiation. Low oxygen 
tension is thought to promote cell proliferation whilst high oxygen tension favours 
differentiation towards the invasive phenotype (Pijnenborg et al., 2006). Initial data 
suggest that apoptotic mechanisms may also play a role in the regulation of EVT invasion. 
EVTs that display characteristics of the late apoptotic changes were localised in the 
deeper part of the endometrium suggesting that interactions between maternal decidual 
cells and EVTs may regulate EVT apoptosis and thus contribute to the spatial regulation 
of EVT invasion to the decidua, the upper part of the myometrium (Huppertz and Peeters, 
2005). Further research is likely to characterise EVT invasion in more detail and identify 
more pathways that participate in the regulation of EVT differentiation and mediate the 
interactions between maternal and fetal cells at the placental bed. 




Figure 1-2: The transformation of maternal spiral arteries during intrauterine pregnancy 
occurs in three phases. (A) The first phase is independent of trophoblast invasion. It 
involves the disorganisation of maternal vascular smooth muscle cells and the 
perturbation of arterial walls leading to lumen dilation and it is believed to be regulated 
by paracrine interactions between maternal smooth muscle cells and endothelial cells. (B) 
In the second phase, interstitial EVTs invade the maternal myometrium. (C) During the 
third phase, endovascular EVTs reach the spiral arteries where they initially create 
arterial plugs (C1). After week 12 of pregnancy arterial plugs are dislocated and EVTs 
replace the endothelial smooth muscle cells resulting in dilated non-contractile vessels 
and thus allowing unobstructed blood flow to the intervillous space (C2). Figure modified 
from (Huppertz and Peeters, 2005). 
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1.1.2 Intrauterine growth restriction (IUGR) 
IUGR is the failure to achieve the genetic growth potential of the fetus (Scifres and 
Nelson, 2009). IUGR has an impact on the function of various fetal organs including the 
cardiovascular system, lungs, pancreas, skeletal muscle and the brain. IUGR is a 
significant cause of perinatal mortality and morbidity (Sankaran and Kyle, 2009) with 
10% of very low birthweight babies having some physical handicap (Gaffney et al., 1994) 
and a further 5% demonstrating neurodevelopmental delay at the age of 9 years (Kok et 
al., 1998). Furthermore, IUGR is associated with a life-long increased risk for 
hypertension, cardiovascular disorders and susceptibility to diabetes (Sankaran and Kyle, 
2009, Scifres and Nelson, 2009). Estimated fetal weight less than the 10th percentile for 
gestational age in combination with increased head/abdomen circumference ratio, reduced 
amniotic fluid volume (oligohydramnios), vasodilation of the fetal middle cerebral artery 
circulation and increased impedence to pulsatile blood flow in the umbilical arteries are 
the criteria used for the diagnosis of IUGR (Chang et al., 1993). The causes of IUGR are 
diverse and include aneuploidies, non-aneuploid genetic syndromes, infections, such as 
cytomegalovirus infection, metabolic factors and placental disorders (Scifres and Nelson, 
2009). Uteroplacental insufficiency is associated with 80-90% of all IUGR cases 
(Sankaran and Kyle, 2009) as evidenced by the significantly smaller size of the IUGR 
placenta (Mayhew et al., 2003). Other cases are associated with maternal calorie 
restriction, low protein diet or maternal diabetes (Sankaran and Kyle, 2009). 
1.1.2.1 Impaired placental development in IUGR 
Histological assessment of placental and placental bed sections from IUGR 
pregnancies has revealed changes in both spiral artery remodelling and placental 
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morphology in pregnancies complicated by IUGR. In normal pregnancies, maternal spiral 
arteries in both the decidua and the endometrium are transformed by endovascular EVTs 
leading to replacement of the contractile smooth muscle cells by endovascular EVTs and 
to vasodilation. Maternal spiral artery remodelling is defective in IUGR (Pijnenborg et al., 
2006) particularly in the myometrial section (Burton et al., 2009b) (Figure 1-3).  
 
Examination of spiral artery segments in the decidua and endometrium regions of 
placental bed biopsies revealed that in sections from IUGR pregnancies 60% of the spiral 
arteries were transformed in the decidua and only 10% were transformed in the 
Figure 1-3: Intrauterine growth restriction is associated with inefficient 
transformation of the maternal spiral arteries resulting in a smaller lumen 
diameter of spiral arteries in IUGR compared with normal pregnancies. Figure 
modified from (Moffett-King, 2002). 
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endometrium, in contrast to complete transformation of spiral arteries in both regions in 
normal pregnancy sections (Khong et al., 1986). Examination of placental sections from 
normal and IUGR pregnancies revealed that in addition to the smaller placental size in 
IUGR pregnancies, the intervillous space volume was reduced and there was a decrease in 
villous tissue that equally affected trophoblast, stromal and capillary components of the 
villous structure and was accompanied by smaller exchange surface area (Mayhew et al., 
2003). 
Although, IUGR is normally not manifested until the second half of pregnancy, it 
is thought that the placental maldevelopment that is associated with IUGR is established 
in early pregnancy when maternal spiral artery remodelling normally takes place. 
However, the factors that result in insufficient transformation of the maternal spiral 
arteries in IUGR are not completely understood. Insufficient invasion and transformation 
of the maternal spiral arteries in the first trimester may occur as a result of impaired 
decidualisation or impaired invasion by EVTs or as a combination of both. Decidual 
remodelling normally occurs during the menstrual cycle, and is priming the endometrium 
and the maternal spiral arteries for invasion by EVTs. In pregnancies complicated by 
IUGR there are changes in the recruitment of uNKs and the secretion of cytokines, such 
as IFN-γ, that impair the transformation of the maternal endometrium (Brosens et al., 
2002). Furthermore, increased recruitment of macrophages (Reister et al., 1999, Reister et 
al., 2001) and failure of maternal endothelial cells to express selectins (Burrows et al., 
1994) may contribute to the decreased spiral artery remodelling observed in IUGR 
pregnancies. Insufficient spiral artery remodelling in IUGR could also result from 
abnormalities in the differentiation of trophoblasts along the invasive phenotype. Even 
though, no changes have been observed in interstitial trophoblast invasion with IUGR 
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(Pijnenborg et al., 1991), there is reduced endovascular invasion characterised by reduced 
number of EVTs in arterial walls and increased incidence of apoptosis in endovascular 
EVTs with IUGR (Kadyrov et al., 2006). It is likely that the aforementioned changes in 
maternal cells contribute to the reduced endovascular invasion in IUGR pregnancies. 
Reduced expression of adhesion molecules, such as selectins, by maternal endothelial 
cells is likely to impair the ability of endovascular EVTs to migrate within the lumen of 
the spiral arteries. Furthermore, changes in immune responses of maternal cells may 
induce apoptosis of endovascular EVTs as evidenced by the ability of activated 
macrophages to induce apoptosis of EVT-like cells in vitro (Reister et al., 2001). 
Insufficient endovascular invasion results in high resistance spiral arteries that 
retain their contractility. Initially it was thought that impaired spiral artery remodelling 
would alter blood flow resulting in placental hypoxia or hyperoxia (Huppertz and Peeters, 
2005). However, it is now thought that impaired spiral artery remodelling that prevents 
vasodilation of the maternal spiral arteries does not alter the amount of blood and thus 
oxygen that reaches the placenta, but it increases the velocity of the blood flow from the 
maternal circulation (Burton et al., 2009a). Furthermore, untransformed maternal spiral 
arteries retain their contractility resulting in intermittent blood flow (Scifres and Nelson, 
2009). Increased velocity of the blood flow from the maternal circulation may cause 
damage to the villous structure and it could be responsible for the cystic lesions observed 
in IUGR placentae. Villous damage could extend to rupture of the chorionic villi, which 
would result in reduced supply of EVTs from CT columns (Burton et al., 2009a). In 
addition, intermittent perfusion of the placenta is likely to cause oxidative stress and 
endoplasmic reticulum (ER) stress and thus activate the complement cascade resulting in 
tissue damage (Burton et al., 2009a, Scifres and Nelson, 2009). This is supported by 
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evidence that there is inhibition of protein synthesis (Yung et al., 2007) and increased 
activation of the complement cascade in IUGR placentae (Scifres and Nelson, 2009).  
There is accumulating evidence that IUGR is associated with increased apoptosis 
in the ST. Histological examination of placental sections from IUGR pregnancies 
demonstrated that there is increased caspase activity in the IUGR placenta (Ishihara et al., 
2002, Smith et al., 1997). Furthermore, the increased cell death in the IUGR villi is not 
balanced by changes in cell proliferation (Crocker et al., 2004, Heazell et al., 2008) 
suggesting that increased cell death could be partly responsible for the smaller size of the 
IUGR placenta. Ischaemia reperfusion injury caused as a result of insufficient spiral artery 
remodelling may contribute to the increased apoptosis in IUGR placental villi. In vitro 
experiments have demonstrated that IUGR CTs show increased susceptibility to apoptosis 
in response to hypoxia or hypoxia and reoxygenation (Crocker et al., 2004). The increased 
apoptotic susceptibility of IUGR CTs appears to be mediated by increased p53 activity 
(Heazell et al., 2008, Levy et al., 2002) and increased expression of the pro-apoptotic 
molecule Mtd-1 (Soleymanlou et al., 2007, Soleymanlou et al., 2005). In addition to 
increased apoptosis, there is also increased fibrin deposition at tips of IUGR villi, which is 
also thought to be a result of hypoxia-reoxygenation injury particularly due to increased 
complement activation (Scifres and Nelson, 2009). Fibrin deposits co-localise with the 
C5b-9 membrane attack complex (MAC) and this co-localisation is increased in IUGR ST 
(Rampersad et al., 2008). Furthermore, MAC binds to trophoblasts in vitro and modulates 
trophoblast apoptosis and differentiation.  
The increased apoptosis and fibrin deposition in IUGR villi are likely to result in 
reduction in the functional mass of the ST and may induce changes in ST permeability 
ultimately resulting in inadequate transplacental exchange. Furthermore, villous damage 
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may affect the metabolic function of the placenta and could impair energy-dependent 
placental functions, such as active transport, conversion of glucose to lactate, regulation 
of amino acid availability and the production and secretion of placental hormones, such as 
hCG, hPL and PGH. Changes in placental endocrine function could in turn result in 
defective adaptation of the maternal metabolism to pregnancy causing further 
complications (Huppertz and Peeters, 2005). It is therefore obvious that IUGR is 
associated with gross placental abnormalities that compromise placental function and thus 
fetal growth. Better understanding of the mechanisms that alter maternal and trophoblast 
cell behaviour in IUGR can help to develop therapeutic strategies for this pregnancy 
complication. 
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1.2 Thyroid hormones 
In humans, the thyroid hormones (THs) are synthesised in the thyroid gland and 
released into the circulation. THs have an impact on almost all tissues via their effects on 
the regulation of cell differentiation, growth and metabolism (Yen, 2001). The role of THs 
can vary in different tissues. THs affect bone growth and development by regulating the 
activity of osteoblast and osteoclast cells. In the heart, THs have effects on cardiac 
function and can regulate cardiac output. THs regulate lipolysis, lipogenesis and oxidative 
processes in the liver and they control the development and function of white and brown 
adipose tissue. Regulation of TH availability is essential for brain development both in 
utero and during the neonatal period. THs affect the differentiation of cells in the cerebral 
cortex, the visual and auditory cortex, the hippocampus and the cerebellum (Yen, 2001). 
TH availability is thus essential for the regulation of the differentiation and growth of 
many tissues. 
1.2.1 Mechanisms controlling TH action 
The cellular supply of THs is regulated by the circulating concentration of free 
THs, the expression of TH transporters at the plasma membrane of target cells, the 
activity of deiodinase enzymes and the expression of TH receptors (TRs) that mediate TH 
action at the target tissues. 
1.2.1.1 Circulating concentrations of THs 
The synthesis and secretion of THs is regulated by the hypothalamus-pituitary-
thyroid axis (HPT axis) via a negative feedback system (Figure 1-4). Thyrotropin 
releasing hormone (TRH) is a tripeptide synthesised by the paraventricular nucleus of the 
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hypothalamus that binds to TRH receptors on thyrotrope cells in the pituitary and 
stimulates the secretion of thyroid stimulating hormone (TSH). TSH binding to TSH 
receptors that are expressed in thyroid follicular cells increases the expression of the 
Na+/I- symporter (NIS), of thyroglobulin (Tg) and of the enzyme thyroid peroxidase 
(TPO), that are all required for TH synthesis. NIS facilitates the transport of iodide into 
the thyroid, while TPO oxidises iodide in the thyroid in the presence of hydrogen 
peroxide, which is generated from oxygen in a reaction catalysed by NADPH oxidases. 
The oxidised form of iodide is incorporated in the tyrosine residues of Tg resulting in the 
production of monoiodinated (MIT) and diiodinated (DIT) tyrosine residues that are 
enzymatically coupled to form the THs thyroxine (T4) and 3,3’,5-tri-iodothyronine (T3). 
The iodinated Tg is internalised from the apical surface of the thyroid follicular cell and is 
incorporated in lysosomes, where it undergoes proteolytic digestion causing the release of 
T4, T3, MIT and DIT into the cytoplasm of the cell. T4 and T3 are then released into the 
circulation from the basal surface of the follicular cell. The optimal levels of TH secretion 
are maintained since T4 and T3 regulate the secretion of TSH and TRH by a negative-
feedback system. Most of the circulating TH is in the form of T4 with total serum T4 
concentration being approximately 90 nM versus 2 nM of total serum T3 (Yen, 2001). The 
majority of circulating THs are bound to proteins such as thyroxine binding globulin, 
albumin and transthyretin with the concentration of free circulating T4 amounting to 
0.03% of total serum T4, whilst 0.3% of total serum T3 is free. Only unbound THs can 
enter cells and generate a biological response (Yen, 2001). 
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1.2.1.2 TH transport 
Although it was previously thought that due to their lipophilic nature THs entered 
the cells by passive diffusion, it is now known that transporter proteins are required to 
facilitate the passage of THs into and out of cells (Hennemann et al., 2001). Several 
proteins that facilitate TH transport have been identified to date and they belong to 
Figure 1-4: The hypothalamus-pituitary-thyroid axis. The secretion of THs is 
regulated by a negative feedback system that involves the hypothalamus, 
pituitary and thyroid. The hypothalamus secretes thyrotropin releasing 
hormone (TRH) that binds to TRH receptors (TRHR) in the pituitary and 
promotes the secretion of thyroid stimulating hormone (TSH). TSH binds to 
TSH receptors (TSHR) in the thyroid gland and promotes the expression of the 
molecules necessary for the production of THs via iodination of tyrosine 
residues. THs (T4 and T3) are then released into the circulation. THs negatively 
regulate the secretion of TRH and TSH thus controlling TH production. 
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different families including the monocarboxylate transporter (MCT) family, L-Type 
Amino acid transporters (LATs), organic anion transporting polypeptides (OATPs) and 
the Na+-taurocholate cotransporting polypeptide (NTCP). These TH transporters differ in 
their tissue distribution, substrate specificity and affinity for TH transport. The 
characteristics of the TH transporters identified to date are described in the following 
paragraphs and summarised in Table 1. As shown in Table 1, the reported Km values for 
the TH transporters indentified to date are in the nM or µM range. However, the 
circulating concentration of free T4 and free T3 is in the pM range. The high Km values of 
the TH transporters compared with the circulating concentration of free THs could 
indicate that in vivo TH transport cannot be saturated by circulating THs and that there is 
a linear relationship between the circulating concentration of TH and the amount of TH 
transported into the cells (Hennemann et al., 2001). TH transport could be regulated by 
the number of TH transporters present at the cell membrane and by the circulating 
concentration of inhibitors for TH transport (Hennemann et al., 2001). Furthermore, the 
reported Km values of the TH transporters for T4 and T3 were determined in experiments 
with Xenopus oocytes and therefore no intracellular THs were present initially. As a 
result, these are “zero trans entry” kinetics and they may not be representative of the in 
vivo condition. That TH uptake requires transporters is strongly suggested by the finding 
that it is energy-dependent both in vitro and in vivo, (Hennemann et al., 2001) and, as 
discussed in section 1.4, patients affected by mutations of the TH transporter, MCT8 have 
altered circulating concentrations of THs (elevated serum T3 and low serum T4) 
(Dumitrescu et al., 2004, Friesema et al., 2004). In mice, MCT8 knock-down results in 
the same changes in the serum concentration of THs (Dumitrescu et al., 2006, Trajkovic 
et al., 2007). This evidence strongly indicates that MCT8 has a role in TH transport in 
vivo. 
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1.2.1.2.1 MCT8 and 10 
The MCT family consists of 14 members, of which four (MCT1-4) have been 
characterised as monocarboxylate transporters. Two members of the MCT family, MCT8 
and MCT10, that share 49% amino acid identity, have been identified as TH transporters 
(Friesema et al., 2003, Friesema et al., 2008). MCT8 and MCT10 have similar structures: 
they consist of 12 hydrophobic transmembrane domains (TMD) (Kim et al., 2002, 
Lafreniere et al., 1994) and have a leucine zipper-like motif located in a transmembrane 
region (Kim et al., 2002, Lafreniere et al., 1994) and a N-terminal sequence rich in 
proline, glutamic acid, serine and threonine repeats (PEST domain) (Lafreniere et al., 
1994, Ramadan et al., 2006). The structure of MCT8 is illustrated in Figure 1-5. The 
predicted molecular mass of the human MCT8 and MCT10 proteins are 67 kDa 
(Lafreniere et al., 1994) and 56 kDa (Kim et al., 2001), respectively. 
Figure 1-5: Simplified diagram of the MCT8 protein structure. The MCT8 
protein has 12 transmembrane domains shown as blue rods. Both the N 
terminus and the C terminus of the MCT8 protein are located intracellularly. 
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MCT8 was first characterised by Lafreniere et al. while investigating genes 
associated with X chromosome inactivation (Lafreniere et al., 1994). The authors 
identified a gene (official gene symbol: SLC16A2) that was only expressed from the 
active X chromosome and encoded for a protein that shared sequence homology and 
structural similarities with transporter proteins and they designated it XPCT for X-linked 
PEST containing transporter. It was subsequently demonstrated by Friesema et al. that 
MCT8 facilitates the transport of THs with a preference for T3 over T4 (Friesema et al., 
2003, Friesema et al., 2006). Transfection of rat MCT8 in Xenopus oocytes resulted in a 
ten-fold increase in the uptake of T3 (Km: 4.0 µM), T4 (Km: 4.7 µM) and their metabolic 
derivatives rT3 and T2 (Km: 2.2 µM). Transport of T4 was strongly inhibited by L-T4, D-
T4, L-T3, D-T3, 3,3’,5-triiodothyroacetic acid (Triac), N-bromoacetyl-T3 (BrAcT3) and by 
the organic anion bromosulphophthalein (BSP), whilst T3 transport was less affected by 
these inhibitors. T3 transport was Na+-independent, whilst the transport of T4 was slightly 
inhibited in the absence of Na+. The possible transport of other compounds by MCT8 was 
investigated and it was found that MCT8, unlike monocarboxylate transporters, does not 
transport lactate. Furthermore, MCT8 does not facilitate the transport of leucine or of the 
aromatic amino acids phenylalanine, tyrosine or tryptophan (Friesema et al., 2003). 
Transfection of human choriocarcinoma JEG-3 and simian kidney fibroblast-like COS-7 
cells with human MCT8 also increased TH transport and stimulated intracellular TH 
metabolism by deiodinase enzymes (Friesema et al., 2008, Friesema et al., 2006). 
Furthermore, co-transfection of simian kidney trophoblast-like COS-1 cells with MCT8 
and the cytosolic protein µ-crystallin (CRYM) that binds to intracellular THs, 
demonstrated that MCT8 facilitates both TH uptake and efflux (Friesema et al., 2008). 
MCT8 mRNA is highly expressed in adult liver, kidney, heart, lung, and placenta and in 
adult and fetal brain (Chan et al., 2006, Friesema et al., 2003, Lafreniere et al., 1994, 
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Roberts et al., 2008). Furthermore, the presence of MCT8 protein has been demonstrated 
in the placenta and in adult and fetal brain (Chan et al., 2006, Roberts et al., 2008). 
The human MCT10 (SLC16A10), also known as T-type amino acid transporter-1 
(TAT1), was characterised in 2002 (Kim et al., 2002). MCT10 was initially identified as a 
system T amino acid transporter that facilitated Na+-independent transport of aromatic 
amino acids (Kim et al., 2001, Kim et al., 2002). It was later reported that MCT10 
functions as a net efflux pathway for aromatic amino acids (Ramadan et al., 2006). 
Although it was previously reported that MCT10 does not mediate the transport of THs 
(Kim et al., 2001, Kim et al., 2002), in a recent study, Friesema et al. demonstrated that 
transfection of COS-1 cells with MCT10 caused a marked stimulation of cellular T3 and 
T4 uptake and increased intracellular TH metabolism (Friesema et al., 2008). Co-
transfection with CRYM demonstrated that MCT10 also facilitates efflux of T3 and T4. T3 
uptake by MCT10-transfected COS-1 cells was inhibited in the presence of the aromatic 
amino acids phenylalanine, tyrosine and tryptophan. However, T3 efflux was not affected 
by these inhibitors (Friesema et al., 2008). MCT10 mRNA is highly expressed in adult 
human intestine, kidney, heart and placenta (Kim et al., 2002). 
1.2.1.2.2 LAT1 and 2 
LAT1 and 2, also known as system L, are members of the heterodimeric amino 
acid transporter (HAT) family. They consist of the heavy chain 4F2hc (SLC3A2), also 
known as CD98, that can form disulphide bonds with the light chain LAT1 (SLC7A5) or 
LAT2 (SLC7A8) (Pineda et al., 1999, Prasad et al., 1999, Rossier et al., 1999, Yanagida et 
al., 2001). Human LAT1 and LAT2 share 50% amino acid identity and the predicted 
molecular mass of the LAT1 and LAT2 proteins are 55 kDa and 58 kDa, respectively. 
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Both proteins are predicted to have 12 TMDs and their N and C termini are likely to be 
located intracellularly (Pineda et al., 1999, Prasad et al., 1999, Rossier et al., 1999). 
Heterodimers of LAT1/4F2hc and LAT2/4F2hc facilitate the Na+-independent transport 
of neutral amino acids (Verrey, 2003). It has been shown that the system L can facilitate 
both amino acid uptake and efflux and thus provides a transport system for amino acid 
exchange (Pineda et al., 1999, Rossier et al., 1999, Yanagida et al., 2001). LAT1 mRNA 
is expressed widely including human liver, kidney, heart, bone marrow, brain, testis, 
placenta and skeletal muscle (Prasad et al., 1999, Yanagida et al., 2001), whilst LAT2 is 
primarily expressed in the human kidney, intestine and placenta (Rossier et al., 1999). 
Based on the localisation of LAT1 and LAT2 mRNA, it has been postulated that LAT1 is 
responsible for cellular exchange of amino acids, whilst LAT2 is involved in epithelial re-
absorption of amino acids in the kidneys and intestine (Pineda et al., 1999, Rossier et al., 
1999).  
The involvement of the system L in TH transport was recognised following reports 
that amino acid transport by system L was inhibited by T3 in a competitive manner 
(Taylor and Ritchie, 2007). The ability of the system L to facilitate transport of 
iodothyronines as well as amino acids was investigated using Xenopus oocytes, which 
have negligible expression of system L, and the choriocarcinoma cell line BeWo, which 
has high endogenous expression of system L, as models (Friesema et al., 2001, Ritchie et 
al., 1999, Ritchie et al., 2003, Ritchie and Taylor, 2001). System L-mediated transport of 
THs was first demonstrated when Ritchie et al. co-injected Xenopus oocytes with 4F2hc 
and IU12, the Xenopus homologue of mammalian LAT1 (Ritchie et al., 1999). The 
authors reported that 4F2hc/IU12 co-expression induced saturable, Na+-independent 
transport of T3 and T4 that was inhibited by rT3, and tryptophan, but not by Triac, a TH 
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analogue lacking the amino acid moiety. Furthermore, it was shown that T3 inhibits 
tryptophan uptake in a competitive manner. Following injection of Xenopus oocytes with 
human LAT1 and 4F2hc, Friesema et al. confirmed the ability of human LAT1/4F2hc 
heterodimers to transport THs, with a preference for T3 over T4 and reported Km values of 
0.8 µM and 7.9 µM, respectively (Friesema et al., 2001). The authors demonstrated 
reciprocal inhibition of TH transport by the amino acids phenylalanine, tyrosine, leucine 
and tryptophan and they reported that in contrast to system L, the Na+-dependent system 
y+L does not facilitate TH transport. The reciprocal inhibition of TH transport by amino 
acids was further confirmed by uptake studies using the choriocarcinoma cell line, BeWo 
(Ritchie and Taylor, 2001). In a subsequent study, Ritchie et al. used Xenopus oocytes co-
transfected with 4F2hc/IU12 and cDNA encoding for the TH receptor dimer TR/RXR 
under the control of a luciferase promoter, to demonstrate that system L-mediated TH 
transport is important for nuclear accumulation of T3 and activation of TH receptors 
(Ritchie et al., 2003). 
1.2.1.2.3 OATPs 
The OATP family (SLCO) includes eleven plasma membrane transporters in 
humans, all containing twelve TMDs. OATPs show wide tissue distribution and substrate 
specificity (Hagenbuch, 2007). They mediate Na+-independent transport of a variety of 
amphipathic organic compounds, such as bile acids, steroid hormones and their 
conjugates, linear and cyclic peptides, prostaglandins, drugs and xenobiotics (Hagenbuch, 
2007). 
Of the eleven human OATPs, seven have been reported to facilitate the transport 
of THs. These transporters are OATP1A2, OATP1B1, OATP1B3, OATP1C1, OATP3A1, 
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OATP4A1 and OATP4C1 and they differ in their tissue distribution and substrate 
specificity (Hagenbuch, 2007). OATP1A2 is a 670 amino acids-long protein that exists in 
different glycosylation states. It has a wide tissue distribution including the blood-brain 
barrier, kidney, lung, placenta and testis (Fujiwara et al., 2001, Kullak-Ublick et al., 2001, 
Patel et al., 2003). In studies using Xenopus oocytes injected with OATP1A2, it was 
demonstrated that OATP1A2 mediates the transport of T4 (Km: 8.0 µM), T3 (Km: 6.5 
µM) and rT3 (Hagenbuch, 2007). OATP1B1 and 1B3 are liver-specific transporters with 
80% amino acid identity and can both be glycosylated (Abe et al., 1999, Kullak-Ublick et 
al., 2001). Using Xenopus oocytes, it was shown that both OATP1B1 and 1B3 also 
transport the THs, T4 and T3 (Kullak-Ublick et al., 2001). OATP1C1 is exclusively 
expressed in the blood brain barrier and the choroid plexus (Pizzagalli et al., 2002). It 
facilitates the transport of BSP, estrone-3-sulphate and estradiol-17β-glucuronide. Uptake 
studies using Chinese hamster ovary cells (CHO) overexpressing OATP1C1, 
demonstrated that OATP1C1 is the OATP transporter with the highest affinity for THs, 
since the estimated Km values for T4 and T3 transport were 90.4 nM and 127.7 nM, 
respectively (Pizzagalli et al., 2002). OATP1C1 transports rT3 but not T2. The gene 
OATP3A1 encodes for two splice variants with different tissue distributions: OATP3A1v1 
that shows ubiquitous expression and OATP3A1v2 that is predominantly expressed in the 
brain and testis. Both proteins facilitate the transport of T4 as shown in CHO cells (Huber 
et al., 2007). OATP4A1 is a transporter with wide tissue distribution and narrow substrate 
specificity. OATP4A1 expression is higher in the heart, placenta, lung, liver, skeletal 
muscle, kidney and pancreas. OATP4A1 transports taurocholate, benzylpenicillin, steroid 
conjugates and the THs, T4, T3 (Km: 0.9 µM) and rT3 (Fujiwara et al., 2001). OATP4C1 
is expressed predominantly in the kidney and it transports the cardiac glycosides digoxin 
and ouabain, methotrexate and cAMP. OATP4C1 facilitated cellular uptake of T4 and T3 
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(Km: 5.9 µM) (Mikkaichi et al., 2004). These molecules are likely to play a tissue-
specific role in the transport of THs and other substrates. Their relative contribution for 
TH transport is likely to depend on the circulating concentration of THs and other 
substrates that could inhibit TH transport and their co-localisation with other transporters 
with different affinities for THs and other substrates. 
1.2.1.2.4 NTCP 
NTCP is facilitating Na+-dependent transport of bile acids in the liver. NTCP, 
which has seven TMDs, is exclusively expressed in hepatocytes and transports all 
physiological bile acids including taurocholate, glycocholate, taurochenodeoxycholate 
and tauroursodeoxycholate (Trauner and Boyer, 2003). In addition to bile acids, NTCP 
facilitates the transport of other compounds such as oestrogen conjugates, BSP, 
dehydroepiandrosterone sulphate and THs. 
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(human) T4 T3 Other substrates 
MCT8 
(SLC16A2) 
Liver, kidney, brain, 
blood-brain barrier, 
heart, lung, placenta 
(Chan et al., 2006, Lafreniere 




(Friesema et al., 
2003) 
Human MCT8: 
0.86 µM (Kinne et 
al., 2009) 
Rat MCT8: 4.0 





Intestine, kidney, heart, 
placenta (Kim et al., 2002) 
Not reported Not reported Aromatic amino acids 
(Kim et al., 2001, Kim et al., 
2002, Ramadan et al., 2006) 
LAT1 
(SLC7A5) 
Liver, kidney, heart, 
bone marrow, brain, 
skeletal, muscle, testis, 
placenta (Prasad et al., 
1999, Yanagida et al., 2001) 
LAT1/4F2hc: 
7.9 µM 
(Friesema et al., 
2001) 
LAT1/4F2hc: 
0.8 µM (Friesema 
et al., 2001) 
Neutral amino acids 





placenta (Rossier et al., 
1999) 
Not reported Not reported Neutral amino acids 
(Pineda et al., 1999, Rossier 




kidney, lung, testis, 
placenta (Kullak-Ublick et 











Liver (Abe et al., 1999, 
Kullak-Ublick et al., 2001) 





Liver (Abe et al., 1999, 
Kullak-Ublick et al., 2001) 






choroid plexus and 
testis (Hagenbuch, 2007, 
Pizzagalli et al., 2002) 
90.4 nM 
(Pizzagalli et al., 
2002) 
127.7 nM 







Variant 1: ubiquitous 
expression. Variant 2: 
Brain and testis (Huber et 
al., 2007) 





Heart, placenta, lung, 
liver, skeletal muscle, 
kidney, pancreas 
(Fujiwara et al., 2001) 
Not reported 0.9 µM (Fujiwara 




(Fujiwara et al., 2001) 
OATP4C1 
(SLCO4C1) 
Kidney (Mikkaichi et al., 
2004) 
Not reported 5.9 µM 








Liver (Trauner and Boyer, 
2003) 
Not reported Not reported Bile acids, oestrogen 
conjugates (Trauner and 
Boyer, 2003) 
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1.2.1.3 TH metabolism 
1.2.1.3.1 Deiodination 
The major pathway that controls TH metabolism is deiodination by iodothyronine 
deiodinases (Figure 1-6). The deiodinases are selenocysteine-containing enzymes that 
remove iodine moieties from the outer (phenolic) or the inner (tyrosine) ring on THs. T3 is 
produced locally by the outer-ring deiodination (ORD) of T4, whilst inner-ring 
deiodination (IRD) of T4 and T3 convert them to their inactive metabolites rT3 and T2 
(figure). It is estimated that peripheral T3 production by T4 deiodination accounts for 
approximately 80% of the T3 produced daily (Bianco and Kim, 2006). Therefore, 
deiodinases play a major role in determining the availability of the active TH ligand, T3, 
within tissues. There are three deiodinase subtypes, type I (D1), type II (D2) and type III 
(D3) (Bianco and Kim, 2006). All types of deiodinases form homodimers and are integral 
membrane proteins (Gereben et al., 2008). The expression of the deiodinase genes Dio1, 
Dio2 and Dio3, encoding for D1, D2 and D3 proteins respectively, is regulated by 
different factors including cAMP, glucocorticoids and cytokines and by THs themselves. 
T3 upregulates the expression of D1 and D3, whilst it downregulates D2 expression. 
Furthermore, T4 induces the ubiquitination of D2 and thus downregulates its activity 
(Gereben et al., 2008).  
D1 is expressed in many tissues including the human liver, kidney, thyroid gland, 
pituitary and intestine. It is localised in the plasma membrane with its active site in the 
cytoplasm. D1 has both ORD and IRD activity and can thus catalyse the conversion of T4 
to either T3 or reverse T3 (rT3) and the deiodination of rT3 to diiodothyronine (T2). 
However, D1 is not as efficient as D2 and D3 in the deiodination of T4, since its Km for 
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T4 is in the µM range compared with D2 and D3 that have a Km in the nM range for T4. It 
is thought that D1 plays a balancing role in maintaining optimal T3 levels in cases of 
altered thyroid function (Bianco and Kim, 2006, Gereben et al., 2008).  
D2 has ORD but not IRD activity and can thus catalyse the monodeiodination of 
T4 to T3 and the conversion of rT3 to T2. D2 is the primary activating enzyme in tissues 
and is thus the major source of intracellular and plasma T3 (Salvatore et al., 1996). D2 is 
expressed widely including in the human brain, anterior pituitary, thyroid, brown fat, 
skeletal muscle, heart and is present at low levels in the placenta (Croteau et al., 1996, 
Kuiper et al., 2005). D2 is an ER-resident protein with its N-terminus in the ER lumen 
and its catalytic domain in the cytoplasm (Gereben et al., 2008).  
D3 is the deactivating enzyme that catalyses the monodeiodination of T4 to rT3 and 
of T3 to T2 by IRD (Gereben et al., 2008). It is present in the placenta, pregnant uterus, 
fetal tissues and in the brain (Chan et al., 2003, Chan et al., 2002, Gereben et al., 2008, 
Koopdonk-Kool et al., 1996, Kuiper et al., 2005). D3 has been localised in the plasma 
membrane and it has been shown that it is internalised into clathrin-coated endosomes and 
is recycled between the plasma membrane and early endosomes (Baqui et al., 2003). 
There is evidence that the catalytic subunit of D3, when membrane-bound, is located 
extracellularly thus allowing the rapid inactivation of circulating T4 and T3 (Baqui et al., 
2003, Gereben et al., 2008), however this view has been challenged by recent findings 
that MCT8 increases D3-mediated deiodination (Gereben et al., 2008). D3 is thought to 
be important in limiting the exposure of developing fetal tissues to T3 (Gereben et al., 
2008). The physiological roles of rT3 and T2 have not been elucidated. Since they cannot 
bind to TRs it was thought that they are inactive metabolites, however recent evidence 
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suggests that rT3 plays a role in actin polymerisation and T2 is involved in mitochondrial 
respiration (Davis et al., 2008, Wrutniak-Cabello et al., 2001). 
 
1.2.1.3.2 Alternate pathways 
Although deiodination is the major metabolic pathway that controls TH 
metabolism, THs are also metabolised by sulphation, glucuronidation, deamination, 
decarboxylation and ether-link cleavage (Figure 1-7).  
Figure 1-6: Deiodination of THs. Intracellular availability of the different TH 
forms is regulated via the activity of deiodinase enzymes. Deiodinase 1 (D1) 
has both inner and outer ring deiodination activity and can thus convert T4 to 
either T3 or rT3 and it can facilitate the conversion of rT3 to T2. Deiodinase 2 
(D2) facilitates the conversion of T4 to T3 and rT3 to T2 via outer ring 
deiodination. Deiodinase 3 (D3) has inner ring deiodination activity and 
converts T4 to rT3 and T3 to T2. Iodine moieties are represented by blue 
spheres. Figure from (Bianco and Kim, 2006). 
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TH sulphation is the transfer of a sulphonate group from the sulphonate donor, 3’-
phosphoadenosine 5-phosphosulphate to the phenolic hydroxyl group of THs and is 
catalysed by sulphotransferase enzymes (Wu et al., 2005). Sulphotransferases (SULTs) 
are cytosolic enzymes composed of two subunits and they belong to three superfamilies: 
SULT1, SULT2 and SULT3. Sulphotransferases have overlapping substrate specificity 
and they are not specific for THs. The human sulphotransferases that are active towards 
THs are SULT1A1, SULT1A3, SULT1A5, SULT1B1, SULT1B2, SULT1C1, SULT1E1 
and SULT2A1. They are expressed in the human liver, thyroid gland and uterus. T3 and 
rT3 are converted to T3S and T2 to T2S and their sulphation accelerates their deiodination. 
On the other hand, T4 is a poor substrate for sulphotransferases and following its 
sulphation to T4S, it cannot be deiodinated to T3S. Sulphated THs can be hydrolysed to 
their precursors in liver, brain and other tissues. It is therefore postulated that T3S 
functions as a reservoir for T3 (Wu et al., 2005). 
Glucuronidation is the phenolic conjugation of THs with glucuronic acid that is 
catalysed by uridine diphosphate-glucuronosyltransferase (UGT), thus converting T4 to 
T4G. The glucuronidation of T3 is minimal in humans (Wu et al., 2005). Glucuronidation 
occurs primarily in the human liver and kidney by UGT1A1 and UGT1A9, respectively 
and precedes the biliary or fecal excretion of THs. In the intestinal lumen, T4G is 
converted to T4 via a reaction catalysed by β-glucuronidase. Therefore, it is thought that 
T4G functions as a reservoir for T4 (Wu et al., 2005). 
Other TH metabolites arise from the deamination or decarboxylation of the alanine 
side chain of THs (Wu et al., 2005). Deamination is catalysed by L-amino acid oxidase 
(expressed in the kidney) and TH aminotransferase (expressed in the liver and kidney) 
and leads to the formation of the acetic analogues, Triac and Tetrac. Triac and Tetrac have 
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thyromimetic activity and can regulate the secretion of TSH. Furthermore, Triac can bind 
to TRs with a higher affinity than T3, with a preference for TRβ1. Tetrac can be converted 
to Triac by D2. Decarboxylation of the alanine side chain of THs leads to the formation of 
Tetram, Triam, T1am or T0am. Although the in vivo occurrence of Tetram and Triam has 
not been confirmed, T1am and T0am were found in the rodent brain indicating that they 
may have a biological role (Wu et al., 2005). 
Cleavage of the ether-link of THs by peroxidases is thought to be a minor pathway 
in TH metabolism (Wu et al., 2005). Ether-link cleavage leads to the production of DIT 
and iodine. The circulating concentration of DIT is between 0.02 and 0.55 nM and it is 
thought that DIT is secreted by the thyroid rather than produced by cleavage of THs. 
However, it has been shown that during infection the circulating concentration of DIT 
increases dramatically to > 5 nM and it has been postulated that ether-link cleavage of 
THs may play a role in bacterial clearing by leukocytes (Wu et al., 2005). 
 
Figure 1-7: Alternate pathways of TH metabolism. THs can be converted to 
different metabolites by sulphation, glucuronidation, ether-link cleavage, 
oxidative deamination and decarboxylation. The sulphation of THs is 
catalysed by sulphotransferase enzymes that transfer a sulphonate group to the 
phenolic hydroxyl group of THs. Glucuronidation involves the phenolic 
conjugation of THs with glucuronic acid and is catalysed by uridine 
diphosphate glucuronosyltransferase. Ether-link cleavage of THs is catalysed 
by peroxidase enzymes and results in the production of diiodotyrosine (DIT). 
Oxidative deamination of T4 results in the production of Tetrac, whilst 
decarboxylation generates Tetram. Figure adapted from (Wu et al., 2005). 
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1.2.1.4 TH receptors 
T3, the active TH ligand, exerts its biological function by binding to TH receptors 
(TRs), ligand-regulated transcription factors that belong to the nuclear hormone receptor 
superfamily. There are two major TR isoforms (TRα and TRβ) and they are encoded by 
two separate genes, the c-erbAα gene and the c-erbAβ gene respectively, which are 
cellular homologs of the viral oncogene protein V-erbA (Yen, 2001). Alternative splicing 
of TRα generates two different protein species, TRα1 and TRα2, whilst alternative 
splicing of the TRβ gene generates TRβ1 and TRβ2. TRα1, TRβ1 and TRβ2 are known 
to bind T3. In contrast, TRα2 does not bind T3 and may therefore inhibit the function of 
the other TRs by competitive binding to the TRE site (Yen, 2001). TRα1 and TRβ1 are 
ubiquitously expressed. In contrast, TRβ2 is only found in specific tissues, namely in the 
anterior pituitary gland, in the hypothalamus and in the developing brain. TR protein 
structure consists of an amino-terminal region, a central DNA-binding domain that 
contains two zinc fingers, a lysine-rich hinge region that contains a nuclear localisation 
signal and is implicated in TR binding with cofactors and a carboxy-terminal ligand-
binding domain that is essential for TH binding and for TR dimerisation (Yen, 2001). 
TRs exert their function via binding to TH response elements (TREs) upstream of 
TH-regulated genes. TREs are composed of hexamer half-sites with a consensus sequence 
of (G/A)GGT(C/G)A that may exist as direct repeats, palindromes or inverted 
palindromes. TRs bind to TREs as monomers, homodimers or heterodimers with other 
auxiliary protein and initiate or repress gene expression. The major TR auxiliary proteins 
are retinoic acid X receptors (RXRs). TRs also form heterodimers with other auxiliary 
proteins including RAR, PRAP and VDR. TR/RXR heterodimers show enhanced binding 
to TREs compared with TR monomers or homodimers. Furthermore, TRs can be 
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phosphorylated thus increasing DNA-binding (Yen, 2001). TRs can modulate the 
expression of TH-regulated genes depending on the presence of their ligand, T3. 
Unliganded TRs form complexes with corepressor molecules, such as NCoR, SMRT and 
SUN-CoR and they interact with the transcription machinery to repress the transcription 
of positively regulated genes. In contrast, the expression of some negatively regulated 
genes is upregulated by unliganded TR-corepressor complexes. In the presence of T3, TRs 
complex with coactivator molecules such as SRC-1 and with transcription factors to 
activate the expression of positively regulated genes or inhibit the expression of 
negatively regulated genes (Yen, 2001). 
Whilst T3-binding to nuclear TRs is the classical pathway of TH action, it is now 
known that not all the effects of THs are mediated via intranuclear complexing of TRs 
and T3 (Davis et al., 2008, Furuya et al., 2009). Non-genomic effects of THs are mediated 
via binding to extranuclear TRs. TRβ1 and truncated forms of TRα1 are found in the 
cytoplasm where they bind to T3 and initiate protein kinase pathways (Davis et al., 2008, 
Furuya et al., 2009). Furthermore, a novel cell surface TR domain has been identified on 
integrin αVβ 3. T4, and to a lesser extent T3, binds to this receptor and causes the 
activation of protein kinases by phosporylation (Davis et al., 2008). Since this receptor is 
located extracellularly, cellular entry of THs is not necessary for its activation. TH 
binding to extranuclear TRs enhances cell proliferation, motility and angiogenesis of 
tumour cells (Davis et al., 2008). In addition, truncated forms of TRα1 are found in the 
mitochondria where they are thought to initiate T3-dependent transcription of 
mitochondrial genes and partly mediate the influence of THs on mitochondrial oxygen 
consumption (Wrutniak-Cabello et al., 2001). The genomic and non-genomic pathways of 
TH action are summarised in Figure 1-8. 
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Figure 1-8: Genomic and non-genomic pathways of TH action. THs enter the cells via 
TH transporters (MCTs, LATs or OATPs) and are metabolised via the deiodinase 
enzymes (D1, D2 and D3). Genomic TH action (solid black arrow) involves binding of 
the active ligand, T3, to TH receptors (TRs) in the cell nucleus. TRs are nuclear 
transcription factors that heterodimerise with other nuclear receptors such as retinoic 
acid X receptor (RXR) and regulate gene transcrption. Non genomic pathways of TH 
action (dashed arrows) involve binding of T3 to TRs outside the nucleus. A truncated 
form of TRα1 (TRΔα1) is located in the mitochondria. Binding of T3 to this receptor 
regulates mitochondrial gene expression. TRβ1 and TRΔα1 are also found in the 
cytoplasm. T3 binding to these receptors leads to the activation of kinase pathways. 
Furthermore, a new TR has been identified on the integrin αVβ3. T4 binding to this 
receptor that is located extracellularly and does not require T4 entry into the cell 
leads to the activation of kinase pathways. 
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1.3 THs in pregnancy 
Optimal levels of maternal THs are necessary for normal fetal development, 
particularly for the development of the central nervous system (CNS) (Haddow et al., 
1999, Morreale de Escobar et al., 2004, Pop et al., 2003). The transfer of maternal THs to 
the fetal circulation is regulated by the placenta thus preventing toxic concentrations of 
THs from reaching the developing fetus. As well as facilitating the transport of maternal 
TH to the fetal circulation, the human placenta is thought to be sensitive to the action of 
TH for the regulation of its metabolism, differentiation and development (Kilby et al., 
2005). The importance of TH availability on fetoplacental development is highlighted by 
the association of untreated maternal hyperthyroidism and subclinical hypothyroidism 
with pregnancy complications including miscarriages, pre-eclampsia, IUGR and stillbirths 
(Abalovich et al., 2002, Casey et al., 2005, LaFranchi et al., 2005, Mestman, 2004). 
1.3.1 Transplacental transport of THs 
Previously the placenta was considered impermeable to maternal THs, partly 
because it expresses D3 that metabolises T4 and T3 to their inactive metabolites. However, 
there is now evidence that transfer of T3 and T4 occurs from the mother to the fetus since 
the first trimester (Calvo et al., 2002, Calvo et al., 1990, Contempre et al., 1993, Vulsma 
et al., 1989). After the onset of fetal TH production in the mid second trimester, THs in 
the fetal circulation are of both maternal and fetal origin (Chan et al., 2009). Even though 
fetal TH production does not begin until the second trimester of pregnancy, THs are 
present in human embryonic cavities since the first trimester, indicating that maternal THs 
reach the developing fetus (Calvo et al., 2002, Contempre et al., 1993). Furthermore, at 
term T4 was detected in the umbilical cord blood of infants with severe congenital 
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hypothyroidism that cannot produce their own THs, thus providing further proof for the 
transfer of maternal THs to the fetus during gestation (Vulsma et al., 1989). When a rat 
model of congenital hypothyroidism was studied, it was demonstrated that infusion of T4 
into the mothers caused an increase in the concentration of T4 and particularly T3 in the 
fetal brain (Calvo et al., 1990). 
A number of factors may regulate the amount and the different forms of THs that 
are transported from the maternal to the fetal circulation. The human placenta expresses a 
range of transporters that can facilitate TH transport. The TH transporters that have been 
identified in the human placenta to date are MCT8 (Chan et al., 2006), MCT10 (Park et 
al., 2005), LAT1 (Okamoto et al., 2002), LAT2 (Kudo and Boyd, 2001), OATP1A2 
(Patel et al., 2003) and OATP4A1 (Briz et al., 2003, Patel et al., 2003, Sato et al., 2003). 
With the exception of MCT8, all TH transporters expressed in the placenta are involved in 
the transport of substrates other than THs. The relative contribution of each TH 
transporter to transplacental TH transport depends on their affinity for THs, competition 
by other substrates and their localisation within the placenta. The data available to date 
indicate that MCT8, LAT1 and OATP4A1 are localised in the ST, consistent with a role 
of these transporters for transplacental TH transport (Chan et al., 2006, Okamoto et al., 
2002, Ritchie and Taylor, 2001, Sato et al., 2003). The localisation of MCT10, LAT2 and 
OATP1A2 within the placenta has not been elucidated yet. 
TH metabolism by deiodinase enzymes and to a lesser extent by sulphatase 
enzymes within the placenta further modulates TH availability. There is low sulphatase 
activity in the human placenta, suggesting that these enzymes do not play a major role in 
the metabolism of THs within the placenta (Chan et al., 2009). In contrast, substantial D3 
and to a lesser extent D2 activity is present in the human placenta from week 6 of 
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gestation and both mRNA expression and protein activity of D2 and D3 in the human 
placenta decline significantly with advancing gestation (Chan et al., 2003, Koopdonk-
Kool et al., 1996). Therefore, maternal T4 and T3 are probably metabolised within the 
placenta, thus regulating the TH forms available for efflux to the fetal capillaries 
throughout gestation. Recently, it was demonstrated that the placenta synthesises and 
secretes the TH-binding protein transthyretin. Furthermore, it was shown that 
transthyretin binds to T4 extracellularly and the complex is then internalised by placental 
explants (Landers et al., 2009). T4 binding to transthyretin protects it from inactivation by 
D3 and may thus play an important role in the supply of maternal T4 to the fetus. In 
addition to expressing transporter proteins and deiodinase enzymes that facilitate TH 
transport and metabolism, human placental tissue has a high nuclear binding capacity for 
T3 (Ka = 7.0 ×  109 M-1; capacity = 62.7 fmol T3/mg DNA) (Ashitaka et al., 1988, 
Banovac et al., 1986). Furthermore, mRNA and protein of the T3-binding TR isoforms, 
TRα1 and TRβ1, are expressed in the human placenta (Ashitaka et al., 1988, Banovac et 
al., 1986, Kilby et al., 1998). Therefore, binding of T3 to TRs within the placenta may 
further restrict the amount of T3 available for transport to the fetal circulation. 
It is thought that T4 is the major TH crossing the placenta, which is supported by 
the correlation of the concentration of maternal and fetal serum total T4 (Chan et al., 2009, 
Morreale de Escobar et al., 2004). However, there is evidence that CTs can also transport 
T3 (Mitchell et al., 1999, Ritchie and Taylor, 2001). The level of free T4 in the maternal 
circulation increases moderately in the first trimester possibly as a mechanism of ensuring 
adequate supply of maternal THs to the fetoplacental unit. It is thought that this increase is 
triggered by hCG that is secreted by the placenta and has weak TSH-like activity (Chan et 
al., 2009). The concentration of free T4 in the fetal circulation increases throughout 
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gestation and in the third trimester it exceeds the concentration of maternal free T4. In 
contrast, the fetal concentration of free T3 remains lower than the maternal free T3 
throughout gestation (Chan et al., 2009) (Figure 1-9). The TH metabolites, rT3, T4S and 
T3S are also present in the fetal circulation. 
 
1.3.2 Importance of THs for fetal development 
The critical role of THs in growth and differentiation of many organs and thus 
overall development in human is well recognised (Chan and Kilby, 2000, Schwartz et al., 
1983). This is of particular significance for the development of the CNS since TH 
Figure 1-9: Circulating maternal and fetal THs during human pregnancy. 
Before the onset of fetal TH production, around week 14 of human pregnancy, 
THs in the fetal circulation are exclusively of maternal origin. Following fetal 
TH production, there is a mixture of maternal and fetal THs in the fetal 
circulation. The concentration of free T4 in the maternal circulation shows a 
moderate increase during the first trimester, whilst maternal free T3 levels are 
relatively constant throughout pregnancy. Fetal free T4 and reverse T3 
increase following the onset of fetal TH production and towards term free T4 
in the fetal circulation exceeds the concentration of free T4 in the maternal 
circulation. The concentration of free T3 in the fetal circulation remains lower 
than the circulation of free T3 in the maternal circulation throughout 
pregnancy. Figure adapted from (Chan et al., 2009). 
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deficiency has been associated with neurodevelopment morbidity. In many species, THs 
synchronise neuronal differentiation, polarity, synaptogenesis, cytoplasmic outgrowths 
and myelin formation via modulating the expression of TH-responsive genes (Bernal, 
2005, Bernal and Nunez, 1995, Guadano-Ferraz et al., 1999). In humans, the thyroid 
status of neonates and children has a significant long-term impact on their behaviour, 
locomotor ability, speech, hearing and cognition (Legrand, 1986). Development of 
different areas of the CNS has been associated with the timing and duration of TH 
deficiency, suggesting that there are critical periods during which various parts of the 
brain are sensitive to TH supply (Rovet et al., 1992). 
The association of maternal hypothyroidism with poorer neuropsychological 
outcome in the offspring demonstrates the critical role of TH in fetal brain development 
during pregnancy (Haddow et al., 1999, Pop et al., 2003, Pop et al., 1999). Children of 
women with free T4 levels below the fifth and tenth percentile at 12 weeks of gestation 
had significantly lower scores on the Bayley Psychomotor Developmental Index (PDI) 
scale at ten months of age, compared with children of mothers with higher free T4 levels 
(Pop et al., 1999). Furthermore, there was a positive correlation between maternal free T4 
levels and PDI scores. In a three-year follow-up study, children of women with 
hypothyroxinaemia at 12 weeks of gestation had delayed mental and motor functions 
compared with matched controls (Pop et al., 2003). These data suggest that low maternal 
plasma free T4 concentration during early pregnancy is an important risk factor for 
impaired development. Further evidence for the importance of THs on fetal brain 
development was provided by a study using rats where maternal hypothyroxinaemia 
during early pregnancy resulted in altered fetal brain histogenesis and cytoarchitecture 
(Lavado-Autric et al., 2003). 
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The sensitivity of the developing brain to TH is indicated by the presence of 
molecules involved in TH entry, metabolism and action in the fetal brain. The fetal brain 
has the potential for TH uptake as demonstrated by the expression of the TH transporters 
LAT1, OATP1C1 and MCT8 (Friesema et al., 2003, Hagenbuch, 2007, Heuer, 2007, 
Lafreniere et al., 1994, Taylor and Ritchie, 2007, Yanagida et al., 2001). OATP1C1 is 
expressed in the blood-brain barrier, the route by which THs preferentially enter the brain, 
and is thus thought to play an important role in the delivery of THs, mainly T4, to the 
brain (Bernal, 2005, Hagenbuch, 2007, Pizzagalli et al., 2002). MCT8 expression was 
studied in the murine CNS (Heuer et al., 2005). High levels of MCT8 mRNA were 
detected in the choroid plexus and in other brain regions including the olfactory bulb, 
cerebral cortex, hippocampus and amygdala. Moderate levels of MCT8 mRNA were 
found in the striatum and cerebellum and low levels in a few neuroendocrine nuclei. It 
was therefore postulated that MCT8 playa a critical role in facilitating T3 uptake by 
neurons, where T3 acts to regulate cell differentiation and migration. There are limited 
data regarding the expression of MCT8 in the human fetal brain, however recent evidence 
suggests that both MCT8 and OATP1C1 are expressed in the blood-brain barrier (Roberts 
et al., 2008). The psychomotor retardation that has been reported in males affected by 
MCT8 mutations suggests that MCT8 is critical for CNS development and it is postulated 
that this is associated with inadequate supply of THs to the developing brain (Biebermann 
et al., 2005, Dumitrescu et al., 2004, Friesema et al., 2004, Holden et al., 2005, 
Maranduba et al., 2006, Schwartz et al., 2005). 
Deiodinase enzymes are also thought to play a role in TH availability to the fetal 
brain. Previous studies of deiodinases in human fetal cerebral cortex during the first and 
second trimesters of pregnancy showed that whilst the mRNA expression of D1 was 
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variable across gestation and D1 activity was undetectable, D2 mRNA and activity were 
present from 7-8 weeks of gestation and they peaked at 15-16 weeks (Chan et al., 2002). 
D3 mRNA expression and enzymatic activity were detected from early first trimester. The 
D3 activity detected in human fetal cortex was significantly greater than that in adult 
cortex, indicating the importance of this mechanism for the local regulation of T3 levels to 
protect the developing fetal brain from excessive T3 supply. Kester et al. compared 
deiodinase activity in fetal brain samples from terminations of pregnancy (13 – 20 weeks 
of gestation) with neonatal brain samples from premature infants that died postnatally and 
they found that whilst D1 activity was undetectable, there was considerable D2 activity in 
the fetal cortex, which correlated positively with T4 levels (Kester et al., 2004). D3 
activity was found in the cerebellum, midbrain, basal ganglia, brain stem, spinal cord and 
hippocampus, whilst it was lower in the cerebral cortex, choroid plexus and germinal 
eminence regions of the brain. D3 activity decreased after midgestation and was inversely 
correlated with T3 levels in these tissues. These results suggest that the human fetal brain 
has the capacity to locally regulate the availability of T3 via expressing deiodinase 
enzymes. The spatial and temporal changes in the expression of deiodinases might protect 
brain regions from excessive T3 early in gestation. 
TH action within the developing human brain has been demonstrated by the 
presence of nuclear binding sites for T3 from week 10 of gestation with binding increasing 
with gestational age (Bernal and Pekonen, 1984). In a subsequent study, the mRNA 
expression of TR isoforms, TRα1, TRα2 and TRβ1, in first trimester fetal brains was 
demonstrated from as early as week 8 of gestation (Iskaros et al., 2000). Our group has 
reported the presence of TRα1, TRα2, TRβ1 and TRβ2 mRNA in the fetal brain from 
week 7 of human pregnancy (Chan et al., 2002, Kilby et al., 2000). The protein 
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expression of all TR isoforms was most predominant in the pyramidal neurons of the 
cerebral cortex and the Purkinje cells of the cerebellum, indicating that these cell types are 
probably the targets of TH action within the fetal brain. 
1.3.3 Importance of THs for placental development 
A well functioning placenta is essential for normal fetal development, which is 
dependent on the placental-mediated transport of nutrients from the maternal to the fetal 
circulation and on the release of endocrine factors from the placenta (Malassine et al., 
2003). There is evidence that in addition to facilitating transplacental TH transport, the 
human placenta is a target organ for TH action and it has been postulated that the placenta 
is sensitive to the actions of TH for the regulation of its metabolism, differentiation and 
development. This hypothesis is supported by the association of maternal hyperthyroidism 
and hypothyroidism with pregnancy complications, including reduced birth weight, 
IUGR, pre-eclampsia, placental abruption, preterm delivery and spontaneous abortion 
(Davis, 1998; Idris, 2005; Casey, 2005; Blazer, 2003; Luewan, 2010; Pillar, 2010; 
Mestman, 2004). Studies using hypothyroid animal models have provided further 
evidence for the importance of THs in placental development. In rats, maternal 
hypothyroidism resulted in impaired reproduction and IUGR (Kumar and Chaudhuri, 
1989). In similar studies by Pickard et al., although maternal hypothyroxinaemia did not 
consistently affect rat placental development, it resulted in reduced cytosolic protein 
concentration at E15.5 and reduced total placental protein concentration at E19.5 with no 
effect on placental weight (Pickard et al., 1993). 
The hypothesis that THs affect trophoblast behaviour was subsequently confirmed 
by in vitro studies. Maruo et al investigated the effect of T3 and T4 treatment on 
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trophoblast behaviour using explants from early pregnancy and term placentae. Treatment 
with T4 or T3 caused an increase in the secretion of progesterone, estradiol-17β, hCGα, 
hCGβ and hPL by early placenta explants. In contrast, term placenta explants did not 
respond to TH treatment with increased endocrine activity, indicating that TH may play a 
role in the regulation of trophoblast differentiation and endocrine activity in early but not 
late pregnancy (Maruo et al., 1991). Treatment of EVTs isolated from first trimester 
placentae with T3 suppressed apoptosis via downregulating the expression of Fas and Fas 
ligand (Laoag-Fernandez et al., 2004) and promoted invasion by EVTs (Oki et al., 2004). 
These data suggest that the optimal level of TH may be essential in regulating endocrine 
activity, trophoblast differentiation and EVT invasion in early pregnancy. 
It has also been suggested that TH acts in synergy with epidermal growth factor 
(EGF) to regulate placental growth and function. Treatment of first trimester placental 
explants with T3 resulted in increased EGF secretion (Maruo et al., 1995, Matsuo et al., 
1993). On the other hand, EGF increased D2 transcription and activity in the 
choriocarcinoma cell line, JEG-3, indicating that EGF has the potential to regulate T4 
conversion to T3 by D2. Our group investigated the synergistic effects of EGF and T3 on 
the function of CTs isolated from term placenta, JEG-3s and the EVT-like cell line, 
SGHPL-4. Treatment with either T3 or EGF or co-treatment with T3 and EGF promoted 
cell survival and proliferation of CTs and JEG-3s. In contrast, in SGHPL-4s all treatments 
attenuated cell proliferation. EGF treatment increased invasion and motility of SGHPL-4s, 
whilst co-treatment with T3 attenuated invasion and enhanced cell motility (Barber et al., 
2005). These results indicate that THs affect trophoblast behaviour both directly and 
indirectly via interaction with other factors, such as EGF. 
Chapter 1  Introduction 
49 
As mentioned in section 1.3.1 the human placenta expresses TH transporters that 
facilitate TH uptake by trophoblasts, deiodinase enzymes that locally regulate the 
availability of the different TH forms and TRs that mediate the genomic effects of T3. 
There is currently limited information on the localisation of TH transporters in the 
placenta. The data available have demonstrated the presence of MCT8 in ST and CT cells 
throughout gestation. Furthermore, MCT8 protein was localised in interstitial and 
endovascular EVTs in early second trimester placental bed biopsies (Chan et al., 2006). 
Therefore, MCT8 could facilitate TH transport in all these cell types. LAT1 and 
OATP4A1 are preferentially located at the maternal-facing side of ST in term placentae 
and may thus have an important role in the uptake of THs from the maternal circulation, 
however no information is available to date on their expression in early pregnancy 
(Okamoto et al., 2002, Sato et al., 2003). The localisation of MCT10, LAT2 and 
OATP1A2 transporters in the human placenta has not been investigated to date. Further 
studies are necessary to determine the contribution of these TH transporters to TH 
transport in specific placental cells. 
Deiodinases 2 and 3 are present in the placenta throughout gestation and could 
locally modulate TH action. Immunohistochemistry has revealed that D2 and D3 proteins 
are present in both the CT and ST, with highest D2 expression in the CT and highest D3 
expression in the ST (Chan et al., 2003). Therefore, T3 action may be more important in 
the CT, where it may regulate cell differentiation. It has been shown that placental tissue 
has a high nuclear binding capacity for T3 (Ashitaka et al., 1988, Banovac et al., 1986). 
Our own study has demonstrated the expression of TRα1, TRα2 and TRβ1 within the 
nuclei of CTs, STs and stromal placental cells throughout gestation (Kilby et al., 1998). 
TRα1, TRα2 and TRβ1 are also found in EVTs, as demonstrated by 
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immunohistochemistry in first and second trimester placental bed biopsies and in 
expression studies in primary cultures of first trimester EVTs (Barber et al., 2005, Laoag-
Fernandez et al., 2004). These data indicate that the placenta expresses all the molecular 
apparatus required for TH action and metabolism. Further studies are required to better 
understand how these mechanisms regulate TH action within different placental cell 
types. 
1.3.4 Abnormal maternal TH status and pregnancy complications 
As discussed in section 1.1.2, IUGR is associated with increased risk of perinatal 
and neonatal mortality and morbidity and with life-long risk for cardiovascular disorder 
and diabetes in adult life. Thyroid status is one of several factors that have been postulated 
to play a critical role in the pathogenesis of IUGR. Maternal hyperthyroidism and overt 
and even subclinical maternal hypothyroidism have been associated with adverse 
pregnancy outcomes. There is increasing evidence that overt maternal hyperthyroidism is 
a risk factor for preterm delivery, low birth weight and IUGR (Luewan et al., 2010, 
Mestman, 2004, Pillar et al., 2010). Maternal hypothyroidism has been linked with 
increased incidence of placental abruption, preterm delivery and low birth weight (Davis 
et al., 1988). In cases of subclinical hypothyroidism that are characterised by elevated 
concentration of serum TSH but normal serum T4 concentration, even though the risk for 
low birth weight is lower compared with overt hypothyroidism, it is still elevated in 
comparison with the general population (Abalovich et al., 2002, Alvarez-Pedrerol et al., 
2009, Casey et al., 2005, Davis et al., 1988, Idris et al., 2005). Blazer et al. assessed the 
pregnancy outcome in cases where women were treated for hypothyroidism and found 
that birth weight was reduced in these pregnancies, indicating that close monitoring is 
required throughout pregnancy to ensure that treatment is adequate (Blazer et al., 2003). 
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The above evidence has prompted further investigations of TH status in fetuses 
affected by severe, early onset IUGR. Using percutaneous, in-utero fetal blood sampling 
our group has determined that the serum concentrations of free T4 and free T3 are lower in 
fetuses affected by IUGR compared with matched controls, while there is no difference in 
serum TSH levels (Kilby et al., 1998). As discussed in section 1.3.2, fetal development is 
sensitive to THs, thus changes in the concentration of circulating THs in fetuses affected 
by IUGR may contribute to the increased risk of adverse pregnancy outcomes associated 
with IUGR. The THs that are present in the fetal circulation at term originate from both 
fetal TH production and from transplacental transport from the maternal circulation. 
Therefore, reduced concentration of free T4 and free T3 in the fetal circulation with IUGR 
may be a result of either inefficient transplacental transport of maternal THs to the fetal 
circulation or inadequate production of THs from the fetal thyroid. Furthermore, changes 
in the metabolism of THs by deiodinase enzymes during their passage through the 
placenta or in fetal tissues, could also account for the altered concentrations of free T4 and 
free T3 in the fetal circulation. 
Studies in placentae from normal pregnancies and pregnancies complicated by 
severe IUGR indicate that both TH action within the placenta and transplacental TH 
transport may be altered with IUGR. Even though there were no differences at the mRNA 
level, the protein expression of TRα1, TRα2 and TRβ1 was increased in IUGR placentae 
(Kilby et al., 1998). It is postulated that changes in the expression of TRs may alter TH 
action within trophoblasts, and thus affect trophoblast function, which as discussed in the 
previous section is responsive to THs. Altered TH action may thus contribute to the 
reduced placental weight and altered placental morphology observed in IUGR 
pregnancies (see section 1.1.2). Furthermore, increased T3 binding to TRs within the 
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nucleus of trophoblast cells may decrease the amount of T3 available for efflux to the fetal 
circulation and thus contribute to the lower TH circulating levels in IUGR fetuses.  
Comparisons of the mRNA expression and activity of the deiodinase enzymes D2 
and D3 in human placentae from IUGR and normal pregnancies of similar gestational 
ages revealed no significant differences (Chan et al., 2003). Furthermore, treatment of 
CTs isolated from normal term placentae with 10 nM or less T3 did not affect D2 and D3 
mRNA expression. This evidence suggests that unlike other tissues, like fetal brain, where 
increased D2 activity may compensate for low TH levels (Bianco et al., 2002), the 
placenta cannot compensate for decreased THs in the fetal circulation by modulating the 
expression of deiodinases. In contrast, the placental expression of the TH transporter 
MCT8 is increased in IUGR pregnancies compared with gestationally-matched controls 
and it is postulated that increased MCT8 expression in the IUGR placenta may be a 
compensatory mechanism for the reduced TH levels in the fetal circulation (Chan et al., 
2006). Better understanding of transplacental TH transport in normal and IUGR 
pregnancies requires the assessment of the expression of all the TH transporters expressed 
in the human placenta in normal and IUGR pregnancies. This information would help to 
assess the possibility that changes in TH transporter expression in the placenta may 
contribute to the reduced TH levels in the circulation of fetuses affected by IUGR. 
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1.4 Monocarboxylate transporter 8 
Transplacental transport of THs is important for both fetal and placental 
development. However, there is limited information about the mechanisms that may 
regulate TH transport in the human placenta, including the expression of TH transporters. 
Of all the TH transporters reported to date, MCT8 has received special interest following 
reports of mutations of the MCT8 gene that are associated with X-linked severe 
neurodevelopmental disorders in affected males, suggesting that MCT8 has an essential 
role in the developing fetal brain. 
1.4.1 Expression 
The gene encoding human MCT8 is located on the X-chromosome (Xq13.2) and is 
subject to X-chromosome inactivation (Lafreniere et al., 1994). The human MCT8 mRNA 
contains two alternative translation start sites at positions 167 and 389 resulting at the 
production of a protein of either 613 or 659 amino acids (Friesema et al., 2006, Lafreniere 
et al., 1994). Kinne et al. have shown that human cell lines express both transcripts in 
vitro (Kinne et al., 2009). In contrast, rodent species express the shorter form of the 
MCT8 protein (Friesema et al., 2006). The functional characteristics of the short and long 
forms of human MCT8 protein have not been compared to date. 
MCT8 is widely expressed. Lafreniere et al. detected MCT8 mRNA in human 
brain, liver, placenta, heart, lung and kidneys (Lafreniere et al., 1994). The expression of 
MCT8 mRNA and protein in the brain was confirmed by Roberts et al., who 
demonstrated that MCT8 is expressed in cerebral microvessels in human, mouse and rat, 
indicating that MCT8 may play a role in the transport of THs across the blood-brain 
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barrier (Roberts et al., 2008). Furthermore, the expression of MCT8 mRNA and protein in 
the human placenta throughout gestation suggests that MCT8 contributes to transplacental 
TH transport (Chan et al., 2006). Friesema et al. demonstrated the expression of MCT8 
protein in rat brain, liver, kidney and heart (Friesema et al., 2003) and Capelo et al. 
demonstrated the expression of MCT8 mRNA in femurs of mouse fetuses both prenatally 
and postnatally, suggesting a role for MCT8 during bone development (Capelo et al., 
2009). 
1.4.2 TH transport characteristics 
The ability of MCT8 for uptake of THs was first demonstrated by transport studies 
in Xenopus oocytes transfected with rat MCT8 and the calculated Km values were 4 µM 
for T3, 4.7 µM for T4, and 2.2 µM for rT3 (Friesema et al., 2003). Furthermore, it was 
shown that MCT8 does not transport the sulphated forms of T4. In a subsequent study, the 
Km value of human MCT8 transfected in MDCK1 cells for T3 was calculated as 0.86 µM 
(Kinne et al., 2009). Although the two studies were performed in different systems, these 
results indicate that human MCT8 is a more potent transporter for T3 than rat MCT8. The 
study by Friesema et al. also demonstrated that transport of T4 was strongly inhibited by 
L-T4, D-T4, L-T3, D-T3, Triac, BrAcT3 and BSP, whilst T3 uptake was less affected by 
those molecules (Friesema et al., 2003). Transport of T3 and T4 were temperature-
dependent and whilst T3 transport was Na+-independent, T4 transport was slightly 
inhibited in the absence of Na+. The ability of MCT8 to transport amino acids or 
monocarboxylates was tested using leucine, phenylalanine, tryptophan, tyrosine and 
lactate and it was shown that MCT8 does not transport these compounds. The function of 
human MCT8 as a TH transporter was further confirmed by transport studies in COS1 and 
JEG-3 cells transfected with human MCT8 (Friesema et al., 2006). In a subsequent study, 
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it was shown that in addition to mediating uptake of THs, MCT8 also facilitates TH efflux 
(Friesema et al., 2008). 
1.4.3 Mutations 
Mutations of the MCT8 gene have been reported in over 30 unrelated families 
around the world (Figure 1-10). Friesema et al. and Dumitrescu et al. first identified 
MCT8 mutations in the genome of males affected by severe neurological and 
developmental disorder (Dumitrescu et al., 2004, Friesema et al., 2004). The affected 
patients displayed severe mental retardation, lack of speech, rudimentary communication 
skills, feeding problems and inability to sit, crawl or stand. The patients also demonstrated 
altered thyroid status with low total and free T4 and high total and free T3, whilst the 
concentration of TSH ranged from normal to slightly elevated. Due to the location of the 
MCT8 gene on the X chromosome, males that inherit the mutation from their mothers that 
are heterozygous for the mutation display a severe phenotype. In contrast, heterozygous 
female carriers of the mutation in these families had a milder thyroid phenotype with low 
to normal total and free T4, normal to high total and free T3 and normal TSH and 
displayed no neurodevelopmental abnormalities. Several different mutations of the MCT8 
gene were subsequently reported in male patients affected by neurodevelopmental 
abnormalities including paroxysmal kinesigenic dyskinesias and Allan-Herndon-Dudley 
syndrome (Biebermann et al., 2005, Brockmann et al., 2005, Frints et al., 2008, Fuchs et 
al., 2009, Holden et al., 2005, Jansen et al., 2007, Jansen et al., 2008, Kinne et al., 2009, 
Maranduba et al., 2006, Namba et al., 2008, Schwartz et al., 2005, Visser et al., 2009). 
Furthermore, Frints et al. identified a female patient affected by Allan-Herndon-Dudley 
syndrome due to a chromosomal translocation affecting the MCT8 gene accompanied by 
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non-random inactivation of the normal X-chromosome that resulted in loss of MCT8 
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1.4.4 Functional characteristics of wild-type and mutant MCT8 proteins 
The identification of several mutations in male patients displaying 
neurodevelopmental delay revealed variations in the severity of the phenotype. Whilst 
some mutations (L512P, V235M, S448X, insI189, delF230) resulted in inability to stand, 
walk or speak, patients affected by other mutations (L434W, L568P, S194F) could walk 
independently and in some cases developed some dysarthric speech (Dumitrescu et al., 
2004, Jansen et al., 2008). This prompted the investigation of the functional 
characteristics of different MCT8 mutants. Of the MCT8 mutants tested so far A150V, 
A224V, L471P, R245X, delF230, V235M, S448X and insI189 demonstrated no residual 
T3 transport when transfected in MCT8-null cell lines, whilst mutants 1834delC, R271H, 
L434W, L568P and S194F demonstrated residual T3 transport (Biebermann et al., 2005, 
James et al., 2009, Jansen et al., 2007, Jansen et al., 2008, Maranduba et al., 2006). 
Immunohistochemistry revealed changes in the subcellular localisation of the different 
mutants. Wild-type MCT8 protein was found predominantly at the plasma membrane 
consistent with its transporter function. However, mutants A150V, V235M, insI189, 
delF230 and L471P were instead retained in the cytoplasm (Biebermann et al., 2005, 
James et al., 2009, Jansen et al., 2008). Mutants L434W, L568P and S194F were found 
predominantly in the cytoplasm but were also detected in the plasma membrane (Jansen et 
al., 2008). Protein stability was also found to differ between different mutated forms of 
MCT8. When transfected in MCT8-null cell lines, mutants A224V, R271H, L434W and 
S194F were highly expressed, whilst mutants L471P, delF230, R245X, V235M, L568P 
and insI189 showed little protein expression and S448X was undetectable (Jansen et al., 
2007, Jansen et al., 2008). These results demonstrate that the MCT8 mutations tested 
result in complete or partial loss of MCT8 transport function, which is often associated 
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with impaired protein stability and impaired localisation of the mutant protein to the 
plasma membrane. Furthermore, there is a correlation between the functional 
characteristics of mutated MCT8 proteins and the severity of the phenotype in patients 
affected by these mutations. In a subsequent study, Kinne et al. transfected MCT8 
mutants in different cell lines and reported that the protein stability and membrane 
translocation of MCT8 mutants was different depending on the cell line they were 
expressed in, thus raising the possibility that the function of MCT8 mutants in vivo may 
differ in different cell types (Kinne et al., 2009). 
Further in vitro studies have assessed the function of MCT8 in neuronal cells. 
Sugiura et al. assessed the role of MCT8 in the differentiation of mouse embryonic stem 
cells (ES) to neural progenitors and they demonstrated that the expression of MCT8 
increased with differentiation (Sugiura et al., 2007). Furthermore, when MCT8 was 
transfected in ES cells, the expression of neural stem cell markers, SOX-1 and MAP-2 
was sustained for longer compared with cells transfected with an empty vector. However, 
even though TH accelerates the differentiation of neural stem cells to oligodendrocytes, 
transfection with MCT8 did not produce a similar effect. James et al. assessed the role of 
MCT8 in N-Tera2 cells, a cell line that has characteristics of central nervous system 
precursors and found that even though transfection with wild-type MCT8 did not affect 
apoptosis or ER stress, it reduced cell proliferation, whilst the L471P MCT8 mutant had 
no effect on cell number (James et al., 2009). Interestingly, this effect was demonstrated 
both in the absence and in the presence of T3 and it was confirmed in the choriocarcinoma 
cell line JEG-3 that has no endogenous expression of MCT8 or functional TRs. These 
results demonstrate that MCT8 affects cell proliferation via T3-independent mechanisms 
and suggest that MCT8 has an additional role apart from TH transport. 
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There is limited information concerning the regulation of MCT8 expression. 
Capelo et al. demonstrated that MCT8 mRNA in the osteoblastic cell line, MC3T3-E1, 
decreased following treatment with T3, suggesting that the expression of MCT8 may be 
regulated to maintain optimal concentration of intracellular T3 (Capelo et al., 2009). 
However, this observation has not been confirmed in other cell types to date. MCT8 
contains a PEST domain at the N-terminus. PEST domains are associated with rapid 
protein degradation (Rogers et al., 1986). However, in vitro studies suggest that although 
MCT8 protein is a target for the ubiquitin-proteasome pathway, it is not subject to rapid 
degradation (Jansen, 2008). 
Other members of the MCT family function as heterodimers with ancillary 
proteins, such as embigin, basigin and neuroplastin. Even though MCT8 does not 
associate with these proteins, transfected MCT8 forms homodimers and tetramers that are 
detected at 120 kDa, 250 kDa by Western immunoblotting (Visser et al., 2009). 
Biebermann et al. demonstrated the ability of both wild-type MCT8 and of MCT8 A150V 
mutant to form homodimers and to dimerise with each other, indicating that the A150V 
mutation does not affect the ability of MCT8 to form dimers (Biebermann et al., 2005). 
Visser et al. subsequently showed that deletion of the transmembrane domains 4-6 or 
individual mutations of cysteine residues to alanine do not affect MCT8 
homodimerisation (Visser et al., 2009). The occurrence of MCT8 homodimers has not 
been demonstrated in cells or tissues expressing endogenous MCT8 to date. Furthermore, 
the implications of MCT8 homodimerisation on transport function have not been 
investigated. 
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1.4.5 MCT8 knockout mice 
The clinical observations in male patients with MCT8 mutations demonstrate the 
importance of MCT8 for the development of the CNS. In the mouse, the expression of 
MCT8 mRNA was localised in different brain regions by in situ hybridisation including 
the cerebral cortex, basal ganglia, amygdala, olfactory bulb, hippocampus, hypothalamus, 
choroid plexus, median eminence and cerebellum (Heuer et al., 2005). There are 
conflicting reports on the expression of MCT8 at the blood-brain barrier, where it could 
play a role in the supply of THs to the brain. Whilst Roberts et al. detected MCT8 mRNA 
and protein in cerebral microvessels in human, rat and mouse, Heuer et al. detected only 
limited expression of MCT8 mRNA in blood vessels in sections from mouse brain (Heuer 
et al., 2005, Roberts et al., 2008). The detection of MCT8 in murine neurons led to the 
hypothesis that MCT8 has a role in the uptake of T3 by neurons (Heuer et al., 2005, Wirth 
et al., 2009). Dumitrescu et al. and Trajkovic et al. independently generated MCT8 
knockout mouse models to further determine the role of MCT8 in brain development 
(Dumitrescu et al., 2006, Trajkovic et al., 2007). 
In contrast to the adverse neurodevelopmental phenotype observed in human 
patients affected by MCT8 mutations that result in loss of MCT8 function, MCT8 knock-
out mice developed normally and were indistinguishable from their wild-type or 
heterozygous littermates with no differences in postnatal growth rate, brain weight, 
fertility or reproduction (Dumitrescu et al., 2006, Trajkovic et al., 2007). However, 
similar to patients affected by MCT8 mutations, MCT8 knockout mice had altered TH 
status with decreased serum T4 and increased T3 (Dumitrescu et al., 2006, Trajkovic et al., 
2007). Investigation of TH status in different organs revealed that whilst the brain of 
MCT8-null animals was in a hypothyroid state, the liver and kidneys of these animals 
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were in a hyperthyroid state (Dumitrescu et al., 2006, Trajkovic et al., 2007, Trajkovic-
Arsic et al., 2009). Furthermore, injection with [125I]-T4 or [125I]-T3 demonstrated that 
whilst accumulation of T4 in the brain of MCT8-null mice was not altered, T3 
accumulation was severely impaired. This was in contrast to observations in the liver 
where there was no effect on intracellular accumulation of THs (Trajkovic et al., 2007). 
D2 activity was upregulated and D3 activity was downregulated in the CNS of MCT8-
null mice possibly reflecting a compensatory mechanism in response to the low 
concentration of THs. However, these changes they were not sufficient to restore normal 
T3 availability (Trajkovic et al., 2007). These observations suggest that whereas MCT8 
may not have an important role in TH transport in the liver, it is essential in facilitating T3 
entry in the murine brain. In addition, the lack of change in the level of TSH in spite of 
the increased serum T3 in MCT8-null mice suggests that the pituitary is resistant to T3 
possibly due to the impaired T3 entry to the brain (Trajkovic et al., 2007). 
The difference in brain development between mice and humans could explain the 
absence of a neurodevelopmental phenotype in MCT8-null mice. In addition, other TH 
transporters may compensate for the lack of MCT8 in mice. Wirth et al. performed a 
detailed immunohistochemical neurological and behavioural screen of MCT8-deficient 
mice and reported that knockout of MCT8 expression does not alter brain histogenesis 
and is not associated with differences in reflexes, locomotion, grip strength or movement 
co-ordination (Wirth et al., 2009). However, MCT8-null mice developed decreased 
anxiety-related behaviour, hyperalgesia-related behaviour and increased latency to 
grooming. T3 uptake studies in cultures of neurons from MCT8 knockout and wild-type 
mice demonstrated that even thought T3 uptake was significantly decreased in MCT8-null 
neurons, it was not completely diminished suggesting the expression of TH transporters in 
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addition to MCT8 in mouse neurons. The authors assessed the expression of MCT10, 
OATPs and LATs and they reported that LAT2 is co-expressed with MCT8 in mouse 
neurons, but not in human developing neurons (Wirth et al., 2009). Therefore, in mice, 
LAT2-mediated transport of T3 to developing neurons may partially compensate for the 
absence of MCT8 and may partly explain the absence of a severe neurological phenotype 
in MCT8-deficient mice. Furthermore, there is evidence that OATP1C1 is expressed in 
mouse but not human cerebral microvessels suggesting that it could compensate for the 
lack of MCT8 in MCT8-deficient mice (Roberts et al., 2008). 
1.4.6 Implications for transplacental TH transport 
As discussed in section 1.3.1, MCT8 is expressed in the placenta from week 6 of 
gestation, suggesting an important role for the transport of maternal THs to the developing 
fetus throughout gestation (Chan et al., 2006). Furthermore, the expression of MCT8 is 
increased in human placentae from pregnancies complicated by severe IUGR. Assessment 
of the functional role of MCT8 in the human placenta is necessary to elucidate its 
importance for transplacental TH transport and its effects on placental cells. Even though 
the intrauterine growth, as assessed by birth weights, of fetuses affected by MCT8 
mutations is normal (Fuchs et al., 2009, Namba et al., 2008, Schwartz et al., 2005), the 
possibility that transplacental transport of THs is altered in these pregnancies cannot be 
excluded. Such alterations could further affect fetal serum levels of THs and the 
development and maturation of the CNS and other organs. 
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1.5 Aims and hypothesis 
The importance of maternal THs for fetal development is well established. 
However, the mechanisms that regulate transplacental transport of maternal THs in 
normal pregnancies and in pregnancies complicated by IUGR are not well understood. 
Furthermore, there is increasing evidence that THs affect placental development. 
Therefore, TH transporters are likely to play an important role in regulating the supply of 
maternal THs to the fetal circulation as well as to placental cells. 
We hypothesise that the co-ordination of the expression of TH transporters in the 
placenta throughout gestation is important for the regulation of transplacental transport of 
maternal THs and that changes in the placental expression of TH transporters in 
pregnancies complicated by IUGR may affect the supply of maternal THs to the fetal 
circulation. The reports that there is altered expression of the TH transporter MCT8 and of 
TRs in placentae from IUGR pregnancies led to the hypothesis that the effects of T3 on 
trophoblast cells may differ between normal and IUGR pregnancies. Furthermore, we 
hypothesise that the TH transporter MCT8 is likely to have an important role in placental 
function through the facilitation of the effects of THs on trophoblast cells. 
The aims of this thesis were: 
• To describe the expression of TH transporters in the human placenta 
throughout gestation and compare their expression between uncomplicated pregnancies 
and pregnancies complicated by IUGR. 
• To assess the impact of TH on CT cells from normal and IUGR 
pregnancies and to compare TH transport by these cells. 
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• To investigate the function of the TH transporter MCT8 in placental cells 
in vitro using invasive EVT-like cells and primary cultures of CTs from term placentae. 
• To assess the role of MCT8 in placental development and fetal growth in 
vivo using the MCT8 knockout mouse model. 
Chapter 2: Expression of Thyroid Hormone Transporters in 
the Human Placenta across Gestation and Changes with 
Intrauterine Growth Restriction 
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2.1 Introduction 
It is well known that THs are essential for normal fetal growth and development, 
particularly for the development of the CNS (Haddow et al., 1999, Pop et al., 2003, Pop et 
al., 1999). Maternal THs are present in human embryonic cavities since the first trimester 
of pregnancy (Calvo et al., 2002, Calvo et al., 1990, Contempre et al., 1993, Thorpe-
Beeston et al., 1991, Vulsma et al., 1989). Before the onset of fetal TH production at 
week 14 of human pregnancy, maternal THs are the only source of THs in the fetal 
circulation (Morreale de Escobar et al., 2004). There is ongoing fetal demand for maternal 
TH supply throughout pregnancy and it is estimated that maternal T4 comprises 30% of 
the total circulating T4 present in the fetus at term (Chan et al., 2009). 
In addition, it is believed that THs are important for placental development. The 
human placenta expresses the TR isoforms, TRα1, TRα2 and TRβ1, indicating that it is a 
target organ for TH action (Kilby et al., 2005). In vitro, THs promote the invasive 
capacity of primary EVTs and EVT-like cell lines and down-regulate apoptosis in primary 
EVTs (Barber et al., 2005, Canettieri et al., 2008, Laoag-Fernandez et al., 2004, Maruo et 
al., 1991, Maruo et al., 1995, Matsuo et al., 1993, Oki et al., 2004). THs may therefore 
play a role in the regulation of trophoblast invasion and maternal spiral artery 
remodelling. Furthermore, THs increase the endocrine activity of explants from first 
trimester placentae (Maruo et al., 1991). 
Abnormal maternal TH status has been linked with increased risk for pregnancy 
complications associated with malplacentation, such as IUGR (Blazer et al., 2003, Casey 
et al., 2005, Davis et al., 1988, Idris et al., 2005, LaFranchi et al., 2005, Luewan et al., 
2010, Mestman, 2004, Pillar et al., 2010). In IUGR fetuses, the serum levels of free T3 
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and free T4 are reduced (Kilby et al., 1998). Furthermore, there is increased mRNA and 
protein expression of the TH transporter MCT8 in biopsies from IUGR placentae 
compared with gestationally matched controls (Chan et al., 2006). These findings suggest 
that transplacental TH transport may be altered in IUGR pregnancies. 
Therefore, there is a necessity for an efficient TH transport system in the placenta 
to facilitate the uptake of THs from the maternal circulation and their efflux into the fetal 
circulation throughout pregnancy. Indeed, a range of TH transporters have been identified 
in the human placenta to date. These are MCT8 (Chan et al., 2006), MCT10 (Park et al., 
2005), LAT1 (Okamoto et al., 2002), LAT2 (Kudo and Boyd, 2001), OATP1A2 (Patel et 
al., 2003) and OATP4A1 (Briz et al., 2003, Patel et al., 2003, Sato et al., 2003). However, 
there is limited information about the expression of these transporters in the placenta 
throughout gestation. This study aims to describe the ontogeny of these TH transporters in 
a large cohort of placental samples ranging from week six of pregnancy until term and to 
compare their expression between samples from IUGR pregnancies and gestationally 
matched controls. 
Chapter 2  TH transporters in human placenta 
68 
2.2 Materials and Methods 
All chemicals used in this thesis were obtained from Sigma-Aldrich (Dorset, UK), 
unless otherwise stated. 
2.2.1 Tissues 
This study had approval of the Local Research Ethics Committee (South 
Birmingham) and the Research and Development Committee of the Birmingham 
Women’s Hospital. 
Placental biopsies were collected from 110 normal placental samples. The samples 
were grouped as follows. The first group was from 6 to 10 weeks of gestation, which is 
before the oxygen level in the placenta increases (n=39). The second group ranged from 
11 to 14 weeks of gestation, which is before the onset of TH production by the fetus 
(n=18). The third group was from 15 to 20 weeks (n=4). Samples from 27 to 34 weeks are 
from cases that had to be delivered at the early third trimester (n=9). The last group 
consisted of samples obtained at 37 to 41 weeks of pregnancy, for cases that were 
delivered at term (n=40). Samples from 6 to 20 weeks were collected following surgical 
termination of pregnancy for reasons other than fetal abnormality (in accordance with the 
Polkinghorne report and the Human Tissue Act). The gestational ages of the pregnancies 
were determined by ultrasound scan in the first trimester of pregnancy. The normal early 
third trimester group (27-34 weeks) consisted of samples obtained from placentae of 
appropriately grown for gestational age fetuses, which were collected following 
emergency caesarean section without labouring for placenta praevia (n=3), maternal 
tumours (n=3) or prelabour rupture of membranes (with no clinical evidence of infection) 
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with a breech presentation (n=3). The normal late third trimester group (37-41 weeks) 
consisted of placentae from normal pregnancies delivered by elective caesarean section 
for previous caesarean section, breech presentation or patient choice. 
Placental biopsies were also collected from 22 cases of severe IUGR in the 
absence of maternal hypertension. These were diagnosed prospectively using ultrasound 
and they had at least three of the following four characteristics: (i) ultrasound 
measurement of the fetal abdominal circumference of less than or equal to the third centile 
for gestation, (ii) abdominal circumference growth velocity of less than 1.5 standard 
deviations over 14 days, (iii) severe oligohydramnios (amniotic fluid index ≤ tenth centile 
for gestation) and (iv) absent end diastolic flow velocity in the umbilical artery Doppler 
velocity waveform measurements. None of the babies had known chromosomal or 
structural abnormalities. These criteria selected a severe and relatively homogenous 
phenotype. IUGR placenta were collected at 25-32 weeks (early onset IUGR; n=17) and 
at 37-38 weeks (late onset IUGR; n=5); all delivered by caesarean section without 
labouring. The early onset IUGR group represents cases at the more severe end of the 
IUGR disease spectrum with a 53% neonatal mortality in this cohort. 
Immediately after delivery of the placenta, multiple random biopsies were 
obtained by dissecting the placental tissue off the chorionic plate, ensuring that there was 
no residual membrane attached to the sample and washing in sterile saline solution 
(0.9%). The biopsies were snap-frozen in liquid nitrogen and stored at -80ºC until 
required for extraction of RNA or protein. 
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2.2.2 RNA extraction 
Approximately 100 mg of placental tissue were homogenised in 1 ml TRI reagent 
(Ambion, Warrington, UK) and total RNA was extracted following the manufacturer’s 
guidelines. Briefly, the homogenised samples were centrifuged for 10 minutes at 12,000 × 
g at 4°C and the supernatant was transferred to clean tubes. Chloroform (200 µl per ml of 
TRI reagent) was added. The solutions were mixed well, incubated at room temperature 
for 10 minutes and centrifuged for 10 minutes at 12,000 ×  g at 4°C. The aqueous phase 
containing the RNA was transferred to clean eppendorfs and 500 µl of isopropanol were 
added per ml of TRI reagent. The solutions were mixed, incubated at room temperature 
for 10 minutes and centrifuged for 10 minutes at 12,000 × g at 4°C. The supernatant was 
discarded and 1 ml of 75% ethanol was added to each pellet. Following vortexing, the 
samples were centrifuged for 5 minutes at 7,600 × g at 4°C, the supernatant was discarded 
and the pellet was left to air dry for approximately 10 minutes. The RNA pellet was 
dissolved in 100 µl of RNAse-free water and the samples were heated at 55°C for 15 
minutes to dissolve the RNA pellet. The absorbance of the samples at 260 (A260) and 280 
nm (A280) was measured using a spectrophotometer (Geneflow, UK). RNA purity was 
assessed by calculating the A260/A280 ratio, which was consistently between 1.7 and 2. The 
RNA concentration of the samples was calculated using the Beer-Lambert law; an A260 of 
1 corresponds to a RNA concentration of 40 µg/ml in a 1 cm pathlength. The RNA 
samples were stored at -80 °C. 
2.2.3 Reverse Transcription 
RNA was reverse transcribed using Avian Myeloblastosis Virus (AMV) reverse 
transcriptase (Promega, Madison WI, USA). Total RNA (1 µg) was made up to a total 
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volume of 9.75 µl using nuclease free water and it was incubated at 70°C for 10 minutes. 
Then it was mixed with 5 mM MgCl2, 1 × reverse transcription buffer (10 mM Tris-HCl; 
pH 9.0; 50 mM KCl; 0.1% Triton® X-100), 0.5 µg of random hexamer primers, 4 mM of 
deoxynucleotide triphosphate (dNTP) mix, 20 units of ribonuclease inhibitor (RNasin) 
and 15 units of AMV reverse transcriptase in a total reaction volume of 20 µl. The 
reactions were sequentially incubated at room temperature for 10 minutes, at 42°C for 60 
minutes, at 95°C for 5 minutes and at 4°C for 5 minutes. The samples were diluted 1:1 
with RNAse free water and were stored at -20°C. 
2.2.4 Design and validation of primer and probe sets for quantitative TaqMan 
polymerase chain reaction (PCR) 
Primers and probe for MCT8 had been previously designed and validated in our 
laboratory (Chan et al., 2006). Primers and probes for MCT10, LAT1, LAT2, CD98, 
OATP1A2 and OATP4A1 were designed using Primer Express v2.0 software (Applied 
Biosystems, Fostercity, CA, USA) (Table 2-1). All amplicons were crossing an exon-
exon boundary and each set was designed so that the sequence for either the probe or one 
of the primers spanned two adjacent exons. Primers were synthesised by Alta Bioscience 
(Birmingham, UK). TaqMan Probes were synthesised and modified with the fluorophore 
FAM at the 5’ end and the quencher TAMRA at the 3’ end (Eurogentec, Seraing, 
Belgium). Genomic amplification was excluded by comparing the amplification of cDNA 
with control reverse transcriptase reactions without AMV. 
The expression of the target gene was normalised to the expression of the 
housekeeping gene encoding the small subunit ribosomal RNA, 18S. The potential 
housekeeping genes 18S, TATA box-binding protein (TBP), succinate dehydrogenase 
Chapter 2  TH transporters in human placenta 
72 
complex, subunit A (SDHA) and cyclophilin were previously tested in our laboratory on a 
subset of placental samples to assess for stable expression both across gestation and 
between normal and IUGR placentae. Normfinder, a model-based approach was used to 
identifying the most stable housekeeping genes (Andersen et al., 2004) and 18S, TBP and 
SDHA were identified as the genes with the most stable expression, consistent with a 
report on quantitative RT-PCR analysis in human placenta (Patel et al., 2003). 18S was 
amplified using a predeveloped TaqMan assay containing a VIC-labelled probe and 
primers for 18S (Applied Biosystems). Validation experiments were carried out to 
determine if duplex reactions could be performed with amplification of the target gene 
and of the 18S control in the same tube. Serial dilutions of cDNA from term placental 
biopsies ranging between 12.5 and 75 ng per reaction were amplified using primer and 
probe sets for 18S and for the target gene in a duplex reaction. The Ct values (the cycle 
number at which logarithmic PCR plots cross a threshold line) for 18S and for the target 
gene were plotted against the cDNA concentration and a linear regression line was fitted. 
A difference of <0.1 between the gradients of the regression lines indicated that there was 
no interference between the two reactions and the two cDNAs could be detected in duplex 
reactions. 
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Table 2-1: Sequences of primers and probes for TaqMan PCR. 








































































All sequences are given in the 5’-3’ direction. Underlined base pairs correspond to 
boundaries between two adjacent exons. Basepairs (bp). 
2.2.5 Quantitative TaqMan PCR 
TaqMan PCR was carried out using the ABI PRISM 7500 Sequence Detection 
System (Applied Biosystems). cDNA (1 µl) was mixed with 22.5 pmoles of forward 
primer, 22.5 pmoles of reverse primer, 3.75 pmoles TaqMan probe, 1.25 µl of 18S 
predeveloped TaqMan Assay (Applied Biosystems) and 12.5 µl qPCR Mastermix Plus 
QuickGold Star (Eurogentec) in a total volume of 25 µl. All reactions were performed in 
duplicate. The PCR conditions were as follows. The samples were incubated at 50°C for 2 
minutes and then they were heated at 95°C for 10 minutes followed by 40 cycles of 15 
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seconds at 95°C and 1 minute at 60°C. Data were expressed as Ct values. Relative 
quantification of the expression of each gene was determined using the ΔCt method. For 
each sample fold changes in gene expression were calculated with the equation 2-ΔCt (ΔCt 
= sample Ct – calibrator Ct). The calibrator was determined for each gene as the sample 
with the highest expression. For each sample, the expression of the target gene was 
normalised to 18S to correct for differences in the efficiency of the reverse transcription. 
The mean gene expression for the normal term placenta samples was assigned the 
arbitrary value of 1. The relative mRNA expression for each sample compared with the 
mean for term placenta was calculated and these values were used for statistical analysis. 
2.2.6 Generation of MCT8 antisera 
Rabbit polyclonal antisera for human MCT8 (Ab4790; Sigma-Genosys, Suffolk, 
UK) were raised against a synthetic polypeptide conjugated to keyhole limpet 
hemocyanine comprising amino acids 79-92 (SQASEEAKGPWQEA) at the intracellular 
N terminus of the MCT8 protein. The antisera from final bleeds were affinity purified and 
their specificity was confirmed by Western immunoblotting using antibody solutions that 
were pre-incubated with and without the immunising peptide on whole cell protein 
extracted from human placenta or from MCT8-null JEG-3 choriocarcinoma cells 
transfected with either human MCT8 or the empty plasmid vector (VO). 
2.2.7 Protein extraction 
Approximately 100 mg of placental tissue from randomly selected samples from 
each group were homogenised in 1 ml RIPA buffer (pH 7.4; 50 mM Tris-HCl, 150 mM 
NaCl, 1% v/v Igepal CA-630, 6 mM sodium deoxycholate, 1 mM EDTA) containing 60 
µl/ml protease inhibitor cocktail (containing 4-(2-aminoethyl)benzenesulphonyl fluoride, 
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pepstatin A, E-64, bestatin, leupeptin and aprotinin). Protein concentration was 
determined using the colorimetric Bio-Rad Dc protein assay (Bio-Rad, Hertfordshire, 
UK). Protein standards of bovine serum albumin (BSA) in RIPA buffer were prepared at 
the following concentrations: 0, 0.25, 0.5, 0.75, 1 and 2 µg/µl. Equal amounts (5 µl) of 
each standard and sample were added to separate wells of a 96-well plate in duplicate 
followed by 25 µl of Reagent A and 200 µl of Reagent B. The samples were incubated at 
room temperature for 15 minutes and the absorbance at 690 nm was measured using a 
Victor3 multilabel counter (Perkin Elmer, Waltham, MA, USA). The standard curve that 
was produced from the BSA standards was used to determine the protein concentration of 
the samples. 
2.2.8  Western immunoblotting 
Protein samples (30 µg) were mixed with equal volumes of Laemmli buffer (Bio-
Rad) with dithiothreitol (DTT) at a final concentration of 175 mM. The samples were 
sonicated and incubated at room temperature for 1 hour. They were centrifuged at 13,000 
rpm for 10 minutes and loaded on electrophoresis gels made up with 10% (w/v) 
acrylamide resolving gel (7 ml) and 5% (w/v) acrylamide stacking gel (2.5 ml). The 
resolving gel consisted of 8% (w/v) acrylamide 0.2% (w/v) bis-acrylamide, 0.375 M Tris 
HCl, 3.5 mM sodium dodecyl sulphate (SDS), 4.4 mM ammonium persulphate (APS) and 
0.1% (v/v) N,N,N′,N′-Tetramethylethylenediamine (TEMED). The stacking gel consisted 
of 5% (w/v) acrylamide, 0.13% (w/v) bis-acrylamide, 0.2 M Tris HCl, 6.9 mM SDS, 8.7 
mM APS and 0.2% (v/v) TEMED. The gels were immersed in 1× running buffer (pH 8.3) 
containing 25 mM Tris base, 192 mM Glycine and 3.5 mM SDS in distilled water. The 
samples and 6 µl of protein standards (Dual Colour Marker; Bio-Rad) were allowed to 
migrate through the gels by electrophoresis at 70 volts for approximately half an hour and 
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then at 100 volts for approximately 1 hour. Following electrophoresis, the proteins were 
transferred to polyvinylidene fluoride (PVDF) membrane (GE Healthcare, St Giles, UK) 
using a wet system. The PVDF membrane was sequentially soaked in methanol, distilled 
water and transfer buffer (20% (v/v) methanol, 192 mM Glycine, and 25 mM Tris HCl in 
distilled water). Cassettes containing sponges, filter paper, the acrylamide gel and PVDF 
membrane were assembled in the transfer apparatus (Bio-Rad) and they were immersed in 
transfer buffer. The proteins were allowed to transfer to the PVDF membrane by applying 
current (360 Amps) for 1 hour. Following transfer the membranes were incubated for 
approximately 2 hours with 5% skimmed milk in Tris Buffered Saline with Tween (TBS-
T: 20 M Tris HCl pH 7.6, 0.14 M NaCl and 0.025% (v/v) Tween 80 in distilled water) in 
order to block non specific sites. The membranes were incubated overnight at 4°C with 
the primary antibody diluted in 5% skimmed milk in TBS-T. The information for the 
primary antibodies used can be found in Table 2-2. The following day the membranes 
were washed with TBS-T and were incubated for 1 hour at room temperature with 
secondary antibody conjugated to horseradish peroxidase (HRP) (Dako, Glostrup, 
Denmark) diluted 1 in 2,000 in 5% skimmed milk in TBS-T. Unbound antibody was 
removed by washing with TBS-T and antigen-antibody complexes were visualised using 
ECL+ chemiluminescence detection system (GE Healthcare). The membranes were put in 
a cassette with X-ray film (Genetic Research Instrumentation, Essex, UK) in the dark 
room and the film was developed using an X-ray film processor (Xograph, Imaging 
Systems, Gloucestershire, UK). The expression of β-actin was quantified to assess protein 
loading. The membranes were washed in TBS-T and were incubated for 1 hour with 
mouse antibody against human β-actin (Sigma-Aldrich) diluted 1 in 10,000. The 
membranes were washed with TBS-T and were incubated for 1 hour with rabbit anti-
mouse secondary antibody conjugated to horseradish peroxidase (Dako) diluted 1 in 
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2,000. The membranes were washed with TBS-T and the antigen-antibody complexes 
were visualised using SuperSignal West Substrate (Thermo Fisher Scientific, 
Cramlington, UK) on X-ray film. The expression of the protein of interest and of β-actin 
was quantified using the ImageJ software (U. S. National Institutes of Health, Bethesda, 
MD, USA) and the expression of the protein of interest was expressed as a ratio to the 
expression of β-actin. Protein extraction and detection by Western immunoblotting were 
carried out by Dr Laurence Loubière.  
2.2.9 Immunohistochemistry 
The experiments that are described in this section were carried out by Barbara 
Innes in Dr Judith Bulmer’s laboratory in Newcastle, UK. Formalin-fixed paraffin-
embedded sections (3 µm) of placental samples and placental bed biopsies were 
immunostained for MCT10, OATP1A2 and OATP4A1 using an avidin-biotin peroxidase 
technique (Vectastain Elite; Vector Laboratories, Peterborough, UK) (Barber et al., 2005, 
Chan et al., 2006). All reagents were prepared as per the kit instructions. Briefly, after 
dewaxing and rehydration the sections were processed in 0.1 M sodium citrate buffer (pH 
6.0) in a pressure cooker for 60 seconds for antigen retrieval following by incubation with 
1.6% hydrogen peroxide in methanol to block endogenous peroxidase activity. After 
washing in 0.1 M Tris/0.05 M saline (pH 7.6; TBS), the slides were overlaid with the 
supplied blocking serum, before incubation for 60 minutes at room temperature with 
primary antibody (details for antibody dilutions can be found in Table 2-2). Negative 
controls were performed for each sample by replacing the primary antibody with non-
immune serum. After washing in TBS, the sections were incubated with biotinylated 
secondary antibody, washed with TBS and incubated with avidin-biotin-peroxidase 
complex. Following washes in TBS, the reaction was developed by incubation in 3,3’-
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diaminobenzidine. Sections were lightly counterstained with Mayers haematoxylin, 
dehydrated, cleared and mounted in synthetic resin. 
Table 2-2: List of antibodies used for protein detection by Western immunoblotting (WB) 
and by immunohistochemistry (IHC). 
Protein Antibody source 
Species of 
immunised animal Dilution for WB Dilution for IHC 
MCT8 Designed and validated in our lab (Ab4790) Rabbit 1:500 Not applicable 
MCT10 Gift from Prof F Verrey (Ramadan et al., 2006) Rabbit 1:500 1:250 
LAT1 Gift from Dr P Taylor (Ritchie and Taylor, 2001) Rabbit 1:500 Not applicable 
CD98 Santa Cruz Biotechnology (C20: sc7095) Goat 1:250 Not applicable 
OATP1A2 Gift from Prof B Stieger (Huber et al., 2007) Rabbit 1 :500 1 :150 
OATP4A1 Gift from Prof B Stieger (Huber et al., 2007) Rabbit 1:500 1:300 
 
2.2.10 Statistical analysis 
Data were analysed using the Minitab® statistical software (version 15). Analysis 
of variance (ANOVA) was performed using the general linear model followed by Tukey 
all pairwise multiple comparison post-hoc tests to assess differences between individual 
groups and taking into account all variables present as appropriate, i.e. gestation and 
placental type (IUGR or normal). For the mRNA expression data presented in this 
chapter, the residuals (differences between the observed values and the predicted values 
by the general linear model) did not pass the normality test as determined using the 
Kolmogorov-Smirnov test and, thus, required log transformation prior to statistical 
analysis. 
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2.3 Results 
2.3.1 Validation of primer and probe sets 
At first, the newly designed primers and probes were validated to ensure that the 
expression of the target genes could be detected accurately in duplex reactions with the 
control gene 18S. 
Increasing concentrations of cDNA were amplified in multiplex reactions and the 
slope of the linear regression was calculated (Figure 2-1). The difference between the 
gradient of the regression line for 18S amplification and the gradient of the regression line 
for the amplification of each target cDNA was 0.07 for MCT10, 0.01 for LAT1 and 0.01 
for CD98. Therefore, the amplification of these molecules could be accurately detected in 
multiplex with 18S. The values obtained for LAT2, OATP1A2 and OATP4A1 were 0.44, 
0.29 and 0.71, respectively, indicating that 18S amplification may be interfering with the 
detection of these cDNAs. Therefore, the expression of these genes was assessed in 
singleplex reactions.  
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Figure 2-1: Validation of the efficiency of primers and probes for MCT10, CD98, LAT1, 
LAT2, OATP1A2 and OATP4A1 in duplex reactions with the control 18S. Ct values are 
plotted against the concentration of RNA used. RNA was extracted from term placenta 
tissue. The equation of the linear regression line is also shown. Results from one 
representative experiment are shown. The results were confirmed in experiments with two 
different samples. 
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2.3.2 Validation of the MCT8 antibody 
The specificity of the MCT8 antibody was tested using term placenta homogenates 
and lysates of the MCT8-null choriocarcinoma cell line JEG-3 (Friesema et al., 2006) 
transfected with the empty vector (VO) or with MCT8 as controls. In accordance with a 
previous study (Friesema et al., 2006), MCT8 migrated at approximately 60 kDa. This 
band disappeared following pre-incubation of the antibody with the blocking 
(immunising) peptide (Figure 2-2). 
 
2.3.3 MCT8 and MCT10 expression in the human placenta across gestation 
We assessed the relative mRNA expression of MCT8 and MCT10 in the human 
placenta from week 6 of gestation until term. The expression of both MCT8 and MCT10 
increased with gestation (P<0.001 for both) (Figure 2-3). The expression of MCT8 at 6-
10 weeks of gestation was 4-fold lower compared with term (P<0.001). At 11-14 weeks, 
MCT8 expression was 14-fold less than at term (P<0.001) and 10-fold less than at 27-34 
Figure 2-2: Validation of the MCT8 antibody. The specificity of the MCT8 
4790 polyclonal antibody was tested using MCT8-null JEG-3 cells 
transfected with either vector only (VO) or MCT8 and homogenates of 
term placenta tissue (Term PL). The samples were incubated with the 
MCT8 antibody pre-incubated with or without the blocking peptide (BP). 
Immunoreactivity for β-actin was used to assess protein loading. 
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weeks (P<0.01). At 15-20 weeks MCT8 expression was 22-fold less than at term 
(P<0.01). MCT10 expression at 6-10 weeks was 12-fold lower compared with term and 
16-fold lower compared with 27-34 weeks (P<0.001 for both). At 11-14 weeks of 
gestation, MCT10 expression was 8-fold lower compared with term (P<0.001) and 13-
fold lower compared with 27-34 weeks (P<0.01). At 15-20 weeks MCT10 expression was 
6-fold lower compared with term (P<0.05). 
 
Figure 2-3: Relative expression of mRNA encoding MCT8 (A) and MCT10 
(B) in the human placenta from 6 weeks of gestation until term. Gene 
expression is compared with the mean expression at term that was given an 
arbitrary value of 1. Overall ANOVA results are indicated by xxx P<0.001. 
Differences in expression between individual groups were assessed by Tukey 
post-hoc tests. Statistically significant differences in gene expression 
compared to term are indicated by * (P<0.05), ** (P<0.01) and *** 
(P<0.001). Statistically significant differences compared to the 27-34 weeks 
group are indicated by ++ (P<0.01) and +++ (P<0.001). Lines represent 
means ±SEM. The data were log-transformed prior to analysis. 
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The expression of MCT8 and MCT10 protein in the human placenta from week 8 
of gestation until term was assessed by Western immunoblotting (Figure 2-4 and Figure 
2-4). Bands representing MCT8 protein were detected at all gestational ages as a single 
band at approximately 60 kDa (Figure 2-4A). Relative quantification of the bands 
revealed that MCT8 protein expression increased with gestation (Figure 2-4B; P<0.001). 
Expression in the first trimester was 68% less than at term (P<0.001) and 23% less than in 
the second trimester (P<0.05). Expression in the second trimester was 22% less than at 
term (P<0.05). MCT10 protein was detected from week 10 of gestation until term as a 
single band at approximately 50 kDa (Figure 2-5A) and was increased with gestational 
age, as demonstrated by relative densitometry (Figure 2-5B; P<0.05). In the first trimester 
MCT10 expression was 47% less than at term (P<0.01). 
 
Figure 2-4: Western immunoblotting (A) and relative densitometry (B) for MCT8 on 
placental homogenates from week 8 of pregnancy until term. Bands representing MCT8 
were detected at approximately 60 kDa. Immunoblotting for β-actin on the same 
membrane was used to assess protein loading. The protein expression of MCT8 was 
quantified by relative densitometry and shown as a ratio to β -actin protein expression. 
Bars represent means ±SEM. Overall ANOVA results are indicated by xxx P<0.001. 
Statistically significant differences in protein quantification between groups assessed by 
Tukey post-hoc tests are indicated by *** (P<0.001) and * (P<0.05) when compared with 
term and by + (P<0.05) when compared with the 2nd trimester group. 
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We have also localised MCT10 protein in the human placenta using paraffin 
embedded sections from first trimester and third trimester villous placental biopsies and 
first trimester placental bed biopsies (Figure 2-6). Immunohistochemical analysis of first 
trimester biopsies indicated that MCT10 protein is present in both STs and CTs with more 
marked staining in the latter. Analysis of first trimester placental bed sections showed that 
MCT10 protein is also present in EVTs and decidual stroma. At term, MCT10 is mainly 
present in the ST cell layer. Throughout gestation there was also weak immunoreactivity 
within stromal cells of the villous placenta. 
Figure 2-5: Western immunoblotting (A) and relative densitometry (B) for MCT10 on 
placental homogenates from week 8 of pregnancy until term. Bands representing 
MCT10 were detected at approximately 50 kDa. Immunoblotting for β-actin on the 
same membrane was used to assess protein loading. The protein expression of MCT10 
was quantified by relative densitometry and shown as a ratio to β -actin protein 
expression. Bars represent means ±SEM. Overall ANOVA results are indicated by x 
(P<0.05). Statistically significant difference in protein quantification between the 1st 
trimester and the term groups assessed by Tukey post-hoc tests is indicated by ** 
(P<0.01). 
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2.3.4 LAT1, LAT2 and CD98 expression in the human placenta across gestation 
Overall, the mRNA expression of LAT1 and CD98 changed significantly with 
gestation (P<0.001 and P<0.05 respectively) (Figure 2-7A and C). The mRNA 
expression of LAT2 did not change with gestation (Figure 2-7B). The expression of 
LAT1 at 6-10 weeks, 11-14 weeks and 15-20 weeks was significantly lower than at term 
(2.5-fold; P<0.001, 3-fold; P<0.001 and 5-fold; P<0.01 respectively). Furthermore, the 
expression of LAT1 at 6-10 weeks and 11-14 weeks was significantly lower that at 27-34 
weeks (2.8-fold; P<0.05 and 3.6-fold; P<0.02 respectively). The expression of CD98 was 
3-fold lower at 11-14 weeks compared with term (P<0.05), but there was no difference at 
Figure 2-6: Localisation of MCT10 protein in the human placenta. Immunoreactivity for 
MCT10 in representative sections obtained from first trimester (A) and term (B) villi and 
from first trimester placental bed (C). Positive CTs are indicated by closed arrows, STs 
by arrowheads and EVTs by open arrows. 
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6-10 weeks compared with term, suggesting that CD98 mRNA expression reaches a nadir 
at 11-14 weeks. 
 
Figure 2-7: Relative expression of mRNA encoding LAT1 (A), LAT2 (B) and CD98 (C) in 
the human placenta from 6 weeks of gestation until term. Gene expression is compared 
with the mean expression at term that was given an arbitrary value of 1. Overall ANOVA 
results are indicated by xxx P<0.001 or x P<0.05. Differences in expression between 
individual groups were assessed by Tukey post-hoc tests. Statistically significant 
differences in gene expression compared to term are indicated by * (P<0.05), ** 
(P<0.01) and *** (P<0.001). Statistically significant differences compared to the 27-34 
weeks group are indicated by + (P<0.05) and ++ (P<0.01). Lines represent means 
±SEM. The data were log-transformed prior to analysis.
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The expression of LAT1 and CD98 proteins was determined by Western 
immunoblotting (Figure 2-8). Western immunoblotting experiments for LAT1 revealed 
the presence of a band representing the LAT1 monomer at approximately 30 kDa from 
week 32 of gestation. Western immunoblotting for CD98 revealed two bands at 
approximately 70 kDa and 100 kDa, probably corresponding to non-glycosylated and 
glycosylated forms of CD98 (Ritchie and Taylor, 2001). There was no significant 
difference in CD98 protein expression with gestational age (Figure 2-8B2). 
Figure 2-8: Western immunoblotting for LAT1 (A) and CD98 (B1) on placental 
homogenates from week 8 of pregnancy until term. Bands representing LAT1 
were detected at approximately 30 kDa. Bands for CD98 were detected at 
approximately 70 and 100 kDa. Immunoblotting for β-actin on the same 
membrane was used to assess protein loading. (B2) CD98 protein expression 
was quantified by relative densitometry and shown as a ratio to β-actin protein 
expression. Bars represent means ±SEM.  
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2.3.5 OATP1A2 and OATP4A1 expression in the human placenta across gestation 
Overall, the mRNA expression of OATP1A2 and OATP4A1 changed significantly 
across gestation (P<0.05 and P<0.01, respectively) (Figure 2-9). The expression of 
OATP1A2 at 6-10 weeks was significantly lower than at term (1.8-fold; P<0.05). The 
expression of OATP4A1 was significantly lower than at term only at 11-14 weeks (5-fold; 
P<0.05) but not at 6-10 weeks, indicating that OATP4A1 expression is lowest at 11-14 
weeks. 
 
Figure 2-9: Relative expression of mRNA encoding OATP1A2 (A) and OATP4A1 
(B) in the human placenta from 6 weeks of gestation until term. Gene expression 
is compared with the mean expression at term that was given an arbitrary value 
of 1. Overall ANOVA results are indicated by x (P<0.05) and xx P<0.01. 
Differences in expression between individual groups were assessed by Tukey post-
hoc tests and statistically significant differences in gene expression compared to 
term are indicated by * (P<0.05). Lines represent means ±SEM. The data were 
log-transformed prior to analysis. 
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The presence of OATP1A2 and OATP4A1 protein in the human placenta was 
confirmed by Western immunoblotting. Both proteins were detected from week 8 of 
gestation until term (Figure 2-10 and Figure 2-11). Western immunoblotting for 
OATP1A2 revealed multiple bands between 60 and 85 kDa representing different 
glycosylated forms of the protein (Gao et al., 2000, Kullak-Ublick et al., 1997). 
OATP4A1 was detected as a single band at approximately 60 kDa (Kullak-Ublick et al., 
1995). There was no significant change in the protein expression of OATP1A2 or 
OATP4A1 with gestational age. 
 
Figure 2-10: Western immunoblotting (A) and relative densitometry (B) for OATP1A2 on 
placental homogenates from week 8 of pregnancy until term. Bands representing different 
glycosylation states of OATP1A2 were detected between 60 and 85 kDa. Immunoblotting 
for β-actin on the same membrane was used to assess protein loading. OATP1A2 protein 
expression was quantified by relative densitometry and shown as a ratio to β -actin 
protein expression. Bars represent means ±SEM.  
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OATP1A2 and OATP4A1 protein localisation was examined by 
immunohistochemistry (Figure 2-12). OATP1A2 protein was strongly detected in both 
villous CTs and STs in placental sections from first trimester and term biopsies. 
OATP1A2 protein was also present EVTs. In contrast to OATP1A2, 
immunohistochemistry for OATP4A1 protein revealed strong staining in STs but weak 
staining in CTs and EVTs. 
Figure 2-11: Western immunoblotting (A) and relative densitometry (B) for OATP4A1 
on placental homogenates from week 8 of pregnancy until term. OATP4A1 was 
detected as a single band at approximately 60 kDa. Immunoblotting for β-actin on the 
same membrane was used to assess protein loading. OATP4A1 protein expression was 
quantified by relative densitometry and shown as a ratio to β-actin protein expression. 
Bars represent means ±SEM.  
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Figure 2-12: Localisation of OATP1A2 (A, B and C) and OATP4A1 (D, E and F) protein 
in the human placenta. Immunoreactivity for OATP1A2 and OATP4A1 in representative 
sections obtained from first trimester (A and D) and term (B and E) villi and from first 
trimester placental bed (C and F). Positive CTs are indicated by closed arrows, STs by 
arrowheads and EVTs by open arrows. 
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2.3.6 Changes in the expression of TH transporters with IUGR 
Previous data suggest that the mRNA and protein expression of MCT8 in the 
human placenta is increased in IUGR pregnancies (Chan et al., 2006). We therefore 
assessed whether there were any changes in the placental expression of TH transporters in 
normal pregnancies and in pregnancies complicated by IUGR. We compared the 
expression of TH transporters in biopsies from placentae obtained immediately after 
delivery in the early third trimester (25-34 weeks) or at term (37-41 weeks). 
In contrast to the results obtained previously (Chan et al., 2006), in this expanded 
cohort there was no difference in the mRNA expression of MCT8 in normal compared 
with IUGR placentae. However, the expression of MCT8 protein was increased in early 
onset IUGR samples compared with gestationally matched normal controls (P<0.001; 
Figure 2-13). There was no difference in MCT8 protein expression between late onset 
IUGR samples and normal samples delivered at term. According to the overall ANOVA 
results, the mRNA expression of MCT10 was reduced with IUGR (P<0.01; Figure 
2-14A). However there were no statistically differences when the expression between 
individual groups was compared by Tukey post-hoc tests. Assessment of MCT10 protein 
expression by Western immunoblotting did not reveal any significant difference in the 
protein expression of MCT10 between normal and IUGR placental samples (Figure 
2-14B). The mRNA expression of OATP4A1 was different between normal and IUGR 
samples as determined by the overall ANOVA analysis (Figure 2-16B; P<0.05). 
However, no statistically significant differences were found when the mRNA expression 
of OATP4A1 between individual groups was compared by Tukey post-hoc tests. The 
mRNA expression of LAT1, LAT2, CD98 and OATP1A2 did not change significantly 
with IUGR (Figure 2-15 and Figure 2-16). 
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Figure 2-13: Changes in MCT8 expression with IUGR. (A) Relative expression of mRNA 
encoding MCT8 was assessed in placental samples from normal pregnancies and from 
pregnancies complicated by IUGR that were delivered in the early third trimester or at 
term. Gene expression is compared with the mean expression in normal term samples that 
was given an arbitrary vlaue of 1. Lines are representative of the mean ±SEM for each 
group. The data were log-transformed prior to analysis. (B1) Representative Western 
immunoblotting for MCT8 on randomly selected placental homogenates from normal and 
IUGR pregnancies delivered in the early third trimester or at term. A band representing 
MCT8 was detected at approximately 60 kDa. Immunoblotting for β-actin on the same 
membrane was used to assess protein loading. (B2) MCT8 protein expression was 
quantified by relative densitometry and shown as a ratio to β -actin protein expression. 
Bars represent means of four normal and four IUGR samples per gestation ±SEM. 
Statistically significant differences are indicated by *** (P<0.001).  
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Figure 2-14: Changes in MCT10 expression with IUGR. (A) Relative expression of 
mRNA encoding MCT10 was assessed in placental samples from normal pregnancies and 
from pregnancies complicated by IUGR that were delivered in the early third trimester or 
at term. Gene expression is compared with the mean expression in normal term samples 
that was given an arbitrary value of 1. Lines represent means ±SEM. Overall ANOVA 
results between normal and IUGR samples are indicated by xx P<0.01. The data were 
log-transformed prior to analysis. (B) Western immunoblotting for MCT10 on randomly 
selected placental homogenates from normal and IUGR pregnancies delivered in the 
early third trimester or at term. A band representing MCT10 was detected at 
approximately 50 kDa. Immunoblotting for β-actin on the same membrane was used to 
assess protein loading. 
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Figure 2-15: Changes in the mRNA expression of LAT1 (A), LAT2 (B) and CD98 (C) 
with IUGR. Relative expression of mRNA encoding LAT1, LAT2 and CD98 was 
assessed in placental samples from normal pregnancies and from pregnancies 
complicated by IUGR that were delivered in the early third trimester or at term. Gene 
expression is compared with the mean expression in normal term samples that was 
given an arbitrary value of 1. Lines represent means ±SEM. The data were log-
transformed prior to analysis.  
Figure 2-16: Changes in the mRNA expression of OATP1A2 (A) and OATP4A1 (B) with 
IUGR. Relative expression of mRNA encoding OATP1A2 and OATP4A1 was assessed in 
placental samples from normal pregnancies and from pregnancies complicated by IUGR 
that were delivered in the early third trimester or at term. Gene expression is compared 
with the mean expression in normal term samples that was given an arbitrary value of 1. 
Overall ANOVA results between normal and IUGR samples are indicated by x P<0.05.  
Lines represent means ±SEM.. The data were log-transformed prior to analysis.  
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2.4 Discussion and conclusions 
2.4.1 The ontogeny of TH transporters in the human placenta 
This study demonstrates that a range of TH transporters are expressed in the 
human placenta from the first trimester until term and they show different patterns of 
expression with increasing gestational age. MCT8, MCT10, LAT1 and OATP1A2 mRNA 
expression increases with advancing gestation, indicating that there might be increased 
fetal and placental demand for maternal THs and other compounds transported by these 
proteins as the pregnancy progresses. The mRNA expression of CD98 and OATP4A1 
reaches a nadir between weeks 11 and 14 of gestation, which coincides with the onset of 
fetal TH production (Morreale de Escobar et al., 2004), whilst the mRNA expression of 
LAT2 remains constant throughout gestation. Furthermore, the protein presence of these 
transporter proteins in the human placenta throughout gestation was demonstrated (with 
the exception of LAT2) and MCT10, OATP1A2 and OATP4A1 proteins were localised in 
specific cell types in the human placenta and placental bed. 
Our group has previously demonstrated that MCT8 mRNA is expressed in the 
human placenta throughout gestation and its expression increases with gestational age 
(Chan et al., 2006). We have also demonstrated the presence of MCT8 protein in the 
human placenta throughout gestation and we have localised MCT8 protein in villous CTs 
and STs throughout gestation and in decidual stromal cells and EVTs in first and second 
trimester placental bed biopsies. In light of evidence that MCT8 is one of the transporters 
responsible for both TH uptake and efflux (Friesema et al., 2003, Friesema et al., 2008), 
these results suggest that MCT8 can facilitate TH uptake and efflux by the majority of 
placental cell types. MCT8 may therefore mediate the effects of TH on trophoblast 
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differentiation and survival (Barber et al., 2005, Canettieri et al., 2008, Laoag-Fernandez 
et al., 2004, Maruo et al., 1991, Maruo et al., 1995, Matsuo et al., 1993) and contribute to 
transplacental transport of TH, which is essential for fetal development. In the present 
work, we have repeated the assessment of the expression levels of MCT8 in the human 
placenta at the mRNA and protein level due to significantly increased numbers in our 
placental sample cohort. Our results support our previous findings that MCT8 is 
expressed from week 6 of gestation until term and its expression increases as the 
pregnancy progresses. 
MCT10 is known to transport aromatic amino acids and to be primarily 
responsible for their efflux as demonstrated in studies with Xenopus oocytes (Kim et al., 
2002, Ramadan et al., 2006). It has recently been shown that like MCT8, MCT10 can also 
transport THs and facilitate both TH uptake and efflux (Friesema et al., 2008). Although 
it has been shown before that MCT10 is present in the human placenta (Park et al., 2005), 
this is the first study to describe the expression of MCT10 mRNA and protein throughout 
gestation and localise MCT10 expression in the human placenta. We have found that 
MCT10 mRNA and protein expression increases with gestation, suggesting an increased 
demand for TH and aromatic amino acids that are essential for fetoplacental growth. 
Localisation of MCT10 protein by immunohistochemistry showed that MCT10 is 
expressed in EVTs, villous CTs and villous STs and decidual stromal cells during the first 
trimester and is mainly expressed in the ST layer at term. These results suggest that, like 
MCT8, MCT10 may facilitate uptake of THs from the maternal circulation necessary for 
placental development and for transport to the fetal circulation. However, TH transport by 
MCT10 is subject to competitive inhibition by aromatic amino acids (Friesema et al., 
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2008), which are also necessary for fetoplacental growth and this has to be considered 
when investigating its contribution to TH uptake. 
Several studies have demonstrated the expression of LAT1, LAT2 and their 
obligate heterodimer CD98 in the human placenta (Prasad et al., 1999, Ritchie and 
Taylor, 2001, Rossier et al., 1999, Yanagida et al., 2001). System L is an important 
mechanism for amino acid exchange and in addition transports THs (Friesema et al., 
2001, Ritchie et al., 2003, Ritchie and Taylor, 2001). According to our results, placental 
LAT1 mRNA expression increases with gestation, whilst the mRNA expression of LAT2 
does not change across pregnancy. The mRNA expression of CD98 reaches a nadir at 
weeks 11-14 of gestation and it reaches the highest level at term. Recruitment of more 
samples is necessary to assess more accurately the expression of CD98 at 15-20 weeks. In 
the limited samples available, CD98 mRNA expression was the lowest at 15-20 weeks of 
gestation, however this observation did not reach statistical significance possibly due to 
low number of samples available for this gestation. This is in accordance with a previous 
study that described an increase in the protein expression of LAT1 and CD98 at term 
compared with mid-trimester (12-21 weeks) (Okamoto et al., 2002). LAT1 and LAT2 are 
functional only as heterodimers with the heavy chain glycoprotein CD98 (Pineda et al., 
1999, Prasad et al., 1999). Therefore, the transport of amino acids and THs by the system 
L can be regulated by changes in the expression of either of the components of the 
heterodimers. We have demonstrated the presence of CD98 protein in the human placenta 
from week 8 of gestation until term. However, we were only able to detect LAT1 protein 
after week 32 of gestation. Since LAT1 has been previously detected in mid-trimester 
human placenta (Okamoto et al., 2002), it is possible that failure to detect LAT1 protein 
in second trimester samples is due to a low affinity of the antibody used. Due to the lack 
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of a reliable antibody for the detection of LAT2 protein at the time of this study, we were 
unable to show protein expression of LAT2. In previous studies, LAT1 and CD98 have 
been localised in the ST layer of the human placenta (Okamoto et al., 2002, Ritchie and 
Taylor, 2001). Such findings are consistent with a role for LAT1 in transplacental 
transport of amino acids and THs. 
Assessment of the expression of OATP1A2 and OATP4A1 in the human placenta 
revealed an increase in the mRNA expression of OATP1A2 with gestation whilst the 
expression of OATP4A1 reached a nadir between weeks 11 and 14 of gestation. It has to 
be noted that for both OATP1A2 and OATP4A1, mRNA expression was lower at 15-20 
weeks, however this result was not statistically significant possibly due to the low number 
of samples available for this gestation. It would therefore be useful to recruit more 
samples from this gestation in order to assess more accurately the expression of TH 
transporters at 15 to 20 weeks of gestation. In addition, we have shown that OATP1A2 
and OATP4A1 proteins are present in the human placenta throughout gestation. Our 
findings are consistent with previous studies that have demonstrated mRNA and protein 
expression of OATP1A2 and OATP4A1 in the human placenta (Briz et al., 2003, Patel et 
al., 2003, Sato et al., 2003). In the study by Patel et al the authors investigated the mRNA 
expression of OATP1A2 and OATP4A1 in a relatively small sample cohort from first 
trimester (n=8) and term (n=6) placentae and they have shown that whilst OATP4A1 
expression is the same in the first trimester and at term, OATP1A2 expression is reduced 
at term compared with first trimester. In terms of OATP4A1 our results confirm these 
findings since what we observed was that OATP4A1 expression was reduced between 
weeks 11 and 14 of gestation but not between 6 and 10 weeks. In contrast, our results for 
the expression of OATP1A2 show an opposite trend. However, it has to be noted that our 
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data were obtained from a much larger cohort of placental biopsies. Localisation by 
immunohistochemistry revealed the presence of OATP1A2 protein in villous CTs, STs 
and EVTs, consistent with a role for this protein in uptake of THs and a variety of other 
organic compounds. OATP4A1 was predominantly localised in the ST layer both in the 
first trimester and at term, consistent with previous reports that have reported OATP4A1 
expression in the ST of term placenta (Sato et al., 2003). Furthermore, there was low 
expression of OATP4A1 in EVTs. 
2.4.2 Changes in the expression of TH transporters with IUGR 
An additional part of this study was to assess the expression levels of the TH 
transporters in human placentae from pregnancies complicated by early onset and late 
onset IUGR compared with gestationally matched controls. Our results demonstrate that 
although there was no difference in MCT8 mRNA expression between groups, there was 
increased protein expression of MCT8 in placentae from early onset IUGR compared with 
gestationally matched controls. Furthermore, there were significant differences in the 
expression of MCT10 and OATP4A1 between IUGR and normal samples at the mRNA 
level, however there were no significant differences when gestationally-matched groups 
were compared. There was no difference in the mRNA expression of the other TH 
transporters with IUGR. 
Our finding that MCT8 protein expression is increased with early onset IUGR is in 
accordance with our previously published observations (Chan et al., 2006). However, in 
contrast to what we have previously reported, we found no differences in the mRNA 
expression of MCT8 with IUGR possibly due to increased number of samples that were 
included in this cohort. It is possible that the expression of MCT8 protein is regulated 
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post-transcriptionally, thus accounting for the discrepancy between the mRNA and 
protein data. This is the first report that investigates the expression of MCT10 with IUGR. 
Unpublished data by Cleal et al demonstrate that MCT10 mRNA expression in placentae 
from normal pregnancies positively correlates with birth weight, head circumference and 
lean mass (Cleal, 2009), thus supporting our observation that there is a trend of decreased 
MCT10 mRNA expression in the IUGR placenta. There are no previous reports of 
changes in the expression of OATP4A1 with IUGR. Therefore, the expression of MCT10 
and OATP4A1 should be assessed in the future with more samples in order to 
conclusively determine whether the expression of these transporters is altered with IUGR. 
Our data show no differences in the mRNA expression of LAT1, LAT2 and CD98 with 
IUGR. Previous data have shown that in IUGR there is reduced transport of the amino 
acids leucine and lysine (Jansson et al., 1998). It is possible that the expression of L-
System amino acid transporters is altered post-transcriptionally and/or post-translationally 
in IUGR resulting in reduced amino acid and TH transport. 
IUGR is most commonly associated with malplacentation (Khong, 1989). It has 
been shown that in IUGR the numbers of endovascular EVTs are reduced (Huppertz et 
al., 2006) and the transformation of maternal spiral arteries is defective (Brosens et al., 
1977, Brosens et al., 1972). Furthermore, there is increased apoptosis within the ST (Endo 
et al., 2005, Ishihara et al., 2002, Smith et al., 1997) and increased syncytialisation of CTs 
(Newhouse et al., 2007) in IUGR compared with normal placentae. T3 promotes invasion 
and motility (Barber et al., 2005, Canettieri et al., 2008, Maruo et al., 1991, Maruo et al., 
1995, Matsuo et al., 1993, Oki et al., 2004) and downregulates apoptosis (Laoag-
Fernandez et al., 2004) in EVT-like cell lines and EVTs isolated from first trimester 
placentae. Therefore, changes in TH transport early in pregnancy, which is a critical 
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period for normal placentation, may be contributing to the malplacentation associated 
with IUGR. Unfortunately, the clinical manifestation of IUGR can only be diagnosed later 
in pregnancy. It is thus impossible to assess the expression of the molecular apparatus 
regulating TH transport in first trimester placentae from IUGR pregnancies. 
It has been shown by our group and others that the serum concentration of free T3 
and free T4 is reduced in IUGR fetuses compared with gestationally matched controls 
(Kilby et al., 1998, Thorpe-Beeston et al., 1991). The mechanisms that are responsible for 
the reduced TH levels with IUGR have not been elucidated yet. At term, the THs that are 
found in the fetal circulation are a mixture of maternal THs supplied by transplacental 
transport and of THs produced by the developing fetus. Therefore, the reduced 
concentration of THs in the fetal circulation may be due to reduced fetal TH production 
and/or inefficient transplacental transport of maternal THs. It is also possible that the 
IUGR placenta has a reduced capacity for TH transport due to its decreased size. Changes 
in the expression of TH transporters and deiodinase enzymes could also affect 
transplacental transport of THs. Our group has shown before that there are no differences 
in placental deiodinase enzyme activity with IUGR, indicating that deiodinase enzymes 
are not responsible for the hypothyroxinaemia observed in IUGR fetuses (Chan et al., 
2003). Reduced activity of System L with IUGR (Jansson et al., 1998) may contribute to 
the reduced level of circulating THs in the IUGR fetus. In this thesis, a trend of decreased 
MCT10 mRNA expression was observed with IUGR, which could also contribute to 
decreased transplacental transport of THs. The increased MCT8 expression may be an 
attempt of the IUGR placenta to compensate for the decreased TH transport, however, it 
may not be adequate to restore transplacental TH transport to normal levels.  
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2.4.3 Conclusions 
The findings presented in this chapter demonstrate the presence of a range of TH 
transporters in the human placenta throughout gestation. These transporters comprise a 
system that is in place to ensure adequate supply of THs and other substrates essential for 
the development of the fetoplacental unit. Preferential expression of these transporters in 
different cell types in conjunction with deiodinase enzyme expression can regulate the 
uptake and efflux of THs, thus ensuring the availability of the optimal TH levels 
necessary for normal fetal and placental development. Our data suggest that there are 
changes in the placental expression of TH transporters in IUGR pregnancies suggesting 
that transplacental TH transport may be altered. This may be a contributing factor to the 
malplacentation associated with IUGR and to the reduced serum levels of THs in IUGR 
fetuses. Abnormal levels of THs in the fetal circulation could be partly responsible for the 
increased risk for fetal and neonatal mortality and morbidity with IUGR. 
Chapter 3: T3 Responsiveness and Transport by Primary 
Cytotrophoblasts from Normal and IUGR Human Term 
Placentae 
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3.1 Introduction 
IUGR is a pregnancy complication that is characterised by failure to achieve the 
genetic growth potential of a fetus (Scifres and Nelson, 2009) and is a major contributor 
to fetal and neonatal morbidity and mortality (Kok et al., 1998, Tan and Yeo, 2005). 
IUGR can arise due to multiple factors of maternal, placental, fetal or environmental 
origin (Sankaran and Kyle, 2009) and is commonly associated with uteroplacental 
insufficiency (Mayhew et al., 2003, Teasdale, 1984). The remodelling of the maternal 
spiral arteries that facilitates unobstructed blood flow from the maternal circulation 
towards the placenta in normal pregnancies is defective in IUGR pregnancies (Brosens et 
al., 1977, Brosens et al., 1972). Furthermore, histological examination of third trimester 
placentae has revealed that the number of apoptotic nuclei within villous STs is increased 
in IUGR compared with normal placentae (Endo et al., 2005, Ishihara et al., 2002, Smith 
et al., 1997). The differentiation of villous CTs to STs by a process termed 
syncytialisation, is also increased in IUGR as demonstrated in experiments using a 
placental explant model (Crocker et al., 2004, Newhouse et al., 2007) or primary cultures 
of term CTs (Newhouse et al., 2007). 
Maternal TH status is one of several factors that are thought to be involved in 
human placental development. Untreated maternal hyperthyroidism has been associated 
with complications of malplacentation, including IUGR, placental abruption and pre-
eclampsia (Mestman, 2004), whilst maternal subclinical hypothyroidism has been 
associated with increased risks of miscarriage, placental abruption and preterm delivery 
(Abalovich et al., 2002, Casey et al., 2005). In vitro, T3 has been shown to increase the 
invasive ability of first trimester EVTs and EVT-like cell lines (Barber et al., 2005, 
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Maruo et al., 1991, Oki et al., 2004) and suppress their apoptosis (Laoag-Fernandez et al., 
2004). 
Our group has previously reported that the serum concentration of free T4 and free 
T3 is reduced in IUGR fetuses (Kilby et al., 1998). Furthermore, we have shown that there 
is increased protein expression of the TR isoforms TRα1, TRα2 and TRβ1 in the term 
placenta with IUGR (Kilby et al., 1998). As described in the previous chapter, the protein 
expression of the TH transporter MCT8 is increased with early onset IUGR, whilst there 
was a trend of decreased mRNA expression of the TH transporter MCT10 in the placenta 
with IUGR. Previously published data by our group have demonstrated that there is no 
difference in the activity of the deiodinase enzymes D2 and D3 in the placenta with 
IUGR, suggesting that TH metabolism is not altered with IUGR (Chan et al., 2003). 
The finding that the expression of TRs in the placenta is altered with IUGR 
suggests that the IUGR placenta may have altered sensitivity to TH. Furthermore, the 
changes in the expression of the TH transporters MCT8 and MCT10 with IUGR suggest 
that there may be differences in trophoblast uptake of TH and in TH transplacental 
transport with IUGR. Primary cultures of CTs from term placenta are a useful model to 
study placental biology. After plating, these isolates form monolayers of mononucleate 
cells. With time in culture the cells syncytialise to form multinucleate CTs that are 
thought to be representative of STs (Greenwood et al., 1996). Cultures of isolated CTs 
can thus be used to investigate CT behaviour as well as transport by STs in vitro. In this 
study, this cell model was used to assess the T3 responsiveness and transport in CTs 
isolated from placentae from normal pregnancies (normal CTs) or from pregnancies 
complicated by IUGR (IUGR CTs). 
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3.2 Materials and Methods 
3.2.1 Sample collection 
This study had the approval of the Local Research Ethics Committee (South 
Birmingham) and the Research and Development Committee of the Birmingham 
Women’s Hospital. 
Placentae from normal (n=27) and late onset IUGR (n=14) pregnancies were 
collected following delivery by caesarean section. All were delivered after 35 completed 
weeks of gestation, as determined by a first trimester ultrasound scan of crown-rump 
length. The IUGR cases were diagnosed prospectively using ultrasound and they had at 
least two of the following four characteristics: (i) abdominal circumference, measured by 
ultrasound, less than the tenth centile for gestation, (ii) abdominal circumference growth 
velocity of less than 1.5 standard deviation over 14 days, (iii) oligohydramnios defined as 
amniotic fluid index ≤ tenth centile for gestation and (iv) absent or reversed end diastolic 
flow velocity in the umbilical artery Doppler studies. The IUGR fetuses were not known 
to have abnormal karyotypes. None of the pregnancies was complicated by maternal 
hypertension. 
3.2.2 Isolation and culture of CTs from term placenta tissue 
Immediately after delivery by caesarean section, the placentae were transferred to 
the laboratory at room temperature, where they were processed to isolate CTs following 
the method previously published by Kliman (Kliman et al., 1986) and modified by 
Greenwood (Greenwood et al., 1996). 
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The placenta was processed in the tissue culture cabinet using autoclaved 
instruments and glassware and sterile solutions to avoid any contamination. All the 
solutions were warmed to 37°C prior to usage. The edges of the placenta, the umbilical 
cord region and any calcified areas were discarded. The placenta was cut into 
approximately one-inch cubes and placed in a glass beaker with approximately 300 ml of 
0.9% saline. The cubes were retrieved one at a time and the chorionic plate and the 
decidual cell layer were removed and discarded. The villous material was dissected into 
small pieces. Any vessels found in the tissue were removed. The villous material was 
washed in a beaker with fresh saline and was passed through a sterile gauge. The tissue 
was crudely minced using scissors and any unwanted material, such as vessels, decidua 
pieces and blood clots, was removed. The tissue was washed two more times in fresh 
saline and then weighed.  
The tissue (30-32 g) was added to 150 ml Hepes Buffered Salt Solution (HBSS: 
5.40 mM KCl, 0.44 mM KH2PO4, 137 mM NaCl, 0.34 mM Na2HPO4 heptahydrate, 5.55 
mM glucose and 25 mM HEPES; pH 7.4) containing 30 mg of DNAse and 2,250 units of 
trypsin without EDTA, calcium or magnesium (Invitrogen, Paisley, UK) in a 1 L conical 
flask. The flask was placed in a shaking water bath at 37°C and was shaken at 80 
oscillations per minute for 30 minutes. After 30 minutes, the flask was placed horizontally 
in the hood and the tissue was allowed to settle at the bottom of the flask. The supernatant 
(100 ml) was transferred to a glass beaker. Fresh HBSS (100 ml containing 20 mg of 
DNAse and 1,500 units of trypsin) was added to the flask and the flask was returned to the 
shaking water bath for another 30 minutes. The supernatant was carefully layered on top 
of 5 ml Newborn Calf Serum in four 50 ml tubes and the tubes were centrifuged for 10 
minutes at 2,200 ×  g with brake off. The resulting pellets consisted of CTs and other 
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digested cells. They were resuspended in 1 ml Dulbecco’s modified Eagles medium with 
25 mM glucose (DMEM) and they were pooled together. Once the second incubation was 
complete, another 100 ml of supernatant were carefully removed and 75 ml of fresh 
HBSS containing 15 mg DNAse and 1,125 units of trypsin were added. The tissue was 
incubated in the shaking water bath for another 30 minutes. The freshly harvested 
supernatant was centrifuged as before. At the end of the final incubation as much of the 
supernatant as possible was removed without taking any tissue and was centrifuged as 
before. All the pellets were pooled together and DMEM was added to a total volume of 50 
ml. The solution was centrifuged at 2,200 × g for 10 minutes with brake off.  
The resulting pellet was resuspended in 6 ml DMEM with high glucose and was 
carefully layered on top of percoll gradients in order to separate the CTs according to 
cellular density. The percoll gradients were made from previously prepared stock 
solutions ranging from 70% to 10% percoll in HBSS. They were layered in 30 ml glass 
tubes as shown in Figure 3-1 The tubes were centrifuged at 2,800 rpm for 30 minutes 
with brake off. Following centrifugation the top bands were discarded and the bands 
between 35% and 55% percoll, that contained the CTs, were collected in a 50 ml tube. 
The volume was made up to 50 ml with CT culture medium, which was prepared using 
equal amounts of DMEM (with 25 mM HEPES and 25 mM glucose; Invitrogen) and F12 
nutrient mixture (with 10 mM glucose; Invitrogen) and was supplemented with 10% (v/v) 
Fetal Calf Serum (FCS; Invitrogen), 1,000 units/L Penicillin (Invitrogen), 0.001% (w/v) 
Streptomycin (Invitrogen), 0.005% (w/v) Gentamicin and 0.029% (w/v) L-Glutamine 
(Invitrogen). The cell suspension was centrifuged at 2,200 rpm for 10 minutes. The pellet 
was resuspended in 2 ml CT culture medium and the number of cells was counted under a 
microscope using a haemocytometer. Usually the yield was between 60 and 100 ×  106 
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cells. The final concentration of glucose in the CT culture medium was 17.5 mM. 
Although this concentration of glucose is hyperglycaemic, according to a study by Hahn 
et al. cell viability and secretion of hCG by cytotrophoblasts are unaffected by culture in 
media with low (5.5 mM) or high (25 mM) glucose (Hahn et al., 1998).  
 
The cells were resuspended in CT culture medium to a final concentration of 1.5 × 
106 cells per ml and they were transferred to tissue culture plates at a density of 3 × 106 
cells per well of a 6-well plate. They were incubated in a CO2 incubator at 37°C under 
normoxic conditions with 5% CO2. The following day the cultures were washed three 
times with phosphate buffered saline (PBS) containing magnesium chloride and calcium 
chloride to remove dead and floating cells. Fresh CT culture medium was added and the 
cells were returned to the incubator. The cells were washed twice with PBS daily and 
Figure 3-1: Percoll gradient. A gradient ranging from 70% to 10% was layered 
in order to separate the cells on the basis of size. The cells were layered on top of 
the percoll gradient and centrifuged. The CTs were found in the five bands 
between 55 and 35% and they were visualised as pale white cell layers.  
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were maintained for up to four days after isolation. The protocol for CT isolation is 
summarised in Figure 3-2. 
 
Figure 3-2: Isolation of CTs. (A) A placenta was collected immediately after 
delivery by caesarian section. (B) The villous part of the tissue was disected into 
small pieces. (C) The tissue was taken through three rounds of trypsinisation. (D) 
The supernatant was collected after each trypsinisation and centrifuged on top of 
newborn calf serum. (E) The pellets were collected in a tube with DMEM and 
centrifuged. (F) The pellet was resuspended in 6 ml DMEM and was overlayed on 
top of two percoll gradients and centrifuged for separation of the different cell 
types. (G) The cells in the layers between 55 and 35% were collected, 
resuspended in CT culture media and centrifuged. (H) The final pellet was 
resuspended in CT culture media and following cell counting the cells were plated 
in tissue culture dishes. 
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3.2.3 Assessment of cell purity by immunofluorescence 
In order to assess cell purity the cells were stained with antibodies against 
cytokeratin-7 and vimentin. Cytokeratin-7 is a marker for cells of epithelial origin, 
including trophoblast cells, while vimentin is a marker for mesenchymal cells and stromal 
decidua (Maldonado-Estrada et al., 2004). Therefore, CT cells should be positive for 
cytokeratin-7 and negative for vimentin. 
CTs were plated in 24-well plates at a density of 0.75 × 106 cells per well. Three 
days after isolation the cells were washed in PBS and they were fixed and permeabilised 
by incubating for 25 minutes in 100% methanol at -20°C. The methanol was then 
removed and the cells were washed three times with PBS and stored in PBS at 4°C until 
they were stained. The cells were incubated for 30 minutes in blocking solution (10% v/v 
calf serum in PBS) in order to block sites for non-specific binding. They were incubated 
with mouse antibodies against human cytokeratin-7 (Sigma-Aldrich; clone LDS-68; 1:50) 
or vimentin (Sigma-Aldrich; clone V9; 1:100) for 1 hour at room temperature and washed 
three times with PBS. Secondary goat anti-mouse IgG antibody labelled with green-
fluorescent Alexa Fluor 488 dye (1:250; Invitrogen) and blue-fluorescent Hoechst 33258 
stain (Sigma-Aldrich; 1:1,000) were added for 1 hour. The cells were washed three times 
with PBS and stored in PBS at 4°C until they were examined using an inverted 
fluorescent microscope. Pictures from three fields per well were captured and the 
percentage of cytokeratin-7 positive and vimentin positive cells was calculated as a 
measure of cell purity. Isolated CTs usually consist of a relatively pure population. The 
purity of CT cultures was checked regularly and the cultures were consistently ≥  95% 
pure. 
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3.2.4 Assessment of cell syncytialisation 
3.2.4.1 Immunofluorescent staining for desmosomes 
The fusion of mononucleate CTs that results in the formation of syncytialised 
multinucleate cells is complete by 66 to 90 hours after plating the cells. Cell 
syncytialisation can be visualised using antibodies against cell junction proteins, such as 
desmosomes. By counting the total number of nuclei and the number of nuclei that are 
found in a multinucleate cell (a cell with three or more nuclei), one can estimate the 
percentage of nuclei that are found in syncytia. For this purpose the cells were stained 
with mouse antibody against human desmosomal protein (Sigma-Aldrich; clone ZK-31; 
1:200) followed by secondary goat anti-mouse IgG antibody labelled with green-
fluorescent Alexa Fluor 488 dye (1:250; Invitrogen) and blue-fluorescent Hoechst 33258 
stain (Sigma-Aldrich; 1:1,000) using the procedure described in section 3.2.3. 
3.2.4.2 hCG secretion 
In vitro, syncytialisation correlates with increased secretion of hCG by CTs 
(Kliman et al., 1986). Secretion of hCG was assessed using a commercially available 
enzyme-linked immunosorbent assay (ELISA) kit (DRG, Marburg, Germany). The cell 
medium was collected daily before washing the cells in PBS and it was stored at -20°C. 
Protein was also harvested from the same wells with 2% (w/v) SDS. The samples were 
thawed and mixed thoroughly and 25µl of each sample and of standard solutions of hCG 
(5, 50, 200, 500 and 1,000 mlU/ml) were added in duplicate to separate microtiter wells 
coated with anti-β-hCG antibody. Anti-hCG antiserum conjugated to horseradish 
peroxidase was added to the wells (100µl). The samples were thoroughly mixed for 10 
seconds and incubated at room temperature for 30 minutes. Then, the contents were 
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shaken out of the wells and the wells were rinsed five times with distilled water. The 
samples were incubated with 100 µl of substrate solution containing tetramethylbenzidine. 
After 10 minutes the reaction was stopped using the provided solution of 0.5 M sulphuric 
acid and the optical density of the samples at 450 nm was assessed using a Victor3 
multilabel counter (Perkin Elmer). The standard curve was used to determine the hCG 
concentration of the samples. The concentration of the protein harvested from the same 
wells was estimated using the Bio-Rad Dc protein assay as described in section 2.2.7. 
Secretion of hCG was then expressed as mlU of hCG, per hour in culture, per ml of 
medium and was normalised per mg of protein in order to account for differences in cell 
density with time. 
3.2.5 T3 treatment 
In order to assess the impact of T3 on CTs from normal and IUGR pregnancies, the 
cells were treated with increasing doses of T3 for 48 and/or 72 hours. Following isolation 
the cells were plated in CT culture medium supplemented with 10% charcoal-stripped 
fetal calf serum (SFCS; First Link, Birmingham, UK). Charcoal-stripped serum is filtered 
through charcoal to remove non-polar material, such as hormones, including THs that are 
normally present in FCS. After an overnight incubation during which the cells were 
allowed to adhere, the cells were washed three times with PBS and fresh CT culture 
medium supplemented with 10% SFCS and T3 (0, 1, 10 and 100nM) was added. The cells 
were washed daily with PBS and incubated in fresh T3 supplemented medium. 
3.2.5.1 Cell survival 
Cell survival in response to T3 was assessed using the MTT assay. Yellow MTT 
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) is reduced to purple 
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formazan in living cells. Therefore, this assay can provide a relative measure of the 
number of viable cells. As shown by Barber et al, CTs isolated from term placenta do not 
proliferate with time in culture (Barber et al., 2005). Therefore, any changes in cell 
number would reflect differences in cell survival.  
CTs were plated in a 96-well plate at a density of 3 × 105 cells per well and they 
were treated with T3 for 48 hours as described above. The assay was performed 48 hours 
after T3 treatment. MTT was added to the cells at a final concentration of 0.5 mg per ml. 
The cells were incubated with MTT at 37°C for 3 hours. The medium was removed and 
the formazan was solubilised by the addition of 100 µl dimethyl sulphoxide. The 
absorbance of the coloured solution was quantified by measuring the absorbance of each 
sample at 570 nm using a plate reader (Bio-Tek). The background absorbance at 690 nm 
was also measured and subtracted from the absorbance at 570 nm. Four replicates were 
performed within each experiment. The effect of T3 was assessed on CTs from nine 
normal and five IUGR pregnancies. The results were normalised to the average 
absorbance for 0 nM T3 treatment within each experiment. 
3.2.5.2 Apoptosis 
3.2.5.2.1 Caspase 3/7 activity assays 
The effect of T3 on apoptosis was assessed using an assay that measures the 
activity of the effector caspases 3 and 7 (Caspase-Glo 3/7 Assay; Promega). The 
luminogenic substrate provided is cleaved by active caspase 3 or 7 resulting in the 
production of a substrate for luciferase and thus in luciferase activation and light 
production. 
Chapter 3  Effect of T3 on normal and IUGR CTs 
116 
 The cells were plated in a white-walled 96-well plate at a density of 3 × 105 cells 
per well and they were treated with T3 for 48 hours as described in section 3.2.5. The 
reagent provided with the kit and the cells were allowed to equilibrate to room 
temperature before performing the assay. The reagent was added to the cells (100 µl) and 
to wells containing only CT media (blank control). The contents of the wells were mixed 
using a plate shaker at 350 rpm for 30 seconds. The plate was incubated at room 
temperature for 2 hours. The luminescence of each sample was determined using a plate 
reader (Victor3; Perkin Elmer). Each treatment was performed in triplicate and the effect 
of T3 was assessed using CTs from nine normal and five IUGR placentae. The results 
were normalised to the average luminescence for 0 nM T3 treatment within each 
experiment. 
3.2.5.2.2 Immunofluorescent staining for M30 
Apoptosis was also assessed by immunofluorescent staining for M30. M30 is an 
epitope that is revealed when cytokeratin-18 is cleaved by caspase-3 (Kadyrov et al., 
2001). Using an antibody targeting M30 the number of nuclei with perinuclear M30 
staining can be counted in order to determine the number of apoptotic cells. 
CTs were plated in a 24-well plate at a density of 7.5 × 105 cells per well and they 
were treated with T3 for 48 hours as described in section 1.1.1.5. The cells were fixed for 
assessment by immunofluorescence and stained as described in section 3.2.3. The cells 
were stained with an antibody against M30 (1:50; Roche Diagnostics, West Sussex, UK) 
followed by staining with secondary anti-mouse IgG antibody labelled with green-
fluorescent Alexa Fluor 488 dye (1:250; Invitrogen) and with blue-fluorescent Hoechst 
33258 stain (Sigma-Aldrich; 1:1,000). Using an inverted fluorescent microscope pictures 
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were captured from three fields per well using a 20× objective. The number of nuclei with 
M30 perinuclear staining was expressed as a percentage of the total number of nuclei 
within each field. The results were normalised to the average percentage for 0 nM T3 
treatment within each experiment. Each treatment was performed in duplicate. M30 
staining was assessed in CTs from four normal and three IUGR placentae by one 
investigator blinded to placenta type and treatment. 
The above techniques for assessment of cell survival and apoptosis were validated 
for use in this cell model prior to proceeding with the described experiments. The cells 
were treated with increasing doses (0-1,000 µM) of H2O2 that is known to induce 
apoptosis in CTs (Moll et al., 2007). Cell survival and apoptosis were assessed 48 hours 
following H2O2 treatment, using the MTT assay, the caspase 3/7 activity assay and 
immunofluorescent staining for M30 as described above. 
3.2.5.3 hCG secretion 
The effect of T3 on hCG secretion was assessed as described in section 3.2.4.2. 
The cells were plated in a 12-well plate at a density of 1.5 ×  106 cells per well and they 
were treated with T3 as described in section 3.2.5. They were washed daily with PBS. Cell 
media and protein were harvested at 18, 66 and 90 hours post-culture, corresponding to 0, 
48 and 72 hours after T3 treatment. The secretion of hCG was assessed and the results 
were expressed as the percentage change in hCG secretion between 18 and 66 hours and 
between 18 and 90 hours post-culture. The secretion of hCG was assessed in CTs from 
nine normal and six IUGR placentae. 
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3.2.6 [125I]-T3 uptake and efflux assays 
T3 uptake and efflux by CTs from normal and IUGR placentae was assessed at 66 
hours post-culture when most of the cells had syncytialised. The cells were plated in 12-
well plates at a density of 1.5 × 106 cells per well. 
3.2.6.1 T3 uptake 
After 66 hours in culture, the cells were incubated with 0.5 ml of uptake medium 
for 0, 5, 10 and 30 minutes in a CO2 incubator at 37°C. Each time point was performed in 
duplicate. The uptake medium contained serum free media (SFM) with 1 nM total T3 that 
consisted of non-labelled T3 and high specific activity [125I]-T3 (Perkin Elmer) so that the 
final radioactivity added to each well was approximately 200,000 cpm. In order to 
confirm that the system could be saturated, non-labelled T3 (10 µM) was added to control 
samples in addition to [125I]-T3. The exact amount of radioactivity added to the cells was 
determined by measuring the radioactivity in 0.5 ml of uptake medium using a γ-counter 
(Wallac). At the end of each incubation the uptake medium was removed and the cells 
were washed quickly three times with ice cold SFM supplemented with 0.1% BSA and 
were lysed in 2% SDS. The radioactivity in the cell lysates was determined using a γ-
counter. T3 uptake was expressed as a percentage of the amount of radioactivity in the cell 
lysate compared with the amount of radioactivity that was added to the cells. The ability 
of CTs for T3 uptake was assessed using cells from seven normal and six IUGR placentae. 
3.2.6.2 T3 efflux 
For assessment of T3 efflux, CTs were incubated with SFM supplemented with 
1nM T3 containing [125I]-T3 for 10 minutes in a CO2 incubator at 37°C. CTs were briefly 
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washed with SFM with 0.1% BSA and incubated in SFM without T3 (efflux medium) for 
0, 1, 2, 5 or 10 minutes in a CO2 incubator at 37°C. The medium was then removed and 
CTs were lysed in 2% SDS. The radioactivity in the cell lysates was determined using a γ-
counter. The proportion of radioactivity that was retained in the cell lysate was calculated 
and compared with the amount of radioactivity that was added to the cells. T3 efflux was 
expressed as a percentage of the cellular radioactivity before the addition of efflux 
medium. T3 efflux was assessed using cells from six normal and six IUGR placentae. 
3.2.7 RNA extraction and quantitative TaqMan PCR 
RNA was extracted at 18 and 66 hours post-culture in order to assess gene 
expression in CTs from normal (n=8) and IUGR (n=8) pregnancies before and after cell 
syncytialisation. The cells were washed three times with PBS and they were lysed using 1 
ml of TRI reagent per well of a six-well plate. The samples were stored at -80°C. Total 
RNA was later extracted as described in section 2.2.2 and reverse transcribed as described 
in section 2.2.3. The expression of the TH transporters MCT8, MCT10, LAT1, LAT2, 
CD98, OATP1A2 and OATP4A1 and of the TR isoforms TRα1, TRα2α and TRβ1 was 
assessed by quantitative TaqMan PCR following the protocol described in section 2.2.5. 
TRα1, TRα2 and TRβ1 were amplified using previously validated primers and probes 
shown in Table 3-1. Expression was normalised to the housekeeping gene 18S. 
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Table 3-1: Sequences of primers and probes for TaqMan PCR. 



























All sequences are given in the 5’-3’ direction. Underlined base pairs correspond to 
boundaries between two adjacent exons. 
3.2.8 Generation of MCT10 antibody 
Rabbit polyclonal antisera for human MCT10 (Ab2198; Charles River; Germany) 
were raised against a synthetic polypeptide conjugated to keyhole limpet hemocyanine 
comprising amino acids 503-515 (SSGMFKKESDSII) at the intracellular C terminus of 
the MCT10 protein. The antisera from final bleeds were affinity purified and their 
specificity was confirmed by Western immunoblotting using antibody solutions that were 
pre-incubated with and without the immunising peptide on whole cell protein extracted 
from CTs or from HTR8 (an EVT-like cell line with low endogenous MCT10 mRNA 
expression) transfected with either human MCT10 or with VO. 
3.2.9 Protein extraction and Western immunoblotting 
CTs were lysed at 18 and 66 hours post-culture using 2% SDS and the lysates 
were stored at -20°C. Protein concentration was assessed using the Bio-Rad Dc protein 
assay as described in section 2.2.7. Western immunoblotting was performed as described 
in section 2.2.8. CT lysates (30 µg) were probed with the antibody against MCT8 (1:250) 
or MCT10 (1:500). MCT8 protein expression was assessed in two separate Western 
Chapter 3  Effect of T3 on normal and IUGR CTs 
121 
immunoblots in CTs from six normal and five IUGR placentae. MCT10 protein 
expression was assessed in CTs from three normal and three IUGR placentae. The 
expression of β-actin was quantified to assess protein loading. Relative quantification of 
MCT8 and MCT10 protein expression compared with β -actin was performed by 
densitometry using the ImageJ software. 
3.2.10 Statistical analysis 
Data were analysed using the Minitab® statistical software (version 15). Analysis 
of variance (ANOVA) was performed using the general linear model taking into account 
all variables that affected the results, such as placental type (IUGR or normal), T3 
treatment and results obtained from the same placental sample, as appropriate. Tukey all 
pairwise multiple comparisons post-hoc tests were used to assess differences between 
individual groups. Residuals for all data sets passed the normality test as determined using 
the Kolmogorov-Smirnov test, with the exception of the hCG secretion data that required 
log transformation prior to analysis. 
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3.3 Results 
3.3.1 Validation of methods 
3.3.1.1 Cell purity 
The purity of the primary cultures was regularly assessed by immunofluorescent 
staining for cytokeratin-7 and vimentin. Representative pictures of cells stained for 
cytokeratin-7 and vimentin are shown in Figure 3-3. There were consistently >95% 
cytokeratin-7 positive cells and <5% vimentin positive cells. 
3.3.1.2 Cell syncytialisation 
Cell syncytialisation was confirmed by immunofluorescent staining for 
desmosomes and by quantification of hCG secretion. Representative picture of cells 
stained with anti-desmosomal antibody at 18 and 66 hours post-culture can be seen in 
Figure 3-3: Assessment of cell purity. (A) Representative picture of cells stained for the 
trophoblast marker, cytokeratin-7. The nuclei (blue) were stained using Hoescht 33258 
stain. An antibody against cytokeratin-7 was used followed by a secondary anti-mouse 
antibody labelled with green-fluorescent Alexa Fluor 488 dye. (B) Representative 
picture of cells stained for vimentin. Nuclei are shown in blue (Hoescht 33258 stain). 
Vimentin protein was localised by indirect staining using an antibody against vimentin 
and green-fluorescent secondary antibody as described for figure A. All photographed 
with a 20× objective lens. 
Chapter 3  Effect of T3 on normal and IUGR CTs 
123 
Figure 3-4A. Secretion of hCG at 18 and 66 hours post-culture was routinely assessed. 
Results from a representative experiment are shown in Figure 3-4B. The secretion of 
hCG was assessed at 18, 42, 66 and 90 hours post-culture and it was increased 1.3-fold at 
42 hours, 5-fold at 66 hours (P<0.01) and 20-fold at 90 hours (P<0.001) compared with 
18 hours. 
Figure 3-4: Assessment of cell syncytialisation. (A) Representative pictures showing 
immunofluorescent staining for desmosomes at 18 (A1) and 66 (A2) hours post-culture. 
The nuclei, shown in blue, were visualised using Hoescht 33258 stain. Desmosomes were 
visualised using an antibody against desmosomal protein followed by a secondary anti-
mouse antibody labelled with green-fluorescent Alexa Fluor 488 dye. All photographed 
with a 20× objective lens. (B) Assessment of cell syncytialisation using the hCG secretion 
assay. hCG secretion was quantified at 18, 42, 66 and 90 hours post-culture using a 
commercially available ELISA. Bars represent means ±SEM of one experiment performed 
in triplicate. Overall ANOVA results are indicated by xxx P<0.001. Statistically 
significant differences between groups are indicated by ** (P<0.01) and *** (P<0.001). 
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3.3.1.3 Validation of methods for the assessment of cell survival and apoptosis 
The suitability of the MTT assay for the assessment of cell survival was assessed 
using increasing doses of H2O2 to induce cell death by apoptosis. Treatment with H2O2 
reduced cell viability in a dose-dependent manner as expected (Figure 3-5A). Similarly, 
H2O2 was used for the validation of the methods used for the quantification of the number 
of cells undergoing apoptosis. Treatment with increasing doses of H2O2 increased caspase 
3 and 7 activity in the cells, as shown in Figure 3-5B. A similar effect was observed when 
apoptosis in response to H2O2 was assessed by immunofluorescent staining for M30 
(Figure 3-5C). Representative pictures of cells stained with the M30 antibody are shown 
in Figure 3-5D. 
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Figure 3-5: Validation of methods to detect survival and apoptosis of cultured CTs. (A) 
Following treatment with increasing doses of H2O2 for 48 hours cell survival was 
assessed using the MTT assay in one experiment including four replicates. Apoptosis 
was assessed using a caspase 3/7 activity assay (B) and by immunofluorescent staining 
for the apoptotic marker M30 (C); both experiments were performed once in triplicate. 
Bars represent means ±SEM. Overall ANOVA results are indicated by x (P<0.05), xx 
(P<0.01) or xxx (P<0.001). Statistically significant differences between groups are 
indicated by * (P<0.05), ** (P<0.01) and *** (P<0.001). (D) Representative pictures 
of cells stained for M30 are shown. The M30 epitope was visualised by indirect 
staining with an antibody against M30. Nuclei stained with Hoescht 33258 stain are 
shown in blue. 
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3.3.1.4 Validation of the MCT10 antibody 
The specificity of the MCT10 antibody was tested using lysates of CTs that had 
been cultured for 18 hours and lysates of the EVT-like cell line, HTR8, transfected with 
VO or with MCT10 as controls. MCT10 was detected as a band that migrated at 
approximately 50 kDa (Figure 3-6). This band disappeared following pre-incubation of 
the antibody with the blocking peptide and was not present in the negative control sample 
(HTR8 transfected with VO). Non-specific bands of a higher molecular weight were also 
observed, however they were also present following pre-incubation with the blocking 
peptide thus confirming that they were not specific for MCT10. 
 
3.3.2 Clinical characteristics of study groups 
Comparing the demographic data of the normal and IUGR cohorts, there was no 
significant difference in the maternal age, proportion of cigarette smokers, parity and fetal 
sex (Table 3-2). However, the median gestational age of delivery in the IUGR cohort was 
one week less than in the normal (P<0.001). As expected, the birth weights and placental 
Figure 3-6: Validation of the MCT10 antibody. The specificity of the MCT10 
2198 polyclonal antibody was tested using MCT10-null HTR8 cells 
transfected with either VO or MCT10 and lysates of CTs cultured for 18 
hours. The samples were incubated with the MCT10 antibody pre-incubated 
with or without the blocking peptide (BP). Immunoreactivity for β -actin was 
used to assess protein loading. 
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weights of the IUGR group were significantly lower (P<0.001 and P<0.01, respectively) 
compared with the normal group. The birth weight percentile, which was calculated using 
customized growth charts and accounts for parity, ethnicity, maternal BMI, gestational 
age and fetal sex, was also significantly lower in the IUGR group (P<0.001) with a 
median of 2nd percentile compared with 53rd percentile for the normal group. 
Table 3-2: Clinical characteristics of normal and IUGR study groups. 
 Normal (n = 27) IUGR (n=14) P value 
MATERNAL DATA 
 Age (years) 32.0 (41-21) 31.5 (44-24) NS 
 Smokers 3/27 (11%) 4/14 (28%) NS 
 Nulliparous 3/27 (11%) 5/14 (36%) NS 
FETAL DATA 
 Male 9/27 (33%) 5/14 (36%) NS 
 Gestational age (weeks) 39 (40-37) 38 (35-40) 0.0006 
 Birth weight (g) 3320 (2320-4400) 2400 (1565-2960) <0.0001 
 Placenta weight (g) 640 (509-883) 464 (313-700) 0.0012 
 Customized birth weight percentile  53 (23-99) 2 (0-27) <0.0001 
 Abnormal Umbilical Doppler Flow 0/27 (0%) 3/14 (21%) 0.0341 
 Oligohydramnios 0/27 (0%) 8/14 (57%) <0.0001 
Values represent ratios (%) or medians (range). NS = not statistically significant. In 
the IUGR group, (i) one neonate was diagnosed with Prader-Willi syndrome at eight 
months of age, (ii) one woman was epileptic treated with a low dose of Lamotrigine 
(100mg twice daily) and (iii) another woman was a heroin addict who had been taking 
reducing doses of methadone during pregnancy. 
3.3.3 Decreased survival of IUGR CTs in response to T3 treatment 
The effect of T3 on the survival of normal and IUGR CTs was assessed. Although 
T3 treatment did not affect the survival of normal CTs (Figure 3-7A), it significantly 
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decreased the survival of IUGR CTs (Figure 3-7B; P<0.01). Analysis by Tukey multiple 
comparison tests revealed that IUGR CT survival was significantly decreased when the 
cells were treated with 1 or 100 nM T3 (14%; P<0.05 and 18% reduction; P<0.01, 
respectively). Overall, IUGR CTs survived less compared with normal CTs in response to 
T3 treatment (Figure 3-7C; P<0.001). Post-hoc analysis revealed that the difference in 
survival between normal and IUGR CTs was more pronounced when the cells were 
treated with 1 nM T3 (20% reduction; P<0.01). 
Figure 3-7: Effect of T3 on CT survival. CT survival was assessed using the MTT assay 
48 hours after treatment with T3. Cell survival within each experiment is compared with 
the survival following treatment with 0 nM T3. (A) Normal CTs, (B) IUGR CTs, (C) 
Comparison of the survival of normal and IUGR CTs in response to T3. Overall 
ANOVA results are indicated by xx (P<0.01) or xxx (P<0.001). Statistically significant 
differences between groups are indicated by * (P<0.05) and ** (P<0.01). (Normal 
n=9; IUGR n=5). Bars represent means ±SEM 
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3.3.4 Higher apoptosis in IUGR CTs in response to T3 treatment 
The effect of T3 on cell survival was investigated further by studying apoptosis in 
normal and IUGR CTs in response to T3 treatment. Apoptosis was initially assessed using 
an assay that measures the activity of the effector caspases 3 and 7. T3 treatment did not 
affect caspase 3/7 activity in normal CTs (Figure 3-8A). However, in IUGR CTs, T3 
treatment caused an increase in caspase 3/7 activity (Figure 3-8B; P<0.05). The effect 
was most prominent when the cells were treated with 100 nM T3 (P<0.05). Overall, 
caspase 3/7 activity following T3 treatment was higher in IUGR compared with normal 
CTs (Figure 3-8C; P<0.001). Analysis by Tukey post-tests revealed that the difference in 
caspase activity between normal and IUGR CTs was more pronounced when the cells 
were treated with 1 or 100 nM T3 (30% increase for both; P<0.01). 
This result was confirmed by immunofluorescent staining for the apoptotic marker 
M30. The percentage of M30 positive nuclei was not affected by T3 treatment in normal 
CTs (Figure 3-9A). In IUGR CTs, although there was an increasing trend in the 
percentage of M30 positive nuclei with T3 treatment, this effect was not statistically 
significant (Figure 3-9B). However, it was confirmed that apoptosis is increased in IUGR 
CTs in response to T3 treatment compared with normal CTs (Figure 3-9C; P<0.01), 
although no statistical differences were found following comparisons between individual 
groups. 




Figure 3-8: Effect of T3 on apoptosis using the caspase 3/7 activity assay. Caspase 3/7 
activity was assessed 48 hours after treatment with T3. Caspase activity within each 
experiment is compared to the activity following treatment with 0 nM T3. (A) Normal CTs 
(B) IUGR CTs (C) Comparison of apoptosis in normal and IUGR CTs in response to T3 
treatment. Overall ANOVA are indicated by x (P<0.05) or xxx (P<0.001). Statistically 
significant differences between groups are indicated by * (P<0.05) or ** (P<0.01). 
(Normal n=9; IUGR n=5). Bars represent means ±SEM. 
 (AGA n=9; IUGR n=5)  
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3.3.5  Effect of T3 on hCG secretion by IUGR and normal CTs 
As shown before, hCG secretion increases with syncytialisation and thus with time 
post-culture. The rise in hCG secretion was quantified between 18 and 66 hours and 
between 18 and 90 hours post-culture. Overall, the rise in hCG secretion was higher in 
Figure 3-9: Effect of T3 on apoptosis using immunofluorescent staining for the 
apoptotic marker M30. CTs were fixed for immunofluorescent staining 48 hours after 
treatment with T3. The percentage of M30 positive cells was calculated for each 
treatment and it was compared to the percentage of M30 positive cells following 
treatment with 0 nM T3. (A) Normal CTs (B) IUGR CTs (C) Comparison of M30 
immunoreactivity in normal and IUGR CTs in response to T3. Results following 
ANOVA are indicated by xx (P<0.01). (Normal n=4; IUGR n=3). Bars represent 
means ±SEM. 
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IUGR compared with normal CTs (Figure 3-10; Three-way ANOVA: P<0.001). This 
effect was present both in the absence (P<0.001) and in the presence (P<0.01) of T3. 
 
3.3.6 Increased intracellular accumulation of T3 in IUGR CTs 
The experiments investigating the survival and apoptosis of CTs following T3 
treatment revealed that CTs from normal and IUGR placentae respond differently to T3. 
The ability of normal and IUGR CTs for T3 uptake and efflux was assessed in order to 
investigate whether the observed difference in T3 responsiveness could be partly due to 
differences in intracellular T3 availability. 
Figure 3-10: Effect of T3 on hCG secretion. The rise in hCG secretion was assessed 
between 18 and 66 hours post-culture and 18 and 90 hours post-culture. Results following 
analysis by ANOVA are indicated by xxx (P<0.001). Statistically significant differences 
between groups are indicated by ** (P<0.01) or *** (P<0.001). (Normal n=9; IUGR 
n=6). Bars represent means ±SEM. Data were log-transformed prior to analysis. 
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T3 uptake by normal and IUGR CTs was assessed following a time course of 
incubation with [125I]-T3. Overall, T3 uptake was higher by IUGR compared with normal 
CTs ( P<0.001; Figure 3-11). Following incubation with [125I]-T3 for 30 minutes, T3 
uptake by IUGR CTs was 23% higher than uptake by normal CTs (P<0.001). 
 
Assessment of T3 efflux by IUGR and normal CTs revealed no differences 
between the two groups (Figure 3-12). These results therefore suggest that intracellular 
accumulation of T3 is higher in IUGR CTs. 
Figure 3-11: T3 uptake by CTs from normal and IUGR placentae. CTs were 
incubated for 0 to 30 minutes with [125I]-T3 (200,000 cpm) and the amount of 
intracellular radioactivity was assessed. Results following analysis by  
ANOVA are indicated by xxx (P<0.001). Statistically significant differences 
between normal and IUGR CTs at individual time points are indicated by *** 
(P<0.001). (Normal n=7; IUGR n=6). Points represent means ±SEM. 
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3.3.7 TH transporter expression in IUGR and normal CTs 
The expression of the TH transporters in primary cultures of CTs was assessed at 
18 and 66 hours post-culture in order to determine whether changes in the expression of 
TH transporters were associated with the observed changes in TH responsiveness and 
transport between normal and IUGR CTs. There were no differences in the expression of 
MCT8 or MCT10 mRNA with IUGR (Figure 3-13A and B). The protein expression of 
MCT8 and MCT10 was investigated in primary cultures of CTs by Western 
immunoblotting (Figure 3-13C1 and D1). MCT8 protein expression was increased in 
Figure 3-12: T3 efflux by CTs from normal and IUGR placentae. CTs were 
incubated for 10 minutes with [125I]-T3. After brief washing they were 
incubated with serum free media without T3 for 0 to 10 minutes. The amount of 
radioactivity that was retained intracellularly was assessed. Results following 
analysis by two-way ANOVA are indicated by x (P<0.05). (Normal n=6; 
IUGR n=6). Points represent means ±SEM. 
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IUGR samples compared with normal samples, in both samples harvested after 18 hours 
in culture and after 66 hours in culture. Quantification by relative densitometry 
demonstrated that MCT8 protein expression was increased in IUGR compared with 
normal CTs (Two-way ANOVA: P<0.01) particularly at 18 hours post-culture (2.1-fold 
increase; P<0.01) (Figure 3-13C2). In contrast, there were no changes in the protein 
expression of MCT10 between normal and IUGR CTs (Figure 3-13D2). In addition, in 
both normal and IUGR CTs, the expression of MCT8 and MCT10 decreased significantly 
between 18 and 66 hours post-culture at both the mRNA (P<0.001) and protein (MCT8: 
P<0.001; MCT10: P<0.05) levels. 
Relative quantification of the mRNA encoding the TH transporters LAT1, LAT2, 
CD98, OATP1A2 and OATP4A1, which have been reported in the human placenta, 
revealed no significant differences between IUGR and normal CTs (Figure 3-14). 
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Figure 3-13: MCT8 and MCT10 expression in primary cultures of normal and IUGR 
CTs. Relative expression of MCT8 (A) and MCT10 (B) mRNA (mean +SEM) was 
assessed at 18 and 66 hours post-culture. Expresion is compared to the mean mRNA 
expression in normal samples at 18 hours post-culture that was given an arbitrary 
value of 1. (Normal n=8; IUGR n=8). Representative Western immunoblotting for 
MCT8 (C1) and MCT10 (D1) in whole protein lysates obtained from primary cultures 
of normal and IUGR CTs at 18 and 66 hours post-culture. A band representing MCT8 
was detected at approximately 60 kDa. MCT10 was detected at approximately 50 kDa. 
Immunoblotting for β -actin on the same membranes was used to assess protein 
loading. The samples shown were obtained from three normal and three IUGR 
placentae. Changes in the expression of MCT8 (normal n=6; IUGR n=5) (C2) and 
MCT10 (normal n=3; IUGR n=3) (D2) protein were quantified by relative 
densitometry. Expression is shown as a ratio to β -actin protein expression (mean 
+SEM). Results following analysis by two-way ANOVA are indicated by x (P<0.05), 
xx (P<0.01) or xxx (P<0.001). Statistically significant differences between groups are 
indicated by * (P<0.05) ** (P<0.01) or *** (P<0.001). 
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Figure 3-14: Relative mRNA expression of LAT1, LAT2, CD98, OATP1A2 and 
OATP4A1 (mean ± SEM) was assessed at 18 and 66 hours post-culture. Expresion is 
compared to the mean mRNA expression in normal samples at 18 hours post-culture 
that were given an arbitrary value of 1. Results following analysis by ANOVA are 
indicated by x (P<0.01). Statistically significant differences between groups are 
indicated by * (P<0.05) (Normal n=8; IUGR n=8). 
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3.3.8 Expression of TRs in CTs from normal and IUGR placentae 
It was previously reported that the expression of the TR isoforms TRα1, TRα2 and 
TRβ1 was increased in villous placental sections from severe IUGR compared with 
normal pregnancies (Kilby et al., 1998). Increased TR expression may result in increased 
binding of T3 intracellularly and thus explain the increased T3 responsiveness and 
increased accumulation of T3 within IUGR CTs. In order to investigate TR expression in 
primary CT cultures, the mRNA expression of TRα1, TRα2 and TRβ1 was assessed in 
normal and IUGR CTs that were cultured for 18 or 66 hours (Figure 3-15). There were no 
statistically significant differences in the mRNA expression of TRs between normal and 
IUGR CTs. The mRNA expression of TRα2 significantly increased between 18 and 66 
hours as assessed by two-way ANOVA (P<0.001). Analysis by Bonferroni post-tests 
revealed that the increase in TRα2 expression with time in culture was statistically 
significant within the normal group (4-fold increase; P<0.01). In IUGR CTs, TRα2 
mRNA expression increased by 2.5-fold with time in culture but the difference was not 
statistically significant, whilst there were no statistically significant differences in the 
expression of TRα1 or TRβ1 with time. 
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Figure 3-15: Expression of mRNA encoding TRα1, TRα2 and TRβ1 in primary cultures of 
normal and IUGR CTs. Relative mRNA expression was assessed at 18 and 66 hours post-
culture and compared to the mean expression in normal samples at 18 hours post-culture 
that were given an arbitrary value of 1. Results following analysis by two-way ANOVA 
are indicated by xxx (P<0.001). Statistically significant differences in gene expression 
between groups are indicated by ** (P<0.01). (AGA n=8; IUGR n=8). Bars represent 
means +SEM. 
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3.4 Discussion and conclusions 
3.4.1 Differences in T3 responsiveness of CTs from normal and IUGR placentae 
The results described in this chapter demonstrate that CTs from IUGR placentae 
respond differently to T3, compared with CTs from normal placentae in terms of cell 
survival and apoptosis. The findings presented here indicate that T3 does not affect the 
survival of normal CTs, which is in accordance with a previous report (Barber et al., 
2005). However, T3 appears to adversely affect the survival of IUGR CTs. Furthermore, 
there is increased apoptosis in IUGR CTs compared with normal CTs in response to T3 as 
demonstrated using a caspase 3/7 activity assay and immunofluorescent staining for M30. 
These results suggest that increased levels of apoptosis may cause increased cell death of 
CTs from IUGR placentae in response to T3 treatment. 
It has to be noted that the effect of T3 treatment on IUGR CT survival and 
apoptosis was not dose-dependent. Whilst treatment with 1 or 100 nM T3 decreased the 
survival and increased apoptosis of IUGR CTs, treatment with 10 nM T3 did not have a 
similar effect. In a study by Maruo et al., the authors also described that whilst treatment 
with 10 nM T3 induced maximum stimulation of progesterone, oestradiol, hCG and hPL 
secretion by first trimester human CTs, treatment with either higher or lower 
concentrations of T3 gave attenuated effects (Maruo et al., 1991). As discussed in Chapter 
1, T3 exerts its functions by binding to TRs both at the cell membrane and in the 
cytoplasm leading to the activation of kinase pathways (non genomic action) (Davis and 
Davis, 1996, Davis et al., 2008), and in the nucleus, where the expression of genes that 
control cell cycle progression or apoptosis, such as EGF, cyclin D, Mdm2 and p53 are 
regulated (genomic actions) (Puzianowska-Kuznicka et al., 2006, Yen, 2001). Filipcik et 
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al. investigated the relationship between nuclear TR occupancy and biological effects of 
T3 (cell division, TR expression, prolactin secretion and TSH secretion) in the rat pituitary 
tumour cells, GH4C1 and they reported that the intensity of any particular response is not 
directly proportional to TR occupancy (Filipcik et al., 1998). In contrast, the induction of 
a particular biological event requires the occupancy of a different minimal number of 
nuclear TRs by T3 and no full receptor population occupancy was required for maximal 
intensity of the biological events tested apart from TR down-regulation, which was 
observed following treatment with 20 nM T3, which corresponds to 100% TR occupancy 
in these cells. In the case of cell division, occupation of a higher than optimal percentage 
of TRs inhibited the T3-stimulated increase of cell division. It is now known that THs can 
also regulate cell proliferation via the non genomic pathway (Davis and Davis, 1996, 
Davis et al., 2008). Binding of THs to their cell surface receptor on αvβ3 integrin leads to 
MAPK activation and translocation to the nucleus, where it induces serine 
phosphorylation of nuclear TRs and activation of downstream pathways leading to tumour 
cell proliferation (Davis et al., 2000). In contrast, cytoplasmic TRβ interacts with β -
catenin and inhibits the Wnt/β-catenin pathway in thyrocytes resulting in downregulation 
of cell proliferation (Guigon et al., 2008). Whether the mechanism by which T3 induces 
its effects on the survival and apoptosis of IUGR CTs is mediated via the genomic or the 
non-genomic pathway, or both, is unclear. As indicated by the above examples, it is 
possible that one pathway promotes while the other inhibits cell survival and that the 
effect observed is dependent on the balance between the pathways involved. The overall 
effect of T3 on CT survival could thus depend on the affinity of the receptors involved for 
T3, the number of receptors present and which TRs are expressed in the cells. The 
possibility for TR downregulation after treatment with high T3 concentrations, similar to 
the observations in GH4C1 cells (Filipcik et al., 1998), could further modulate T3-
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mediated effects on cell survival. The lack of dose-dependence in these experiments may 
thus reflect the activation of separate pathways that are activated and/or saturated by 
different concentrations of T3. Future studies are required to determine the pathways that 
are mediating the effects of T3 on IUGR CT survival and apoptosis, such as investigating 
kinase activation and changes in the expression of TH-responsive genes that are involved 
in apoptosis. 
The regulation of apoptosis is important for normal placental development. The ST 
layer of the placenta is continuously renewed by CTs fusing into the ST layer. Aged STs 
are being extruded in the maternal circulation as syncytial knots. It is thought that this 
process is regulated by apoptotic mechanisms (Huppertz and Kingdom, 2004). IUGR has 
been associated with increased apoptosis in the placenta. Smith et al and Ishihara et al 
have demonstrated that there are more apoptotic nuclei in IUGR, compared with normal 
placentae, particularly in the ST (Ishihara et al., 2002, Smith et al., 1997). Furthermore, 
the increased level of apoptosis in the IUGR placenta has been previously associated with 
increased caspase 3 activity (Endo et al., 2005). 
Oxidative stress is thought to be one of the factors leading to increased apoptosis 
in IUGR placenta (Scifres and Nelson, 2009). In vitro, altered oxygen tension can cause 
apoptosis in term placental explants (Heazell et al., 2008). EGF on the other hand, can 
rescue apoptosis caused by hydrogen peroxide in vitro (Moll et al., 2007). It has been 
shown before that the IUGR placenta is more susceptible to apoptotic stimuli. Crocker et 
al have shown that explants and isolated CTs from pre-eclamptic or IUGR placentae have 
increased susceptibility to apoptosis induced by exposure to tumour necrosis factor-α or 
hypoxia compared with normal controls (Crocker et al., 2003, Crocker et al., 2004). 
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However, this is the first study to show that T3 can also induce apoptosis in CTs from 
IUGR placentae in vitro, while it has no effect on CTs from normal placentae. 
The results presented in this chapter demonstrate that there is increased hCG 
secretion by IUGR compared with normal CTs, which is in agreement with other studies. 
Crocker et al have assessed hCG secretion and they found that under normoxic conditions 
(17% oxygen) hCG secretion is higher by explants from pre-eclamptic and IUGR 
placentae compared with explants from normal placentae (Crocker et al., 2004). 
Newhouse et al found that there was increased syncytialisation in IUGR compared with 
normal CTs as assessed by immunofluorescent staining for desmoplakin and hCG 
secretion (Newhouse et al., 2007). The factors that result in increased syncytialisation of 
IUGR CTs are not known at present. In the experiments presented in this chapter, 
treatment with 10 nM T3 did not affect the hCG secretion from either normal CTs or 
IUGR CTs. 
3.4.2 T3 transport by normal and IUGR CTs 
TH transplacental transport is of particular interest since it is critical for normal 
fetal development (Haddow et al., 1999, Pop et al., 2003, Pop et al., 1999). It has been 
reported that the serum concentrations of free T4 and free T3 are reduced in IUGR fetuses 
(Kilby et al., 1998). Such changes may arise partly due to inefficient transplacental 
transport of THs. The changes in the expression of the TH transporters MCT8 and 
MCT10 in the placenta with IUGR, presented in Chapter 2, suggest that TH transplacental 
transport may be altered with IUGR. Using primary cultures of CTs from normal and 
IUGR placentae that were allowed to syncytialise in vitro, we observed that net T3 
transport is increased with no change in T3 efflux by IUGR compared with normal CTs. 
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These results indicate that there is increased intracellular accumulation of T3 in IUGR 
CTs, which may contribute to their increased sensitivity to T3 treatment. 
These results are based on primary cultures of in vitro syncytialised CTs that are 
thought to be representative of STs, the cells that constitute the primary barrier for 
transplacental transport. However, TH transplacental transport from the maternal to the 
fetal circulation in vivo is more complicated since it involves more cell types, such as 
endothelial cells and CTs. Therefore, in vivo TH needs to be transported across these cells 
in order to reach the fetal circulation. In this thesis, the transplacental transport of T3, 
which is the active TH ligand, was assessed. Even though both T3 and the prohormone, 
T4, are transported across the placenta, T4 is thought to be the primary TH metabolite for 
transplacental transport (Chan et al., 2009). Therefore, future studies should also assess 
transplacental transport of T4 by normal and IUGR CTs. It is also important to consider 
that the IUGR placentae collected for this study were from late onset IUGR pregnancies 
that are less severe than early onset IUGR. However, assessment of T3 transport in CTs 
from severe IUGR pregnancies was not feasible due to limited access to such tissues and 
due to limited availability of gestationally-matched controls. 
3.4.3 Changes in the mechanisms that regulate TH availability and action in 
normal and IUGR CTs 
The increased accumulation of T3 within IUGR CTs may be due to changes in TH 
transporter expression, changes in T3-binding capacity within CTs, as well as differences 
in individual cell volume due to the increased syncytialisation of IUGR CTs.  
In the previous chapter, it was reported that the protein expression of MCT8 was 
increased and the expression of MCT10 was decreased in whole placental biopsies from 
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pregnancies complicated by severe IUGR compared with gestationally-matched controls, 
but not in placentae from late onset IUGR pregnancies delivered after 37 weeks. In 
mononucleate and multinucleate cultures of CTs, even though there were no changes in 
the mRNA expression of TH transporters, the protein expression of MCT8 was increased 
with IUGR, whilst there were no changes in the protein expression of MCT10. The 
discrepancy between the mRNA and protein levels for MCT8 indicates that MCT8 protein 
levels might be regulated post-transcriptionally, similar to what was observed in whole 
placenta biopsies (see Chapter 2) and to findings that have been reported for other plasma 
membrane transporters (Zlender et al., 2009). 
The samples used for the primary cultures originated from late onset IUGR 
pregnancies and gestationally matched normal pregnancies. When we compared the 
expression of MCT8 between these groups in whole placental homogenates, we found no 
difference. However, in this case the expression of MCT8 was assessed in purified CTs, 
therefore the expression pattern might not match the one described in tissue that contains 
more cell types. The increased protein expression of MCT8 in primary cultures of IUGR 
CTs may contribute to the increased net T3 uptake observed by IUGR CTs. Since MCT8 
can also facilitate T3 efflux, our findings suggest that T3 uptake may be the more 
dominant role of MCT8 in CTs. No changes were observed in the mRNA or protein 
expression of MCT10 or in the mRNA expression of LATs or OATPs in IUGR CTs, 
consistent with previous findings in whole placental biopsies (see Chapter 2). However, 
the possibility that changes in the activity of these TH transporters may also contribute to 
the increased intracellular accumulation of T3 within IUGR CTs cannot be excluded. 
It has been previously reported by our group that the protein expression of the TR 
isoforms TRα1, TRα2 and TRβ1 is increased in the villous placental sections from IUGR 
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compared with normal pregnancies (Kilby et al., 1998). TRs mediate the action of T3 by 
binding to regulatory elements for the DNA and inhibiting or initiating gene expression 
(Kilby et al., 2005). Therefore, changes in the expression of TRs in IUGR CTs may 
explain their increased responsiveness to T3. Furthermore, increased TR expression may 
result in increased binding of T3 intracellularly and thus in increased accumulation of T3 
within IUGR CTs. The mRNA expression of TRα1, TRα2 and TRβ1 was assessed in cell 
lysates from primary cultures and no statistically significant differences were found in the 
mRNA expression of TRs in IUGR compared with normal CTs. This is in accordance 
with the study by Kilby et al. that similarly did not detect changes in the mRNA 
expression of TRs, although TR protein was increased in IUGR compared with normal 
placental tissue (Kilby et al., 1998). Such discrepancies between mRNA and protein 
expression indicate that TR protein expression may be regulated post-transcriptionally. 
Assessment of the protein expression of TRs was not possible in these samples due to 
sample and time limitations. However, these results suggest that assessment of the protein 
expression of TRs should be assessed in the future to further investigate the argument that 
changes in TR expression in combination with changes in T3 transport may lead to altered 
T3 responsiveness in CTs from IUGR placentae. 
In addition, T3 action can be locally modulated by the activity of deiodinase 
enzymes. In a study by Chan et al., it was reported that there were no changes in the 
activity of deiodinase enzymes D2 and D3 between placental biopsies from IUGR and 
normal pregnancies (Chan et al., 2003). Furthermore, treatment of normal term CTs with 
T3 concentrations within the physiological range (10 nM or less) did not alter the 
expression of the deiodinase enzymes D2 and D3 in that study. These observations 
suggest that CTs cannot modulate intracellular T3 concentration through alterations in D2 
Chapter 3  Effect of T3 on normal and IUGR CTs 
147 
and D3 activities, thus rendering IUGR CTs more vulnerable to the increased net T3 
uptake demonstrated in this chapter. 
3.4.4 Conclusions 
IUGR is multifactorial phenomenon. Maternal hypothyroidism and 
hyperthyroidism have been implicated in the pathogenesis of IUGR (Abalovich et al., 
2002, Casey et al., 2005, LaFranchi et al., 2005, Mestman, 2004). The effects of T3 on 
survival and apoptosis of IUGR CTs suggest that abnormal levels of T3 may contribute to 
the increased apoptosis observed in placental tissue with IUGR. The differential effect of 
T3 on CTs from normal and IUGR placentae may be mediated by the herein reported 
changes in the expression of the TH transporter MCT8 and by previously reported 
changes in the expression of TRs with IUGR. However, it is unclear whether the 
differences in T3 responsiveness of normal and IUGR CTs are contributing to the 
aetiology of IUGR or whether they are one of the consequences arising from IUGR. 
Better understanding of the mechanisms involved in the malfunction of the placenta with 
IUGR and the possible contribution of T3 to the pathology of IUGR can help towards the 
clinical management and potential treatment of IUGR pregnancies. 
Chapter 4: The Role of the Thyroid Hormone Transporter 
MCT8 in Human Primary Cytotrophoblasts 
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4.1 Introduction 
MCT8 has been recently identified as a potent TH transporter (Friesema et al., 
2003). Our group has previously reported that MCT8 mRNA is expressed in the human 
placenta from the sixth week of gestation (the earliest gestation studied) and its expression 
increases with advancing gestational age (Chan et al., 2006). As discussed in Chapter 2, 
MCT8 protein is also present in the human placenta from week 8 of gestation until term. 
Furthermore, MCT8 protein expression is localised in extravillous trophoblasts, villous 
STs and villous CTs throughout gestation, with more widespread staining at late gestation 
(Chan et al., 2006). In addition, as discussed in Chapter 2, assessment of the expression of 
MCT8 in placentae from normal and IUGR pregnancies in the early third trimester and at 
term has revealed that, although there are no changes in the mRNA expression of MCT8, 
MCT8 protein is increased with early onset IUGR. This finding was reinforced when 
MCT8 protein expression was also found to be higher in cultures of CTs obtained from 
IUGR placentae delivered at term, compared with gestationally-matched normal 
placentae, as described in Chapter 3. 
These findings indicate that MCT8 is important for placental development and 
strongly suggest that IUGR is associated with changes in the expression of MCT8. These 
results and the previously discussed effects of T3 on placental development lead to the 
hypothesis that MCT8 may affect placental development by mediating the effects of T3 on 
trophoblast cells. In the first instance, this hypothesis was tested on primary cultures of 
CTs obtained from placentae delivered at term. MCT8 expression was silenced or 
upregulated in the absence or presence of T3 and effects on (i) cell survival and (ii) hCG 
secretion were assessed. 
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4.2 Materials and Methods 
4.2.1 Sample collection and CT isolation 
This study had approval of the Local Research Ethics Committee (South 
Birmingham) and the Research and Development Committee of the Birmingham 
Women’s Hospital. Placentae were collected from normal pregnancies following delivery 
at term by caesarean section. The tissue was processed and CTs were isolated as described 
in section 3.2.2. 
4.2.2 Transfection of human wild-type MCT8 
4.2.2.1 Assessment of methods for plasmid transfection 
Two different methods were assessed for plasmid transfection of CTs in an initial 
experiment. The methods tested were transfection using the reagent FuGENE® 6 (Roche) 
or electroporation using the Amaxa® electroporation method (Lonza, Basel, Switzerland). 
The CTs were transfected with plasmid encoding green fluorescent protein (pmaxGFP; 
Lonza) in order to assess and compare transfection efficiency with both methods.  
4.2.2.1.1 Plasmid transfection using the FuGENE® 6 reagent 
CTs were plated in 35 mm2 dishes (3×106 cells per dish), were allowed to adhere 
overnight and were transfected using FuGENE® 6 on the following day. FuGENE® (6 µl 
per 35 mm2 dish) was diluted in serum free medium to a total volume of 100 µl per dish 
and the solution was incubated at room temperature for 15 minutes. The plasmid 
(pmaxGFP or VO) was then added to the mix (1 µg per dish) and the solution was 
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incubated for 20 minutes at room temperature. The mixture was added drop wise to the 
CTs in each dish and the cells were incubated at 37°C in a CO2 incubator for 48 hours. 
4.2.2.1.2 Plasmid transfection using the Amaxa® electroporation method 
The Amaxa® method was used immediately after CT isolation. CTs were 
permeabilised by electroporation using the Amaxa® Electroporation technique. The CTs 
were counted and centrifuged at 100 ×  g for 10 minutes and the cell pellet was 
resuspended in the provided electroporation solution for primary epithelial cells. The 
amount of solution used was 100 µl per 3 ×  106 CTs. The CTs were transferred to 
provided cuvettes (3 ×  106 cells per cuvette) and plasmid (0.83 µg) encoding GFP was 
added to each cuvette. CTs were electroporated using five different programs alongside 
two controls: electroporation in the absence of plasmid DNA or addition of plasmid DNA 
without electroporation. Following electroporation, CTs were resuspended in CT culture 
medium at a final concentration of 1.5 × 106 cells per ml and were plated in 35 mm2 dish 
at a cell density of 3 × 106 cells per dish. 
4.2.2.1.3 Assessment of transfection efficiency and cell recovery 
The efficiency of each method was assessed by flow cytometry using a FACS 
Calibur (BD Biosciences, San Jose, CA, USA) and the data were analysed using the 
FlowJo software (Tree Star, Ashland, OR, USA). CTs were washed with PBS and 
trypsinised using 0.25% (w/v) trypsin. They were resuspended in 1 ml media and 
centrifuged at 1,200 rpm for 10 minutes. The cell pellet was resuspended in 200 µl of 2% 
(w/v) paraformaldehyde (PFA) and CTs were analysed by flow cytometry in order to 
identify the proportion of cells that expressed GFP. 
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In order to assess cell recovery, the cells were counted under a microscope using a 
haemocytometer and the number of cells was compared with the number of cells that were 
not electroporated or incubated with plasmid DNA. As discussed further in the results 
section, the best transfection efficiency was obtained using the Amaxa® method with 
electroporation program T-013. Therefore, this method was used in all subsequent 
experiments. 
4.2.2.2 Assessment of expression of transfected MCT8 
In order to upregulate the expression of MCT8, CTs were transfected with plasmid 
(pcDNA3.1+; Invitrogen) containing the human wild-type MCT8 sequence with a HA tag 
at the C-terminus or with VO as a negative control. The proportion of CTs that expressed 
transfected HA-tagged MCT8 was assessed by flow cytometry 48 hours after transfection. 
The cells were washed with PBS and were detached using 15 mM EDTA. They were 
resuspended in media and centrifuged at 1,200 rpm for 10 minutes. The cell pellet was 
resuspended in 2% PFA (1 ml) and incubated for 10 minutes at 37°C and then chilled on 
ice for 1 minute. The cells were centrifuged at 2,000 rpm for 10 minutes at 4°C and the 
pellet was resuspended in 0.5 ml ice cold 90% methanol. The samples were left on ice for 
30 minutes and stored at -20°C until staining. 
The cells were washed twice in PBS by centrifugation at 2,000 rpm for 10 minutes 
and the cell pellet was resuspended in staining buffer (1% FBS in PBS) for 10 minutes in 
order to block non-specific binding sites. The cells were centrifuged at 2,000 rpm for 5 
minutes and were probed with mouse antibody against the HA tag (1:50; Cell Signalling) 
for 60 minutes in order to detect the transfected MCT8 protein. The cells were rinsed 
twice in buffer by centrifugation and they were probed with secondary anti-mouse 
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antibody labelled with green-fluorescent Alexa Fluor 488 dye (1:1,000; Invitrogen) for 30 
minutes. The CTs were washed in PBS by centrifugation, resuspended in PBS and 
analysed by flow cytometry. 
MCT8 protein expression was also assessed by Western immunoblotting. CTs 
were lysed with 2% SDS 66 hours after transfection. Protein concentration was assessed 
using the Bio-Rad Dc protein assay as described in section 2.2.7. Western 
immunoblotting was performed as described in section 2.2.8. CT lysates (30 µg) were 
probed with the antibody against MCT8 (4790; 1:250) followed by secondary mouse 
HRP-conjugated anti-rabbit antibody (1:2,000; Dako). The expression of β -actin was 
assessed to control for sample loading.  
Transfected MCT8 protein was localised by immunofluorescence. CTs were fixed 
66 hours after transfection as described in section 3.2.3 and were probed with rabbit 
antibody against HA (Santa Cruz; 1:100), followed by secondary anti-rabbit antibody 
tagged with red-fluorescent Alexa Fluor 594 dye (Invitrogen). Nuclei were stained using 
Hoescht 33258 stain. 
4.2.3 Silencing endogenous MCT8 expression 
4.2.3.1 Assessment of methods for transfection with siRNA 
Two different methods were initially assessed for the delivery of small interfering 
RNA (siRNA) into CTs, siPORT™ NeoFX™ transfection reagent (Ambion) or 
electroporation using the Amaxa® electroporation method (Lonza). The MCT8 siRNA 
targeting the third exon of the MCT8 gene was pre-designed and available from Ambion. 
Non-targeting siRNA (Silencer Negative control; Ambion) was used as a negative control. 
Chapter 4  Effect of MCT8 on primary CTs 
154 
The siRNA sequences are shown in Table 4-1. The initial experiments carried out to 
assess the efficiency of siRNA delivery to the cells were performed using the MCT8 
siRNA sequence that was tagged with AlexaFluor 488 green-fluorescent dye (Qiagen, 
West Sussex, UK). 
Table 4-1: Nucleotide sequences for control and MCT8 siRNAs. 
siRNA Sense sequence Antisense sequence 
Negative 
control GGGCCACAGUUUCAGCUUCtt GAAGCUGAAACUGUGGCCCtt 
MCT8 GCCUGCGCUACUUCACCUAtt UAGGUGAAGUAGCGCAGGCtt 
All sequences are given in the 5’ – 3’ direction. 
4.2.3.1.1  Delivery of siRNA using the siPORT™ NeoFX™ transfection reagent 
CTs were treated with siRNA using the siPORT™ NeoFX™ reagent immediately 
after isolation. The siPORT™ reagent was diluted (1:20) in serum free medium (100 µl 
final volume per 35 mm2 dish) and incubated at room temperature for 10 minutes. In 
separate tubes control siRNA and MCT8 green-fluorescent siRNA (0.2 nmoles) were 
diluted in 100 µl serum free medium. The siPORT™ NeoFX™ solution and the siRNA 
solution were combined and incubated for 10 minutes at room temperature to allow 
transfection complexes to form. The solution was then dispensed in empty tissue culture 
dishes (200 µl per 35 mm2 dish). The isolated CTs were diluted at 1.5×106 cells per ml. 
The cell suspension (2 ml) was overlayed on top of the transfection mix and the CTs were 
allowed to adhere overnight. The final concentration of siRNA in the CT media was 100 
nM. 
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4.2.3.1.2 Delivery of siRNA using the Amaxa® electroporation method 
Following CT isolation, CTs were treated with green-fluorescent MCT8 siRNA 
and permeabilised by electroporation using the Amaxa® electroporation technique. The 
CTs were counted and centrifuged at 100×g for 10 minutes and the cell pellet was 
resuspended in the provided electroporation solution for primary epithelial cells. The 
amount of solution used was 100 µl per 3×106 CTs. The CTs were transferred to provided 
cuvettes (3×106 cells per cuvette) containing siRNA (0.2 nmoles) and were electroporated 
using the program T-013 that was previously determined as the optimal setting (see 
section 4.2.2.1.3). The cells were resuspended in CT culture medium at a final 
concentration of 1.5×106 cells per ml and 2 ml were dispensed in each 35 mm2 dish, 
giving a final siRNA concentration of 100 nM. 
4.2.3.2 Assessment of MCT8 siRNA delivery into CTs 
In order to assess the efficiency of the siRNA delivery to the cells, the CTs were 
maintained in culture for 48 hours before they were harvested for analysis by flow 
cytometry in order to determine the proportion of CTs that contained green-fluorescent 
siRNA (for protocol see section 4.2.2.1.3). 
In order to assess cell recovery the cells were counted using a haemocytometer and 
the cell number was compared with the number of cells that not electroporated or 
incubated with siRNA. As discussed further in the results section, the Amaxa® 
electroporation method was the most efficient method tested for siRNA delivery. 
Therefore, this method was used in all subsequent experiments. 
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4.2.3.3 Assessment of the efficiency of silencing endogenous MCT8 
For all subsequent experiments, endogenous MCT8 was silenced using the 
Amaxa® electroporation method and using non-tagged MCT8 siRNA. 
The silencing of endogenous MCT8 mRNA was assessed by semi-quantitative 
TaqMan PCR. Total RNA was harvested 24 hours after electroporation as described in 
section 3.2.7. The RNA was later extracted as described in section 2.2.2 and reverse 
transcribed as described in section 2.2.3. The expression of MCT8 mRNA was assessed 
by quantitative TaqMan PCR following the protocol described in section 2.2.5. MCT8 
expression was normalised to the expression of the housekeeping gene 18S. 
In order to assess the efficiency of MCT8 silencing at the protein level the cells 
were washed in PBS and lysed with 2% SDS 66 hours after electroporation. Protein 
concentration was assessed using the Bio-Rad Dc protein assay as described in section 
2.2.7. Western immunoblotting was performed as described in section 2.2.8. CT lysates 
(30 µg) were probed with the antibody against MCT8 (4790; 1:250) followed by 
secondary goat anti-rabbit HRP-conjugated antibody (1:2,000; Dako). The expression of 
β-actin was assessed to control for sample loading.  
4.2.4 [125I]-T3 uptake assays 
T3 uptake was assessed 66 hours after silencing or transfection following the 
protocol described in section 3.2.6. Due to the limited number of CTs isolated from each 
placenta, a time course of T3 uptake (0 to 30 minutes) was performed in duplicate within 
only one experiment. Subsequently, T3 uptake following a 10-minute incubation with 
[125I]-T3 was assessed in duplicate in four different experiments. 
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4.2.5 Assessment of cell survival 
Following electroporation the cells were seeded in 96-well tissue culture plates at a 
density of 3 ×  105 cells per well in CT media supplemented with 10% SFCS. CTs were 
allowed to adhere overnight and they were then treated with 0 or 10 nM T3 18 hours later 
and maintained in culture for 48 hours. Cell survival was then assessed using the MTT 
assay as described in section 3.2.5.1. Four replicates were performed for each condition 
within each experiment. Cell survival was assessed in six separate experiments. For each 
experiment, absorbance was normalised to the average absorbance detected in CTs 
transfected with control (control siRNA or VO) and treated with 0 nM T3. 
4.2.6 Assessment of apoptosis 
Apoptosis was also assessed 66 hours after electroporation, which is 48 hours after 
T3 treatment, using the Caspase 3/7 activity assay as described in section 3.2.5.2.1. Each 
condition was assessed in triplicate within each experiment. Caspase activity was assessed 
in six separate experiments. For each experiment, caspase 3/7 activity was normalised to 
the average activity present in CTs transfected with control (control siRNA or VO) and 
treated with 0 nM T3. 
4.2.7 Assessment of necrosis 
In order to assess whether CT death was occurring via the necrotic pathway a 
colorimetric assay that measures the activity of lactate dehydrogenase (LDH) released 
from the cytoplasm of damaged cells in the cell culture media was used (Roche). After 
electroporation, CTs were allowed to settle overnight in a 96-well plate (3×105 cells per 
well). CTs were treated with 0 or 10 nM T3 and were maintained in culture for 48 hours. 
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As a positive control, CTs in three control wells were lysed using 5 µl of provided lysis 
solution and they were incubated for 15 minutes with shaking. Reaction mixture (100 µl) 
containing the catalyst (Diaphorase/NAD+) and a dye solution (Iodotetrazolium chloride 
and sodium lactate) was added to all wells followed by a 30-minute incubation in the 
dark. The reaction was stopped by the addition of stop solution (50 µl) to all wells. The 
absorbance of the samples was measured at 490 nm. Each condition was assessed in 
triplicate within each experiment. LDH activity was assessed in three separate 
experiments. Within each experiment, LDH activity for each sample was normalised to 
the average activity present in CTs transfected with control (control siRNA or VO) and 
treated with 0 nM T3. 
4.2.8 hCG secretion 
The effect on hCG secretion was assessed at 18 and 66 hours after silencing or 
transfection (0 and 48 hours after T3 treatment) using the hCG ELISA as described in 
section 3.2.4.2. The change in hCG secretion between 18 and 66 hours was then 
calculated. The secretion of hCG was assessed in three separate experiments. 
4.2.9 Statistical analysis 
Data were analysed using Minitab® statistical software (version 15). When two 
groups were present, statistical significance was assessed by paired t test. When more than 
two groups were present, analysis of variance (ANOVA) was performed using the general 
linear model. Tukey all pairwise multiple comparisons post-hoc tests were used to assess 
differences between individual groups. Residuals for all data sets passed the normality test 
as determined using the Kolmogorov-Smirnov test. 
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4.3 Results 
4.3.1 Validation of transfection methods 
4.3.1.1 Efficiency of transfection with MCT8 
The efficiency of the Amaxa® electroporation method and the FuGENE® 6 method 
were assessed by flow cytometry of CTs transfected with pmaxGFP or with VO control. 
From the Amaxa® electroporation programs tested, program T-013 resulted in the best 
transfection efficiency (53% GFP positive cells) and cell recovery (48%) compared with 
control. In contrast, the proportion of CTs that expressed GFP following transfection with 
FuGENE® 6 was approximately 3% (Figure 4-1; Table 4-2). The Amaxa® method was 
therefore chosen as the most efficient method tested. 
 
Figure 4-1: Assessment of the efficiency of plasmid tranfection of CTs. The 
percentage of cells that were successfully transfected with pmaxGFP by the 
Amaxa® electroporation method (A) or using FuGENE® (B) was assessed by flow 
cytometry. Cells transfected with VO (pcDNA3.1+) were used as negative control. 
One representative experiment out of three is shown for Amaxa nucleofection. 
Transfection efficiency with FuGENE was tested once.
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Table 4-2: Assessment of cell recovery and efficiency of transfection with GFP using 
the Amaxa® method or the FuGENE® 6 reagent. 
Transfection method 
% Cell recovery 
compared with control 
% GFP-positive 
cells 
Amaxa® electroporation   
Program T-009 15 29 
Program X-010 12 42 
Program A-020 38 2 
Program D-024 36 29 
Program T-013 48 53 
No electroporation 28 0 
No DNA (Program T-013) 55 0 
No electroporation; No DNA 
control 
100 0 
FuGENE® 6   
FuGENE:DNA ratio: 6:1 70 3 
 
In order to assess the percentage of cells expressing MCT8 following transfection 
by Amaxa® electroporation, the proportion of cells that expressed transfected (HA-
tagged) MCT8 protein was assessed by flow cytometry. Following transfection with 
MCT8-HA approximately 28% of the cells were positively stained for HA (Figure 4-2A). 
Cells transfected with VO were used as negative control. The increase in the expression of 
MCT8 protein was confirmed by Western immunoblotting using the antibody against 
MCT8 (Figure 4-2B). MCT8 protein was detected as a band at approximately 60 kDa in 
cells transfected with VO. A band with much higher intensity was present in cells 
transfected with MCT8. In addition, transfected MCT8 protein was predominantly 
localised in the cell membrane as detected by immunofluorescent staining using an 
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antibody against HA (Figure 4-2C). Cells transfected with VO were used as a negative 
control. 
 
Figure 4-2: Efficiency of MCT8 transfection. (A) The percentage of cells that were 
successfully transfected with HA-tagged MCT8 was assessed by flow cytometry. The 
cells were probed with anti-HA antibody followed by secondary antibody labelled 
with green-fluorescent Alexa Fluor 488 dye. Cells transfected with VO were used as 
negative control. One representative experiment is shown out of four experiments 
performed. (B) Transfection efficiency was assessed by Western immunoblotting. 
Lysates of CTs transfected with VO or MCT8-HA were probed with anti-MCT8 
antibody followed by secondary anti-rabbit antibody conjugated with HRP (C) 
Localisation of transfected protein at the cell membrane (indicated by arrows) by 
immunofluorescence. CTs transfected with VO or MCT8-HA were probed with anti-
HA antibody followed by secondary antibody labelled with red-fluorescent Alexa 
Fluor 594 dye. Nuclei are shown in blue. Photographed with a 40× objective lens. 
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4.3.1.2 Silencing of endogenous MCT8 
The number of cells that were positive for green-fluorescent MCT8 siRNA 
following transfection using siPORT™ or Amaxa® electroporation was assessed by flow 
cytometry. Cells transfected with non-fluorescent control siRNA were used as negative 
control. The proportion of cells positive for fluorescent siRNA using the Amaxa® method 
was 90% (Figure 4-3A; Table 4-3). Approximately 21% of the cells were positive for 
fluorescent siRNA when using the siPORT™ NeoFX™ reagent (Figure 4-3B; Table 
4-3). Cell viability was 48% and 80%, respectively (Table 4-3). Therefore, the Amaxa® 
method was chosen as the most efficient method tested. 
 
Figure 4-3: Efficiency of siRNA delivery into CTs. The percentage of cells that were 
successfully transfected with siRNA by the Amaxa® electroporation method (A) or 
using siPORT™ (B) was assessed by flow cytometry. Cells were transfected with 
control siRNA (negative control) or with MCT8 siRNA tagged with Alexa Fluor 488 
dye. 
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Table 4-3: Assessment of cell recovery and efficiency of siRNA delivery using the Amaxa® 
method or the siPORT™ NeoFX™ reagent. 
Transfection method % cell recovery % cells with green fluorescent siRNA 
Amaxa® program T-013 48 90 
siPORT™ NeoFX™ 80 21 
 
The silencing of MCT8 mRNA was assessed in three different experiments by 
TaqMan PCR. Endogenous MCT8 mRNA expression was reduced by approximately 90% 
in the samples treated with MCT8 siRNA compared with the samples treated with control 
siRNA (Figure 4-4A). In order to confirm that the changes in mRNA expression were 
translated into changes at protein level, expression of endogenous MCT8 protein was 
assessed by Western immunoblotting (Figure 4-4B). Endogenous MCT8 was detected as 
a band at approximately 60 kDa in samples that were treated with control siRNA. No 
band of that size was present in cells treated with MCT8 siRNA. 
Figure 4-4: Efficiency of MCT8 silencing. (A) Silencing of endogenous MCT8 mRNA 
expression was assessed by semi-quantitative TaqMan PCR. Bars represent mean of 
three experiments ±SEM. MCT8 expression was normalised to the housekeeping 
control 18S and was compared to the average expression in cells treated with control 
siRNA that was given the arbitrary value of one. (B) Silencing of endogenous MCT8 
protein was assessed by Western immunoblotting. Cell lysates were probed with anti-
MCT8 antibody followed by secondary anti-mouse antibody conjugated to HRP. 
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4.3.2 T3 uptake following changes in MCT8 expression 
In order to ensure that changes in protein expression of MCT8 following silencing 
or transfection resulted in functional changes in T3 uptake, the ability of the cells to 
uptake T3 was assessed 66 hours after electroporation. T3 uptake by transfected 
cytotrophoblasts was lower than that observed with untransfected cytotrophoblasts (see 
Chapter 3). This is possibly due to increased death following transfection, resulting in 
decreased cell number. A time course of T3 uptake was performed within one experiment, 
which confirmed that silencing of endogenous MCT8 resulted in a 30% decrease in T3 
uptake following 10 or 30 minutes incubation with [125I]-T3 (Figure 4-5A1). Transfection 
of MCT8 resulted in a 15% increase in T3 uptake following 5 or 10 minutes incubation 
with [125I]-T3 (Figure 4-5B1). However, this difference was not maintained following a 
30-minute incubation period.  
Due to limitations in the number of CTs obtained following isolation from each 
placenta, it was not practical to carry out T3 uptake time courses for more experiments. In 
order to quantify the changes in T3 uptake in more experiments, T3 uptake was assessed 
following incubation with [125I]-T3 for 10 minutes in separate experiments obtained from 
four different placentae. Silencing endogenous MCT8 expression resulted in a 20% 
decrease in T3 uptake (Figure 4-5A2; P<0.05) whilst transfection with MCT8 resulted in 
a 15% increase in T3 uptake (Figure 4-5B2; P<0.05). 
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4.3.3 MCT8 adversely affects CT viability 
CT viability was assessed following silencing or upregulation of MCT8 
expression. Cell viability was increased by approximately 20% following silencing of 
endogenous MCT8 and treatment with either 0 or 10 nM T3 (Figure 4-6A; P<0.05 for 
Figure 4-5: T3 uptake following MCT8 silencing (A) or MCT8 transfection (B). T3 uptake 
time course was performed in duplicate in one experiment following silencing of 
endogenous MCT8 (A1) or transfection with MCT8 (B1). CTs were incubated for 0 to 30 
minutes with [125I]-T3 and the amount of intracellular radioactivity was assessed. T3 
uptake following incubation for 10 minutes with [125I]-T3 was assessed following MCT8 
silencing (A2) or transfection with MCT8 (B2). Bars represent mean of four experiments 
±SEM. Statistically significant differences were determined by paired t tests and are 
indicated by * (P<0.05). 
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both). Transfection with MCT8 decreased cell viability by approximately 20% both in the 
absence of T3 (P<0.05) and following treatment with 10 nM T3 (P<0.01) (Figure 4-6B). 
4.3.4 MCT8 does not appear to affect apoptosis of CTs 
Caspase 3/7 activity levels were assessed as a measure of cell apoptosis. Although 
a trend of increased caspase 3/7 activity following silencing of endogenous MCT8 and 
decreased caspase 3/7 activity following transfection with MCT8 was observed 
independent of T3 treatment, these differences were not statistically significant (Figure 
4-7). 
Figure 4-6: CT survival following silencing of endogenous MCT8 (A) or transfection 
with human wild-type MCT8 (B). Survival was assessed by MTT assay 48 hours after 
T3 treatment. The absorbance of each sample was normalised to the average 
absorbance measured in cells treated with control siRNA and 0 nM T3 (A) or in cells 
transfected with VO and treated with 0 nM T3 (B). The bars represent mean of six 
experiments ±SEM. Results following analysis by ANOVA are indicated by xxx 
(P<0.001). Statistically significant differences between groups analysed by Tukey post-
tests are indicated by * (P<0.05) and ** (P<0.01). 
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4.3.5 MCT8 does not appear to affect necrosis of CTs 
The possibility that cell death occurs via necrosis rather than apoptosis was 
investigated by assessment of the levels of lactate dehydrogenase activity in the cell 
culture media. There was no change in cell necrosis following MCT8 silencing or 
upregulation (Figure 4-8). Cell necrosis was not affected by T3 treatment either. 
Figure 4-7: CT apoptosis following silencing of endogenous MCT8 (A) or transfection 
with human wild-type MCT8 (B). Caspase 3/7 activity was assessed 48 hours after T3 
treatment as a measure of apoptosis. The caspase 3/7 activity in each sample was 
normalised to the average activity present in cells treated with control siRNA and 0 
nM T3 (A) or in cells transfected with VO and treated with 0 nM T3 (B). The bars 
represent mean of six experiments ±SEM. 
 
Figure 4-8: CT necrosis following silencing of endogenous MCT8 (A) and transfection 
of human wild-type MCT8 (B). LDH activity in the cell media 48 hours after T3 
treatment was assessed as a measure of cell necrosis. LDH activity in each sample was 
normalised to the average activity present in cells treated with control siRNA and 0 nM 
T3 (A) or in cells transfected with VO and treated with 0 nM T3 (B). The bars represent 
mean of three experiments ±SEM. 
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4.3.6 MCT8 does not appear to affect hCG secretion 
As discussed in Chapter 3, CTs syncytialise in vitro to form multinucleate CTs 
that secrete hCG. The secretion of hCG was assessed following silencing or upregulation 
of MCT8 expression in the absence or presence of T3. The secretion of hCG was not 
affected either by changes on MCT8 expression or by T3 treatment (Figure 4-9). 
 
Figure 4-9: Secretion of hCG by CTs following silencing of endogenous MCT8 (A) 
and transfection with human wild-type MCT8 (B). The bars represent the percentage 
change in hCG secretion between 18 and 66 hours post-culture. Mean of three 
experiments ±SEM. 
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4.4 Discussion and conclusions 
4.4.1 MCT8 impairs CT viability independently of T3 
The results presented in this chapter indicate that MCT8 overexpression impairs 
the viability of CTs independently of T3. This is in accordance with previous findings that 
MCT8 impairs proliferation of the choriocarcinoma cell line, JEG-3, and of the neuronal 
precursor cell line, N-Tera-2, both in the absence and presence of T3 (James et al., 2009). 
The mechanisms by which MCT8 mediates its adverse effect on cell viability and 
proliferation are presently unknown. The ability of MCT8 to transport compounds other 
than THs, such as monocarboxylates (lactate) and aromatic amino acids (leucine, tyrosine 
and tryptophan) has been tested and it has been shown that MCT8 does not mediate the 
uptake of these compounds (Friesema et al., 2003). The results presented in this chapter 
raise the possibility that MCT8 transports another compound responsible for the observed 
effects on cell viability and proliferation, which has to be investigated further. 
Alternatively, MCT8 may affect the pathways that regulate cell survival and proliferation 
independently of its transporter function. The possibility that MCT8 may act through T3-
independent mechanisms is further supported by the observations that the phenotype of 
males affected by MCT8 mutations fail to replicate those found in congenital 
hypothyroidism (Dumitrescu et al., 2004, Friesema et al., 2004, Schwartz et al., 2005). 
The effect of MCT8 on cell apoptosis was assessed in an attempt to identify the 
mechanisms that mediate the changes in cell viability following altered MCT8 expression. 
Assessment of the activity of the effector caspases 3 and 7 revealed no differences with 
changes in MCT8 expression suggesting that the changes in cell survival are not mediated 
by changes in the level of apoptosis in the CTs. The effect of MCT8 on apoptosis was also 
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investigated in a study by James et al which showed that MCT8 overexpression did not 
affect caspase 3 and 7 activity in JEG-3 and N-Tera-2 cells (James et al., 2009), similar to 
the results observed here in CTs. The possibility that cell death following MCT8 
upregulation occurs by necrosis was also investigated and it was shown that there were no 
changes in cell necrosis, as assessed by measurement of LDH activity in the cell media. 
CT viability was assessed using the MTT assay, which measures the activity of 
mitochondrial reductase enzymes and therefore reflects differences in the number of 
living cells. Since primary cultures of CTs are post-mitotic and do not proliferate in vitro 
any differences in cell number can only be attributed to cell death. Although the activation 
of caspase 3 is occurring at the final stages of cell death by apoptosis, cell death can also 
occur via caspase-independent pathways (Lockshin and Zakeri, 2002). Therefore, the 
possibility that CT cell death is occurring without cell necrosis or apoptosis via caspase 
activation has to be considered. In addition, it should also be considered that the 
differences observed using the MTT assay might reflect changes in cell metabolic activity 
or in mitochondrial number. Counting the number of cells or nuclei following silencing or 
upregulation of MCT8 expression in future studies, could better define whether CT death 
occurs in response to MCT8 upregulation. 
4.4.2 MCT8 does not affect hCG secretion 
As discussed in chapter 3, T3 did not have an effect on the secretion of hCG by 
CTs. In this chapter, hCG secretion was assessed following changes in MCT8 expression 
and as shown MCT8 silencing or upregulation did not affect hCG secretion either. 
Previously, it has been postulated that MCT8 overexpression may suppress proliferation 
and induce differentiation of neuronal cells (James et al., 2009). In primary CTs, MCT8 
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appears to impair cell viability but it does not affect hCG secretion, which correlates with 
CT syncytialisation. 
4.4.3 Changes in MCT8 expression and impact on T3 uptake 
Changes in the expression of MCT8 resulted in limited but consistent changes in 
the ability of CTs for T3 uptake. Although, silencing the expression of MCT8 resulted in 
complete silencing of MCT8 protein expression, as determined by Western 
immunoblotting, this only resulted in a 20% decrease in T3 uptake. Similarly, 
overexpression of MCT8 transiently increased the ability of CTs for T3 uptake by only 
15%. The small magnitude of the changes in T3 uptake following MCT8 upregulation 
could be partly attributed to the transfection efficiency, since only 20% of the cells were 
successfully transfected with MCT8. However, the change in T3 uptake following MCT8 
silencing does not reflect the change in MCT8 expression, since MCT8 siRNA was 
successfully delivered to 90% of the cells and resulted in undetectable MCT8 protein 
level, when assessed by Western immunoblotting. As discussed in Chapter 2, six 
transporters that mediate TH uptake have been identified in the human placenta to date. 
Apart from MCT8, these also include MCT10 (Park et al., 2005), LAT1 (Okamoto et al., 
2002), LAT2 (Kudo and Boyd, 2001), OATP1A2 (Patel et al., 2003) and OATP4A1 (Briz 
et al., 2003, Patel et al., 2003, Sato et al., 2003). The transporters with the highest affinity 
for T3 are the system L (Km = 0.8 µM (Friesema et al., 2001)), OATP4A1 (Km = 0.9 µM 
(Fujiwara et al., 2001)) and MCT8 (rat MCT8 Km = 4.0 nM (Friesema et al., 2003); 
human MCT8 Km = 0.86 µM (Kinne et al., 2009)). Therefore, the high residual T3 uptake 
following MCT8 silencing is possibly due to the presence of the above TH transporters 
that can facilitate T3 uptake in the absence of MCT8. These results indicate that there is a 
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redundancy in the TH transport system in the human placenta and suggest that MCT8 is 
only responsible for a proportion of the T3 uptake that is occurring by CTs. 
It is thought that both T4 and T3 are transported across the placenta (Chan et al., 
2009). In this thesis, the focus was on the role of MCT8 in the uptake of T3, which is the 
active TH ligand. However, the circulating concentration of T4 is higher than that of T3 
and it is thought that T4 is the predominant TH that is transported from the maternal to the 
fetal circulation (Chan et al., 2009). It is therefore essential to assess the role of MCT8 in 
the transport of T4 by trophoblast cells in future studies. 
4.4.4 Study limitations 
In this study, the role of MCT8 in CTs was investigated by siRNA-mediated 
knockdown of endogenous MCT8 protein and by upregulation of MCT8 expression by 
plasmid transfection of human wild-type MCT8. In previously published studies, cell 
lines have been used to investigate the effects of gene knock-down or upregulation, as the 
transfection of primary cell cultures has proved challenging. The cell lines that were used 
to investigate CT function (JEG-3, JAR, BeWo) originate from choriocarcinomas. 
Although using cell lines is associated with ease of use and good transfection efficiencies, 
there is criticism on the use of cell lines as models of CTs and the use of primary cultures 
is advocated instead. It has therefore been essential to identify techniques that result in 
efficient transfection of primary CTs. In this study the Amaxa® electroporation method 
was successfully used to transfect primary CTs. As described in the results section, this 
method was the most efficient of the methods tested for transfection with either siRNA or 
plasmid vectors. However, it has to be noted that cell viability was impaired following 
electroporation. Therefore, it would be useful to continue testing new techniques for 
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transfection of primary cells as they develop in the future. Recently, Forbes et al reported 
on the efficiency of different techniques for the transfection of primary CTs with siRNA 
and they have identified a reagent (DharmaFECT) that resulted in good transfection 
efficiency (95%) and good cell viability (85%) (Forbes et al., 2009). Furthermore, in 
another report published recently, microporation was used for the delivery of siRNA to 
primary CTs from term placenta with 80-90% transfection efficiency and limited cell 
death (Vargas et al., 2009). 
4.4.5 Conclusions 
This is the first study to investigate the effect of MCT8 on primary cultures of 
CTs. The adverse effect of MCT8 on the cell viability of primary CTs is consistent with 
the postulation that the increased placental expression of MCT8 in IUGR pregnancies 
may contribute to the maldevelopment and malfunction of the placenta in IUGR 
pregnancies. The results described here are similar to the effects previously observed in 
the choriocarcinoma cell line, JEG-3 and further support the evidence that MCT8 has T3-
independent actions. Further studies are necessary in order to elucidate the mechanisms 
by which MCT8 affects cell proliferation or viability. Such studies in placental cells are of 
great importance especially in light of the evidence that placental MCT8 expression is 
increased in IUGR pregnancies. In addition, such investigations can help to improve our 
understanding of the importance of MCT8 not only in placental development but also in 
the development of the CNS as clearly displayed in males with MCT8 mutations.  
 
Chapter 5: The Role of the Thyroid Hormone Transporter 
MCT8 in the Human Extravillous Trophoblast-like Cell Line, 
SGHPL-4 
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5.1 Introduction 
In the previous chapter, the role of MCT8 in CT cells isolated from term placentae 
was investigated. As discussed, MCT8 overexpression decreases CT viability 
independently of T3, which is of importance for cell turnover and transplacental transport 
in late pregnancy. Invasion of EVTs into the maternal myometrium and transformation of 
the maternal spiral arteries are critical events for normal placentation that are initiated 
early in pregnancy (Fisher et al., 1989). It is therefore important to also assess the role of 
MCT8 in placental development in early pregnancy and particularly in EVTs. 
The human placenta is TH responsive from early gestation. As discussed in 
Chapter 2, a range of TH transporters are expressed in the human placenta from week 6 of 
gestation suggesting that first trimester placental tissue has the capacity for TH uptake. 
Our group has previously reported that mRNA and protein of the TR isoforms TRα1, 
TRα2 and TRβ1 are expressed in first trimester human placenta (Kilby et al., 1998) and 
TRα1, TRα2 and TRβ1 proteins were localised in both endovascular and interstitial EVTs 
in placental bed biopsies (Barber et al., 2005). Furthermore, deiodinases 2 and 3 are 
present and functional in first trimester placenta indicating that there is the potential for 
the regulation of TH action in the placenta in early pregnancy (Chan et al., 2003). 
Previous reports on the effect of T3 on invasion by cultured primary EVTs suggest that T3 
increases the invasive potential of EVTs (Oki et al., 2004) and suppresses EVT apoptosis 
in vitro (Laoag-Fernandez et al., 2004). 
 Our group has previously reported that MCT8 mRNA and protein are detected in 
the human placenta from gestational week 6 and 8, respectively and MCT8 protein was 
localised in EVTs, CTs and STs in the first trimester (Chan et al., 2006). MCT8 may thus 
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play a role in placental development during the first trimester possibly by regulating T3 
availability. The hypothesis that MCT8 may modulate EVT invasion and cell growth was 
investigated using SGHPL-4s, an immortalised cell line derived from primary EVTs 
transfected with the early region of Simian virus 40 (Choy et al., 2000). In this study, 
SGHPL-4s were used to investigate EVT-like cell proliferation, apoptosis and invasion (i) 
in response to T3 treatment and (ii) following silencing or upregulation of MCT8 
expression in the absence or presence of T3. 
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5.2 Materials and Methods 
5.2.1 Culture of SGHPL-4 cells 
The SGHPL-4 cells were kindly provided by Prof G Whitley (St George’s 
University, London, UK). The cells were cultured in F10 Ham media (Sigma-Aldrich) 
supplemented with 10% (v/v) FCS, 1,000 units/L Penicillin, 0.001% (w/v) Streptomycin 
and 0.029% (w/v) L-Glutamine (all from Invitrogen). The cells were passaged twice every 
week at a split ratio of 1:4 and were used up to passage 25. In order to assess whether 
SGHPL-4s expressed TRs, total mRNA was extracted and reverse transcribed as 
described previously (sections 2.2.2 and 2.2.3) and the mRNA expression of TRα1, TRα2 
and TRβ1 relative to the expression in biopsies from term placenta was assessed by 
TaqMan PCR as described in section 2.2.5. 
5.2.2 T3 treatment 
The effect of T3 on SGHPL-4 proliferation and invasive capacity was investigated. 
Media supplemented with SFCS, which is stripped of THs, was used instead of normal 
FCS. SGHPL-4s did not survive when plated in tissue culture wells using SFCS-
supplemented media. For this reason, the cells were seeded in tissue culture plates in 
media supplemented with 10% FCS and were allowed to adhere overnight. The medium 
was then replaced with 10% SFCS supplemented medium and the cells were incubated for 
4 hours. Following this washing period, the medium was replaced with fresh 10% SFCS-
supplemented medium and the cells were treated with T3 (0, 1, 10 or 100 nM) for 48 
hours. In contrast, SGHPL-4 viability was not affected when the cells were seeded on 
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Matrigel® coated cell culture inserts using SFCS-supplemented medium and thus an initial 
incubation with FCS-supplemented medium was not required for these experiments. 
5.2.2.1 Cell invasion through Matrigel® 
SGHPL-4 invasion following treatment with 0 or 10 nM T3 was assessed using 
cell culture inserts for 24-well plates with 8 µm membrane pore size (BD Biosciences, 
Erembodegem, Belgium) that were coated with 10µl of growth factor-reduced Matrigel® 
matrix (BD Biosciences) diluted in PBS. The Matrigel® was allowed to set and the inserts 
were added into 24-well tissue culture plates that contained 0.8 ml 10% SFCS-
supplemented media. SGHPL-4s (5×104) were added on top of each insert in a total 
volume of 0.2 ml 10% SFCS supplemented media (Figure 5-1). The cells were allowed to 
invade through Matrigel® by incubating in a tissue culture incubator (37°C, 5% CO2) 
under normoxic conditions for 48 hours. The Matrigel® and the cells that remained at the 
top of the membrane were removed and the cells at the bottom of the membrane were 
stained with Mayer’s haematoxylin for 10 minutes, washed quickly in tap water and 
incubated for 1 minute in Scott’s tap water. The filters were incubated in eosin for 5 
minutes followed by a quick wash in tap water. The cells were dehydrated by incubating 
sequentially in 90% and 99% ethanol. The filters were allowed to air-dry, they were 
detached and mounted in Vectamount (Dako) on microscope slides. The cells were 
examined using a microscope with a 20× objective and the cells that invaded through 
Matrigel® were counted and the percentage of cell invasion relative to the cells that were 
not treated with T3 was determined. Each condition was performed in triplicate within 
three separate experiments. All the invasion experiments described in this chapter were 
performed by Dr Laurence Loubière. 
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5.2.2.2 Cell proliferation and apoptosis 
Cell proliferation was assessed 48 hours after T3 treatment in 96-well plates using 
the MTT assay as described in section 3.2.5.1. Each condition was repeated four times 
within four different experiments. Apoptosis was assessed in white-walled 96-well plates 
48 hours after T3 treatment by determining caspase 3/7 activity as described in section 
3.2.5.2.1. Each condition was performed in triplicate within four different experiments. 
5.2.2.3 mRNA expression assays 
The cells were lysed at 0, 2, 6, 16, 24 and 48 hours after T3 treatment with TRI 
reagent (Sigma-Aldrich) and total mRNA was extracted as described in section 2.2.2 and 
reverse transcribed as described in section 2.2.3. Each treatment was performed in 
duplicate within four different experiments. The mRNA expression of the TH responsive 
genes Malic Enzyme 1 (ME1) and Connexin 43 (Cx43) in each sample was assessed in 
duplicate by quantitative TaqMan PCR as described in section 2.2.5 using primers and 
probes that were previously designed and validated (Table 5-1). Expression was 
normalised to the housekeeping gene 18S. 
Figure 5-1: Diagram of cell culture insert set-up for 
invasion assays. 
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A diagram of the timeline of T3 treatment and the subsequent experiments can be 
seen in Figure 5-2. 
Table 5-1: Primer and probe sequences for quantification of ME1 and Cx43 mRNA 
expression by TaqMan PCR. 



















All sequences are given in the 5’-3’ direction. Underlined base pairs correspond to 
boundaries between two adjacent exons. 
 
Figure 5-2: Diagram of T3 treatment experiments. SGHPL-4s were incubated in 
10% FCS supplemented media in tissue culture plates overnight. The media was 
replaced with 10% SFCS supplemented media. After a 4-hour washing period the 
media was replaced with fresh 10% SFCS media containing 0,1,10 or 100 nM T3. 
The cells were lysed for mRNA extraction at 0, 2, 6, 16, 24 and 48 hours after T3 
treatment. Cell proliferation and apoptosis assays were performed 48 hours after T3 
treatment. 
 
Chapter 5    Effect of MCT8 on EVT-like cells 
181 
5.2.3 Silencing and upregulation of MCT8 expression in SGHPL-4s 
5.2.3.1 Optimisation of transfection 
The SGHPL-4 cells were transfected using the Amaxa® electroporation method 
(Lonza) following the protocol described in section 4.2.2.1.2. Initially the cell line 
optimisation kit provided by the manufacturer was used to identify the optimal solution 
and electroporation program for the transfection of SGHPL-4s. Cells were harvested by 
trypsinisation when they were 70-80% confluent and were transfected (2 ×  106 cells per 
cuvette) with plasmid encoding GFP (pmaxGFP) by electroporation using a selection of 
seven different programs and two different suspension solutions. Cells that were 
electroporated in the absence of plasmid DNA and cells that were not electroporated were 
used as negative controls. The percentage of cells that were successfully transfected and 
were expressing GFP was assessed by flow cytometry 24 hours after electroporation as 
described in section 4.2.2.1.3. Furthermore, the cells were counted under a microscope 
using a haemocytometer in order to assess cell recovery compared with cells that were not 
electroporated or incubated with plasmid DNA. As described further in the results section, 
the condition that resulted in the greatest transfection efficiency and cell viability 
(solution V; program X-001) was identified and used for the transfection of SGHPL-4s in 
subsequent experiments. 
5.2.3.2 Transfection of human wild-type MCT8 
MCT8 expression was upregulated by transfection with plasmid (pcDNA3.1+) 
containing the human wild-type MCT8 sequence with a HA tag attached at the C-
terminus or with VO as a negative control. SGHPL-4s (2×106 cells per cuvette) were 
resuspended in solution V, transferred to cuvettes containing 2 µg of plasmid DNA and 
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electroporated using program X-001. Following electroporation, the cells were 
resuspended in 10% FCS-supplemented media at a final concentration of 2.25×105 cells 
per ml. The proportion of the cells that expressed transfected HA-tagged MCT8 72 hours 
after electroporation was assessed by flow cytometry using an antibody against the HA 
tag as described in section 4.2.2.2. MCT8 protein expression was also assessed by 
Western immunoblotting. SGHPL-4 cells were lysed with 2% SDS 72 hours after 
transfection with MCT8 or VO. Western immunoblotting was performed as described in 
section 2.2.8. Cell lysates (70 µg) were probed with the antibody against MCT8 (4790; 
1:250) followed by secondary anti-rabbit HRP-conjugated antibody (1:2,000; Dako). The 
expression of β-actin was used to assess protein loading. Transfected MCT8 protein was 
localised by immunofluorescence as described in section 3.2.3. SGHPL-4s were fixed 72 
hours after transfection and they were probed with antibody against HA (1:100; Cell 
Signalling) followed by secondary anti-mouse antibody tagged with green-fluorescent 
Alexa Fluor 488 dye (Invitrogen). Nuclei were stained using Hoechst 33258 stain. 
5.2.3.3 Silencing endogenous MCT8 expression 
Endogenous MCT8 expression was silenced by transfection with siRNA targeting 
MCT8 or with non-targeting siRNA as negative control as described in section 4.2.3.1. 
SGHPL-4s (2×106 cells per cuvette) were resuspended in solution V, transferred to 
cuvettes containing 0.45 nmoles siRNA and electroporated using program X-001. They 
were resuspended in 10% FCS-supplemented media at a final concentration of 2.25×105 
cells per ml, giving a final siRNA concentration of 50 nM. 
The efficiency of the silencing of endogenous MCT8 mRNA expression in 
SGHPL-4s was assessed by quantitative TaqMan PCR. The cells were lysed with TRI 
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reagent (Sigma-Aldrich) 24 hours after transfection. Total mRNA was extracted and 
reverse transcribed as described previously (sections 2.2.2 and 2.2.3) and the expression 
of MCT8 mRNA was assessed in extracts from two separate experiments. MCT8 protein 
expression was assessed by Western immunoblotting. The cells were lysed with 2% SDS 
72 hours after electroporation and Western immunoblotting was performed as described 
in section 2.2.8. SGHPL-4 cell lysates (70 µg) were probed either with the 4790 antibody 
against MCT8 (1:250), which targets the N-terminus of MCT8, or with the 1306 antibody 
against MCT8 (1:100; gift from Prof T. Visser), which targets the C-terminus. The blots 
were then probed with secondary anti-rabbit HRP-conjugated antibody (1:2,000; Dako). 
The expression of β-actin was used to assess protein loading. 
5.2.3.4 [125I]-T3 uptake assays 
In order to assess the effect of MCT8 silencing or upregulation on T3 transport, 
SGHPL-4s were transfected with MCT8 siRNA or with plasmid encoding human MCT8. 
In addition, SGHPL-4s were co-transfected with CRYM, a cytosolic protein that binds to 
T3 intracellularly and thus prevents T3 efflux. Cells that were transfected with control 
siRNA, VO or CRYM alone were used as controls. T3 uptake was assessed 72 hours after 
transfection. SGHPL-4s were incubated with [125I]-T3 for 0, 2, 5, 10 and 30 minutes and 
the proportion of radioactivity that was retained intracellularly was determined as 
described in section 3.2.6. Each condition was performed in duplicate within three 
different experiments. 
5.2.3.5 Assessment of SGHPL-4 invasion through Matrigel® 
Following transfection with siRNA (MCT8 siRNA or control siRNA) or plasmid 
DNA (VO or MCT8) by Amaxa® electroporation the cells were cultured on top of 
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Matrigel® in 10% SFCS-supplemented medium and were treated with 0 or 10 nM T3. Cell 
invasion through Matrigel® was assessed 48 hours later as described in section 5.2.2.1. 
Each condition was performed in triplicate in five (MCT8 silencing) or eight (MCT8 
upregulation) separate experiments and the percentage of cells that invaded relative to 
controls (cells transfected with control siRNA or VO and treated with 0 nM T3) was 
determined. 
5.2.3.6 Assessment of cell proliferation, apoptosis and necrosis 
Following transfection with siRNA or plasmid DNA by Amaxa® electroporation, 
the cells were plated in 96-well plates and were allowed to adhere during an overnight 
incubation in 10% FCS-supplemented media. The media was replaced with 10% SFCS-
supplemented media and after a 4-hour washing period, the media was replaced with fresh 
10% SFCS-supplemented media containing 0 or 10 nM T3. The cells were cultured in this 
media for 48 hours, which is 72 hours post-transfection, and cell proliferation, apoptosis 
and necrosis were assessed. Cell proliferation was assessed using the MTT assay as 
previously described (section 3.2.5.1). Four replicates were performed for each condition 
within five different experiments. The caspase 3/7 activity assay was used to assess 
apoptosis as described in section 3.2.5.2.1. Each condition was assessed in triplicate 
within five different experiments. Necrosis was assessed using the LDH activity assay as 
detailed in section 4.2.7. Each condition was performed in triplicate in three different 
experiments. For each assay, the results are expressed relative to controls (cells 
transfected with control siRNA or VO and treated with 0 nM T3). The timeline of 
SGHPL-4 transfection, T3 treatment and the subsequent experiments are summarised in 
Figure 5-3. 
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5.2.4 Statistical analysis 
Data were analysed using Minitab® statistical software (version 15). Residuals for 
all data sets passed the normality test as determined using the Kolmogorov-Smirnov test. 
When two groups were present, statistical significance was assessed by paired t test. 
When more than two groups were present, analysis of variance (ANOVA) was performed 
using the general linear model. Tukey all pairwise multiple comparisons post-hoc tests 
were used to assess differences between individual groups. 
Figure 5-3: Diagram of MCT8 silencing and upregulation experiments. SGHPL-4s 
were transfected with siRNA or plasmid DNA and incubated in 10% FCS-
supplemented media in tissue culture plates overnight. The media was replaced with 
10% SFCS-supplemented media. After a 4-hour washing period the media was 
replaced with fresh 10% SFCS media containing 0 or 10 nM T3. Cell proliferation and 
apoptosis assays were performed 48 hours after T3 treatment. 
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5.3 Results 
5.3.1 Effect of T3 treatment on SGHPL-4s 
As shown in Table 5-2, SGHPL-4s express TRα1, TRα2 and TRβ1, suggesting 
that they are sensitive to the actions of THs. 
Table 5-2: mRNA expression of TRs in SGHPL-4s 
compared with term placenta tissue 
Gene 
Fold Change compared 




Values are means ±SEM 
Initially the responsiveness of the EVT-like cell line, SGHPL-4, to treatment with 
different doses of T3 in terms of invasive ability, proliferation and apoptosis was 
investigated. Furthermore, the expression of the TH responsive genes, ME1 and Cx43, 
and of the TH transporter MCT8 was assessed following T3 treatment. 
5.3.1.1 Effect of T3 treatment on SGHPL-4 invasion 
Treatment with 1 or 10 nM T3 increased SGHPL-4 invasion by approximately 2-
fold compared with treatment with 0 nM T3 (Figure 5-4A). However, this trend was not 
statistically significant. A representative picture of SGHPL-4s that invaded through 
Matrigel® and adhered at the bottom of the tissue culture insert can be seen in Figure 
5-4B. 
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5.3.1.2 Effect of T3 treatment on SGHPL-4 proliferation and apoptosis 
T3 treatment did not have an effect on either SGHPL-4 proliferation, assessed by 
the MTT assay, or on caspase 3/7 activity in SGHPL-4s (Figure 5-5). 
 
Figure 5-5: Effect of T3 treatment on SGHPL-4 proliferation (A) and apoptosis (B). 
SGHPL-4 proliferation and apoptosis were assessed 48 hours after treatment with T3 
using the MTT assay or the Caspase 3/7 activity assay, respectively. Within each 
experiment the result was normalised to the control group that was treated with 0 nM 
T3. The bars represent average of four experiments ±SEM. 
 
Figure 5-4: (A) Effect of T3 treatment on SGHPL-4 invasion through Matrigel®. 
Invasion was assessed 48 hours after treatment with T3. The bars represent average of 
three experiments ±SEM. Within each experiment the result was normalised to the 
control group that was treated with 0 nM T3. (B) SGHPL-4s that invaded through 
Matrigel® and adhered to the bottom of the tissue culture insert. Cells (indicated by 
white arrows) were fixed and stained with H&E. Photographed with a 20× objective 
lens. 
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5.3.1.3 Expression of TH responsive genes following T3 treatment 
The mRNA expression of the TH responsive genes ME1 and Cx43 was assessed 
following a time course of treatment with 0 or 10 nM T3. Overall, T3 treatment had no 
effect on the expression of either ME1 or Cx43, although the expression of both genes 
significantly changed with time (P<0.05 for both; Figure 5-6). Post-hoc analysis by 
Tukey tests revealed no significant differences between individual time points. These 
results suggest that the expression of ME1 and Cx43 in SGHPL-4s is not regulated by T3. 
Figure 5-6: Relative mRNA expression of the TH responsive genes Malic Enzyme 1 
(ME1; A) and Connexin 43 (Cx43; B) in response to T3 treatment. Relative 
expression of ME1 and Cx43 was assessed following a time course of treatment 
with 0 or 10 nM T3. Expression was normalised to the housekeeping control 18S 
and was compared with the mean mRNA expression following 0 hours of treatment 
with T3 that was given the arbitrary value of one. The points represent average of 
four experiments ±SEM. 
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5.3.1.4 Expression of MCT8 following T3 treatment 
The mRNA expression of the TH transporter MCT8 was also assessed following a 
time course of treatment with 0 or 10 nM T3 in order to find out if T3 can regulate the 
expression of its transporter. Overall, MCT8 expression did not change with T3 treatment 
but it was significantly altered with time (P<0.01; Figure 5-7). Post-hoc analysis by 
Tukey tests revealed no significant differences between individual time points.  
5.3.2 Effect of silencing and upregulation of MCT8 expression in SGHPL-4s 
5.3.2.1 Optimisation of MCT8 silencing and upregulation 
In order to investigate the role of MCT8 in the EVT-like cell line, SGHPL-4, 
MCT8 expression was silenced or upregulated. In the first instance, transfection of 
SGHPL-4s with the Amaxa® electroporation method was optimised, followed by 
experiments to confirm changes in MCT8 expression following transfection. 
Figure 5-7: Relative mRNA expression of MCT8 in response to T3 treatment. 
Relative expression of MCT8 was assessed after a time course of treatment with 0 
or 10 nM T3. Expression was normalised to the housekeeping control 18S and was 
compared with the mean MCT8 expression following 0 hours of treatment with T3 
that was given the arbitrary value of one. The points represent average of four 
experiments ±SEM. 
 
Chapter 5    Effect of MCT8 on EVT-like cells 
190 
5.3.2.1.1 Optimisation of transfection of SGHPL-4s 
SGHPL-4s were transfected with pmaxGFP using a combination of two 
electroporation solutions and seven electroporation programs in order to identify the 
optimal conditions for transfection. The outcome of each condition on transfection 
efficiency and cell recovery is reported in Table 5-3. Following this experiment, 
programs X-001 and X-005 in combination with solution V were identified as the optimal 
conditions tested for the transfection of SGHPL-4s. Program X-001 and solution V were 
used in all subsequent experiments. 
Table 5-3: Cell recovery and transfection efficiency following electroporation. 
Solution Program setting % Cell recovery 
compared with control 
% GFP 
positive cells 
A-020 43 42 
T-020 18 59 
T-030 28 80 
X-001 36 57 
X-005 57 58 
L-029 52 49 
D-023 25 54 
No electroporation 66 0 
L 
No DNA (T-020) 50 0 
A-020 54 39 
T-020 25 87 
T-030 21 88 
X-001 82 78 
X-005 78 82 
L-029 53 69 
D-023 42 70 
No electroporation 83 0 
V 
No DNA (T-020) 43 0 
No electroporation; No DNA 100 0 
 
5.3.2.1.2 Detection of endogenous MCT8 protein in SGHPL-4s 
When SGHPL-4 cell lysates from cells transfected with MCT8 were probed with 
the 4790 antibody against MCT8, a strong band was detected at approximately 60 kDa 
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and more bands of higher molecular weight were seen between 150 and >250 kDa 
(Figure 5-8A). However, when cells transfected with VO, control siRNA or MCT8 
siRNA were probed with the 4790 MCT8 antibody, there was no detectable band at the 
expected size even after a long exposure (60 minutes). Following repeated attempts to 
detect endogenous MCT8 in SGHPL-4 lysates an alternative antibody was used for the 
detection of endogenous MCT8 in SGHPL-4s (1306 Ab; Figure 5-8B). A band was 
detected at approximately 60 kDa in the sample that was transfected with MCT8, although 
weaker than the band observed when the 4790 antibody was used. Bands of higher 
molecular weight (between 150 and >250 kDa) were also present in that sample. A single 
band at approximately 60 kDa, representing endogenous MCT8 protein, was present in 
the samples transfected with VO or control siRNA. No bands were detected in the sample 
that was transfected with MCT8 siRNA, following a 60-minute exposure. 
 
Figure 5-8: Detection of endogenous MCT8 protein in SGHPL-4s by Western 
immunoblotting. Whole protein lysates of SGHPL-4s (70 µg) were harvested 48 hours 
after transfection with siRNA (control siRNA or MCT8 siRNA) or plasmid DNA (VO or 
MCT8) and they were probed with the 4790 MCT8 antibody (Ab) (A) or the 1306 MCT8 
Ab (B). Transfected MCT8 was detected at approximately 60 kDa (solid line arrows). 
More bands were present between approximately 150 and 250 kDa (dashed line arrows). 
Endogenous MCT8 was only detactable in SGHPL-4s using the 1306 MCT8 Ab as a 
single band running at the same size as transfected MCT8 (approximately 60 kDa). 
Immunoblotting for β-actin was used to assess protein loading.  
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5.3.2.1.3 Efficiency of upregulation of MCT8 expression 
The proportion of the cells expressing transfected MCT8 was assessed by flow 
cytometry (Figure 5-9A). Cells transfected with VO were used as negative control. 
Following transfection with HA-tagged MCT8, 41% of the cells were positively stained 
for HA. The increase in the expression of MCT8 protein in cells transfected with MCT8 
compared with VO was confirmed by Western immunoblotting using the 4790 MCT8 
antibody (Figure 5-9B). A band representing MCT8 was detected at 60 kDa and bands 
possibly representing MCT8 multimers were identified between 150 and >250 kDa in the 
sample transfected with MCT8. No band was present in the sample transfected with VO. 
In addition, transfected MCT8 protein was detected by immunofluorescent staining of the 
HA tag (Figure 5-9C). 




Figure 5-9: Efficiency of MCT8 transfection. (A) The percentage of cells that expressed 
HA-tagged MCT8 was assessed by flow cytometry 72 hours post-transfection. The cells 
were probed with anti-HA antibody followed by Alexa Fluor 488 labelled secondary 
anti-mouse antibody. Cells transfected with VO were used as negative control. (B) 
Lysates of SGHPL-4s transfected with MCT8 or VO were probed with the 4790 MCT8 
antibody followed by secondary anti-rabbit antibody conjugated with HRP. The band at 
60 kDa representing the MCT8 monomer is indicated by solid line arrows. The bands 
representing MCT8 multimers are indicated by dashed line arrows. Immunoblotting for 
β-actin was used to assess protein loading. (C) Localisation of transfected MCT8 protein 
by immunofluorescence. SGHPL-4s transfected with MCT8-HA or VO were fixed 72 
hours after transfection and were probed with antibody against the HA tag followed by 
secondary anti-rabbit antibody labelled with green-fluorescent Alexa Fluor 488 dye. 
Nuclei were stained blue using the Hoescht 33258 stain. The cells were photographed 
using a 40× objective lens. Cells expressing HA-tagged MCT8 are indicated by white 
arrows. 
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5.3.2.1.4 Efficiency of silencing endogenous MCT8 expression 
The silencing of MCT8 mRNA was assessed by TaqMan PCR 24 hours post-
transfection. Endogenous MCT8 expression was reduced by approximately 70% in the 
samples transfected with MCT8 siRNA compared with those transfected with control 
siRNA (P<0.05; Figure 5-10A). MCT8 silencing at the protein level was confirmed 72 
hours post-transfection by Western immunoblotting using the 1306 MCT8 antibody 
(Figure 5-10B). A band representing endogenous MCT8 was present at approximately 60 
kDa in the sample that was transfected with control siRNA. There was no band detectable 
in the sample transfected with MCT8 siRNA, following exposure for 60 minutes. 
 
Figure 5-10: Efficiency of MCT8 silencing. (A) Silencing of endogenous MCT8 mRNA 
expression was assessed by semi-quantitative PCR 24 hours after transfection. Bars 
represent average of two experiments ±SEM. Statistically significant differences are 
indicated by * (P<0.05). MCT8 expression was normalised to the housekeeping 
control 18S and was compared to the average expression in cells transfected with 
control siRNA that was given the arbitrary value of one. (B) Silencing of endogenous 
MCT8 protein was assessed by Western immunoblotting. Lysates of SGHPL-4s 
transfected with MCT8 siRNA or control siRNA were harvested 72 hours post-
transfection and were probed with the 1306 MCT8 antibody followed by secondary 
anti-rabbit antibody conjugated to HRP. Immunoblotting for β -actin was used to 
assess protein loading.  
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5.3.2.2 T3 uptake following changes in MCT8 expression 
The impact of MCT8 silencing or upregulation on T3 uptake was assessed 72 
hours post transfection. Overall, silencing of endogenous MCT8 significantly reduced T3 
uptake by SGHPL-4s (Figure 5-11A; P<0.001). When compared with control siRNA, 
transfection with MCT8 siRNA resulted in a 40% reduction in the proportion of [125I]-T3 
that was retained intracellularly following 10 (P<0.05) or 30 minutes (P<0.01) of 
incubation with [125I]-T3. This effect remained significant following co-transfection of 
MCT8 siRNA with CRYM. Transfection with CRYM alone did not affect T3 uptake when 
compared with cells transfected with control siRNA. 
Upregulation of MCT8 expression resulted in an increase in T3 uptake by SGHPL-
4s (Figure 5-11B; P<0.001). Compared with transfection with VO, transfection with 
MCT8 resulted in a 25% increase in the proportion of [125I]-T3 that was retained 
intracellularly after a 5- or 10-minute incubation period (P<0.05 for both). However, this 
difference in T3 uptake was not maintained following 30 minutes of incubation with [125I]-
T3. Following co-transfection of MCT8 with CRYM, the increase in T3 uptake was even 
more pronounced and it was sustained for up to 30 minutes, which was the longest 
incubation period tested. Transfection with CRYM alone did not affect T3 uptake when 
compared with transfection with VO. 
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5.3.2.3 MCT8 potentiates the pro-invasive effect of T3 on SGHPL-4s 
T3 promotes invasion by primary EVTs (Oki et al., 2004). As shown in section 
5.3.1.1, there was a trend of increased invasion by SGHPL-4s following T3 treatment, 
however this trend was not statistically significant. In order to investigate the hypothesis 
that MCT8 may amplify the effect of T3 on invasion, invasion by SGHPL-4s was assessed 
following silencing or upregulation of MCT8 expression and treatment with 0 or 10 nM 
T3. Silencing endogenous MCT8 expression did not significantly affect invasion by 
SGHPL-4s (Figure 5-12A). Following upregulation of MCT8 expression, treatment with 
10 nM T3 resulted in a 3.3-fold increase in invasion compared with treatment with 0 nM 
Figure 5-11: T3 uptake by SGHPL-4s 72 hours after MCT8 silencing (A) or MCT8 
transfection (B). SGHPL-4s were incubated for 0-30 minutes with [125I]-T3 and the 
amount of intracellular radioactivity was assessed. Points represent average of three 
experiments ±SEM. Statistically significant differences were assessed by ANOVA 
followed by Tukey posttests. (A) Statistically significant differences are indicated by * 
(control siRNA vs MCT8 siRNA), + (control siRNA vs MCT8 siRNA + CRYM), x (MCT8 
siRNA + CRYM vs CRYM) and ^ (MCT8 siRNA vs CRYM). (B) Statistically significant 
differences are indicated by * (VO vs MCT8), + (VO vs MCT8 + CRYM), x (MCT8 + 
CRYM vs CRYM) and § (MCT8 vs MCT8 + CRYM). *P<0.05, **P<0.01 and 
***P<0.001.  
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T3 (Figure 5-12B; P<0.05). In contrast, in cells that were transfected with VO, treatment 
with 10 nM T3 resulted in a 1.8-fold increase in invasion compared with treatment with 0 
nM T3 (not statistically significant). 
 
5.3.2.4 MCT8 does not affect SGHPL-4 proliferation 
As discussed in the previous chapter, upregulation of MCT8 resulted in decreased 
survival of primary CTs (section 4.3.3) and in reduced proliferation of the 
choriocarcinoma cell line JEG-3 (James et al., 2009). In order to investigate whether 
MCT8 has a similar effect on SGHPL-4s, SGHPL-4 proliferation was assessed by MTT 
following silencing and upregulation of MCT8 expression and culture in the absence or 
Figure 5-12: SGHPL-4 invasion through Matrigel® following silencing of endogenous 
MCT8 expression (A) or transfection with MCT8 (B) and treatment with 0 or 10 nM T3. 
Invasion was assessed 72 hours after transfection. Within each experiment, the number of 
invading cells was normalised to the average number of invading cells in the control 
groups that were transfected with control siRNA (A) or VO (B) and treated with 0 nM T3. 
Bars represent average of five (silencing) or eight (upregulation) experiments ±SEM. 
Results following analysis by ANOVA are indicated by xx (P<0.01). Statistically 
significant differences between groups analysed by Tukey post-tests are indicated by 
*(P<0.05). 
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presence of T3. In contrast with the results observed in other cell types, there was no 
significant difference in SGHPL-4 proliferation either with changes in MCT8 expression 
or with T3 treatment (Figure 5-13). 
 
5.3.2.5 Silencing of MCT8 expression reduces SGHPL-4 apoptosis 
The effect of MCT8 on SGHPL-4 survival was further assessed by investigating 
apoptosis in response to changes in the expression of MCT8 in the absence or presence of 
T3 using the caspase 3/7 activity assay. Overall, silencing of MCT8 expression caused a 
reduction in caspase 3/7 activity (Figure 5-14A; P<0.01). Compared with control siRNA, 
transfection with MCT8 siRNA caused a 10% reduction in caspase 3/7 activity both in 
cells treated with 0 nM T3 and in cells treated with 10 nM T3 (P<0.05 for both). In 
contrast, upregulation of MCT8 expression did not have an effect on caspase 3/7 activity 
in SGHPL-4s (Figure 5-14B). 
Figure 5-13: SGHPL-4 proliferation following silencing of endogenous MCT8 expression 
(A) or transfection with MCT8 (B) and treatment with 0 or 10 nM T3. Absorbance at 570 
nm was determined 72 hours after transfection and was normalised to the absorbance in 
the control groups that were transfected with control siRNA (A) or VO (B) and treated 
with 0 nM T3. Bars represent average of five experiments ±SEM. 
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5.3.2.6 MCT8 does not affect necrosis of SGHPL-4s 
In addition, the possibility that MCT8 causes necrosis of SGHPL-4s was 
investigated by assessment of the level of LDH activity in cell culture media following 
MCT8 silencing or upregulation. There was no change in cell necrosis either with changes 
in MCT8 expression or with T3 treatment (Figure 5-15). 
Figure 5-14: SGHPL-4 apoptosis following silencing of endogenous MCT8 expression 
(A) or transfection with MCT8 (B) and treatment with 0 or 10 nM T3. Apoptosis was 
assessed 72 hours after transfection by assessing the activity of caspase 3/7. Caspase 3/7 
activity was normalised to the activity in the control groups that were transfected with 
control siRNA (A) or VO (B) and treated with 0 nM T3. Bars represent average of five 
experiments ±SEM. ANOVA results are indicated by xx (P<0.01). Statistically significant 
differences between groups as assessed by Tukey post-tests are indicated by * (P<0.05). 
 




Figure 5-15: SGHPL-4 necrosis following silencing of endogenous MCT8 expression (A) 
or transfection with MCT8 (B) and treatment with 0 or 10 nM T3. Necrosis was assessed 
72 hours after transfection by determining the LDH) activity in the cell culture media. 
LDH activity was normalised to the activity in the control groups that were transfected 
with control siRNA (A) or VO (B) and treated with 0 nM T3. Bars represent average of 
three experiments ±SEM. 
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5.4 Discussion and conclusions 
In this study, the role of MCT8 in EVTs was investigated using the EVT-like cell 
line, SGHPL-4. According to the findings presented here, MCT8 mediates the pro-
invasive effect of T3 on SGHPL-4s. Furthermore, silencing MCT8 expression reduces 
SGHPL-4 apoptosis in a T3-independent manner. 
5.4.1 Use of SGHPL-4s as an EVT-like cell line model 
The development of EVT-like cell lines has been useful for the investigation of 
EVT cell biology and function, particularly because of the difficulties in obtaining first 
trimester placental tissue for primary cultures. However, there is ongoing debate about the 
validity of the use of cell lines as models of EVTs (Shiverick et al., 2001). SGHPL-4s, an 
immortalised cell line derived from primary EVTs, express MHC Class I antigens, human 
placental lactogen, human chorionic gonadotropin, integrin α1 and cytokeratin 7, which 
are also expressed in EVTs and they therefore have characteristics of EVTs (Choy et al., 
2000, Lash et al., 2007). However, in contrast to EVTs, SGHPL-4s do not express HLA-
G (Lash et al., 2007). Furthermore, the responsiveness of cell lines to stimuli such as 
hypoxia and TGF-β1 has been shown to differ from primary EVT cultures (Lash et al., 
2007). 
5.4.2 Effects of T3 treatment on SGHPL-4 cells 
Prior to investigating the role of MCT8 in SGHPL-4s, the effects of T3 treatment 
were assessed. The presence of mRNA encoding TRα1, TRα2 and TRβ1 in SGHPL-4s 
suggests that these cells can respond to T3 treatment. Treatment with T3 resulted in 
increasing trend in cell invasion by SGHPL-4s, which did not reach statistical 
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significance, whilst SGHPL-4 proliferation and apoptosis were not affected by T3 
treatment. In a previous report from our group, T3 increased the motility of SGHPL-4 
cells but did not affect significantly the number or length of the invasive processes formed 
(Barber et al., 2005). Furthermore, in the report by Barber et al. T3 treatment had an anti-
proliferative effect on SGHPL-4s. The discrepancy on the effect of T3 on SGHPL-4 
proliferation may be due to the differences in the cell culture conditions and in the time 
point that was used to assess the effect of T3 on cell proliferation. In the study by Barber 
et al. the cells were cultured in 0.5% FCS, and were therefore exposed to lower 
concentrations of all serum constituents, in contrast to 10% SFCS, which was used in the 
experiments described here and is only devoid of lipophilic substances, such as hormones. 
Furthermore, in the study by Barber et al. effects were assessed 72 hours after treatment 
with T3 instead of 48 hours that was the time point used in the experiments described in 
this thesis (Barber et al., 2005). Previous studies have shown that T3 promotes invasion 
(Oki et al., 2004) and decreases apoptosis (Laoag-Fernandez et al., 2004) in primary 
EVTs. In contrast, T3 had a modest effect on SGHPL-4 invasion, which did not reach 
statistical significance. This together with the differential effect of T3 on apoptosis of 
EVTs and SGHPL-4s suggests that there may be differences between the T3 
responsiveness of EVTs and SGHPL-4s. It has to be noted, however, that in the quoted 
studies, EVTs were cultured in media supplemented with 4% FCS, which would therefore 
contain more hormones compared with media supplemented with 10% SFCS. 
The expression of the TH responsive genes Cx43 and ME1 was investigated 
following treatment with T3 in order to demonstrate the induction of genomic TH actions 
by T3 treatment in SGHPL-4s. It has been shown that TRs bind to a response element in 
the promoter of the rat gap junction protein, Cx43, (Stock and Sies, 2000) suggesting that 
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THs can regulate the expression of Cx43. This was confirmed by further evidence that 
treatment with T3 increased the expression of Cx43 in rat liver epithelial cells (Stock et 
al., 1998), in cultured rat heart myocytes (Tribulova et al., 2004) and in mouse Sertolli 
cells (Gilleron et al., 2006). In addition, TH response elements have been identified in the 
promoter region of the human cytosolic enzyme ME1 (Gonzalez-Manchon et al., 1997). 
However, the effect of genomic TH action on ME1 expression is cell type-specific with 
T3 stimulating an increase in ME1 expression in chick embryo hepatocytes whereas it had 
little or no effect on ME1 expression in chick embryo fibroblasts and in quail QT6 cells 
(Hillgartner et al., 1992). Data on the regulation of ME1 expression by THs suggest that 
cell-type specific differences may be mediated by non-receptor proteins that augment the 
transcriptional activity of TRs in hepatocytes (Hillgartner et al., 1992). In SGHPL-4s, 
treatment with T3 did not affect the mRNA expression of either Cx43 or ME1, which is 
consistent with previous findings in primary cultures of human term CTs (Barber, 2005). 
Therefore, it was not possible to demonstrate genomic action of TH in SGHPL-4s using 
these genes. 
5.4.3 Changes in SGHPL-4 MCT8 expression and impact on T3 uptake 
In this study, MCT8 expression was silenced or upregulated in order to elucidate 
the role of MCT8 in SGHPL-4s. The validation of MCT8 silencing at the protein level 
was hindered by the problems in detecting endogenous MCT8 expression in SGHPL-4s 
using the 4790 MCT8 antibody produced by our group (Loubière et al., 2010), even 
though this antibody has been successfully used to detect endogenous MCT8 protein in 
other cell types, such as CTs (see Chapters 3 and 4) and N-Tera-2 cells. However, 
TaqMan PCR revealed that MCT8 mRNA is present at high levels in SGHPL-4s, and 
furthermore there was a reduction of MCT8 mRNA following transfection with MCT8. 
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Despite the problems in the detection of endogenous MCT8 protein in SGHPL-4s using 
the 4790 antibody, detection was possible using the 1306 MCT8 antibody and the 
downregulation of MCT8 following transfection with MCT8 siRNA was confirmed at the 
protein level. It is not clear why there is a difference in the detection of MCT8 using the 
two different antibodies. It is possible that the difference is associated with the different 
epitopes targeted by the two antibodies. Antibody 4790 recognises an epitope at the N-
terminus of the MCT8 protein, whilst antibody 1306 recognises an epitope on the C-
terminus of MCT8. 
The functional impact of changes in MCT8 expression was confirmed by changes 
in T3 uptake by SGHPL-4s. Furthermore, co-transfection with CRYM was used to inhibit 
T3 efflux. CRYM is a cytosolic protein that binds to T3 (Vie et al., 1997) and increases the 
concentration of intracellular T3 (Suzuki et al., 2007). It is thought that CRYM may 
regulate TH action by regulating they cytoplasmic and nuclear distribution of T3 and thus 
regulating the expression of T3-responsive genes (Suzuki et al., 2007). In humans, CRYM 
mRNA has been detected in skeletal muscle, heart, kidney, brain, retina and in the inner 
ear (Kim et al., 1992) and CRYM mutations have been associated with deafness (Abe et 
al., 2003, Oshima et al., 2006). Silencing of MCT8 expression considerably reduced T3 
uptake by SGHPL-4s and this difference was maintained following incubation with [125I]-
T3 for 30 minutes. This suggests that T3 uptake by SGHPL-4s transfected with MCT8 
siRNA does not reach the same level of uptake as in cells with basal MCT8 levels, at least 
in the timeframe that was investigated. The impact of MCT8 silencing on T3 uptake is 
highlighted by the inability of cells transfected with MCT8 siRNA to accumulate higher 
levels of intracellular T3 following co-transfection with CRYM. The capacity of SGHPL-
4s for T3 uptake following MCT8 silencing amounted to 60% of the uptake by cells 
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transfected with control siRNA. Since, it was shown that MCT8 silencing in SGHPL-4s 
resulted in undetectable MCT8 protein, other TH transporters present in SGHPL-4s are 
probably responsible for the residual T3 uptake following MCT8 silencing. 
Transfection of SGHPL-4s with human wild-type MCT8 resulted in an initial 
increase in T3 uptake by SGHPL-4s, which however was not maintained following a 
longer (30 minute) incubation with [125I]-T3. Although an increase in MCT8 expression 
results in increased ability of the cells to uptake T3, it does not affect the amount of T3 that 
was retained intracellularly when transport was allowed to occur for longer and 
equilibrium was approached due to T3 efflux taking place. This was confirmed when T3 
uptake by SGHPL-4s that were co-transfected with MCT8 and CRYM was investigated. 
In these cells, the proportion of T3 that was retained intracellularly following 30 minutes 
of incubation with [125I]-T3 was higher compared with cells transfected with MCT8. This 
result confirms that increased T3 efflux limits the amount of T3 that is retained in cells 
transfected with MCT8 following long incubations with [125I]-T3. However, when T3 
efflux in cells transfected with MCT8 is prevented by co-transfection with CRYM, 
intracellular accumulation of [125I]-T3 continues to increase after a 30-minute incubation 
period and equilibrium is not reached. 
5.4.4 MCT8 potentiates the pro-invasive effect of T3 on SGHPL-4s 
As discussed in section 5.4.1, treatment with T3 results in an increasing trend in 
SGHPL-4 invasion through Matrigel®. Transfection with MCT8 amplifies the pro-
invasive effect of T3 on SGHPL-4s. Conversely, silencing of MCT8 expression attenuates 
the pro-invasive effect of T3. These results suggest that MCT8 may play a role in 
regulating invasion into the maternal endometrium by controlling T3 transport into EVTs.  
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Invasion of EVTs in the maternal endometrium during early pregnancy is critical 
for normal placental development. Deficient EVT invasion has been associated with 
malplacentation and pregnancy complications such as IUGR (Brosens et al., 1977), pre-
eclampsia (Brosens et al., 1972), preterm delivery (Norwitz, 2006) and late (≥13 weeks) 
but not early (<12 weeks) pregnancy loss (Ball et al., 2006a, Ball et al., 2006b). Maternal 
hyperthyroidism has been associated with IUGR and pre-eclampsia (Mestman, 2004), 
whilst maternal subclinical hypothyroidism has been associated with increased risks of 
miscarriage, placental abruption and preterm delivery (Abalovich et al., 2002, Casey et 
al., 2005). These observations suggest that an optimal supply of maternal THs is 
important for normal placental development.  
In accordance to previous reports (Barber et al., 2005, Oki et al., 2004), the results 
presented in this chapter suggest that THs may affect early placental development by 
promoting invasion by EVTs. Furthermore, they suggest that changes in the expression of 
the TH transporter MCT8 can regulate the effect of T3 on EVT invasion by controlling 
intracellular T3 availability. The expression of MCT8 and of other TH transporters that 
have been localised in EVTs, such as MCT10 and OATP1A2 (Chapter 2), may thus be 
important in the regulation of EVT invasion in early pregnancy. Further studies would be 
necessary to further elucidate the mechanisms that regulate the pro-invasive effect of T3 
on EVT invasion and the importance of MCT8 in mediating the action of T3. Assessment 
of the motility of the cells by time-lapse microscopy can be used to support the evidence 
that MCT8 potentiates the pro-invasive effect of T3 on SGHPL-4s. Deiodinase enzymes 
may play a role in the regulation of the pro-invasive effect of T3. A previous report 
suggests that T3 treatment does not alter the mRNA expression levels of D2 and D3 in 
primary cultures of term CTs (Chan et al., 2003). Assessment of the expression and 
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activity of deiodinase enzymes following changes in MCT8 expression and treatment with 
T3 would help elucidate the possibility that there is lack of regulation by deiodinases 
following increased T3 uptake by SGHPL-4s. 
T3 has also been shown to have a pro-invasive effect on the human hepatocellular 
carcinoma cell line, HepG2 (Chen et al., 2008b). In the report by Chen et al., it was 
shown that T3 promotes invasion by upregulating the expression of furin, a protease that 
activates matrix metalloproteinases (MMP) 2 and 9. Furin is present in the human 
placenta and its expression is higher in the first trimester (Zhou et al., 2009). Using the 
EVT-like cell line HTR-8, Zhou et al. have shown that furin upregulates HTR8 invasion 
through Matrigel® via upregulation of MMP-9 activity. It is therefore possible that T3 
exerts its pro-invasive effect on EVTs via upregulation of furin expression, which in turn 
may upregulate the activity of MMP-9 resulting in increased invasion. 
5.4.5 Effects of MCT8 on SGHPL-4 growth 
MCT8 did not affect SGHPL-4 proliferation, as assessed by MTT assay. However, 
silencing of MCT8 expression decreased apoptosis independently of T3 treatment, 
assessed by changes in caspase 3/7 activity, in contrast with upregulation of MCT8 
expression, which did not affect apoptosis. In contrast to the effect of MCT8 on CT 
survival (Chapter 4) and on the proliferation of JEG-3 and N-Tera-2 cells (James et al., 
2009), this is the only cell type where we did not observe an effect of MCT8 on cell 
number. Furthermore, this is the first time that MCT8 is reported to affect apoptosis. At 
present, the mechanisms that are involved in the T3-independent effects of MCT8 are 
unknown. It is therefore difficult to postulate on the molecular pathways that may be 
responsible for the differential effect of MCT8 on SGHPL-4s compared with the other 
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cell types that have been investigated so far. However, it has to be noted that in contrast to 
JEG-3, which is a proliferating choriocarcinoma cell line, SGHPL-4 cells have an 
invasive phenotype and a lower proliferating rate. Therefore, the molecular apparatus that 
controls cell proliferation might be different in SGHPL-4s compared with JEG-3 cells. In 
future work, assessment of the effects of MCT8 on cell cycle in different cell types could 
help elucidate the effects of MCT8 on cell survival and proliferation and could lead to the 
identification of the pathways that are regulated by MCT8. Furthermore, it would be 
important to confirm these findings using primary cultures of EVTs, especially since that 
there was no effect of T3 on SGHPL-4 apoptosis is contrast to what has been previously 
reported using primary EVT cultures (Laoag-Fernandez et al., 2004). 
5.4.6 Conclusions 
The data presented in this chapter demonstrate that changes in the expression of 
MCT8 affect the EVT-like cells, SGHPL-4s, via both T3-dependent and T3-independent 
mechanisms. These observations are consistent with the hypothesis that MCT8 may 
mediate the promoting effect of TH on the invasive ability of EVTs and EVT-like cells. 
Furthermore, the T3-independent effect of MCT8 silencing on SGHPL-4 apoptosis is 
consistent with the postulation that MCT8 may transport other compounds in addition to 
THs. The role of THs and of MCT8 on the regulation of EVT apoptosis and invasiveness 
needs to be investigated further in order to confirm these findings on primary cultures of 
EVTs and to elucidate the mechanisms that mediate these effects. Further understanding 
of these mechanisms will help to better define the contribution of MCT8 and THs in the 
regulation of EVT invasion into the maternal myometrium and transformation of the 
maternal spiral arteries, events that are critical for normal placentation. 
Chapter 6: The Role of MCT8 in Placental Development Using 
a MCT8-knockout Mouse Model
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6.1 Introduction 
In the previous chapters, the effect of MCT8 on placental development was 
investigated using in vitro approaches. The outcomes of these experiments were that 
MCT8 affects both EVT-like cells and CT cells via either T3-dependent or T3-independent 
mechanisms. MCT8 promotes the pro-invasive effect of T3 on invasion by EVT-like cells 
whilst MCT8 knockdown decreases apoptosis of EVT-like cells independently of T3. 
Furthermore, MCT8 appears to impair the survival of CT cells regardless of T3 
availability. These results suggest that MCT8 may play a role in placentation by 
regulating trophoblast invasion and placental growth and this could be further investigated 
by assessing the effect of MCT8 on placental development in vivo. 
Recently, two MCT8-deficient mice models have been developed by two different 
laboratories (Dumitrescu et al., 2006, Trajkovic et al., 2007). Both the models have 
revealed that knockout of MCT8 in mice results in changes in TH metabolism similar to 
the ones observed in patients affected by MCT8 mutations. Serum T4 is reduced whilst 
serum T3 is increased in MCT8-null mice compared with wild-type littermates. However, 
unlike the situation in human patients affected by MCT8 mutations, who suffer from 
severe neurological impairment and locomotion deficits, MCT8-deficient mice do not 
exhibit any overt neurodevelopmental disorders. Furthermore, there are no differences in 
the fertility and reproduction of MCT8-deficient mice and no changes in growth rate 
postnatally. However, the effect of MCT8 deficiency on fetoplacental growth has not been 
investigated so far. 
Mouse models are often employed to study pathways that may affect fetoplacental 
development (Watson and Cross, 2005). There are both similarities and differences 
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between human and mouse placental structures (Figure 6-1). The labyrinth region of the 
mouse placenta is thought to be analogous to the chorionic villi in humans (Rossant and 
Cross, 2001). In both cases, a ST cell layer is in direct contact with maternal blood and 
controls transplacental transport. The middle region of the mouse placenta, the junctional 
zone, consists of spongiotrophoblast cells. Cells from the junctional zone are thought to 
differentiate to polyploid trophoblast giant cells that are found in the decidua basalis, the 
outer region of the mouse placenta (Rossant and Cross, 2001). Trophoblast giant cells 
mediate the invasion of the maternal uterus. Therefore, the junctional zone of the mouse 
placenta is thought to be analogous to the CT columns that are found in the chorionic villi 
of the human placenta and the trophoblast giant cells are thought to have similar 
behaviour and function in the mouse placenta as EVTs in human (Rossant and Cross, 
2001). 
 
Figure 6-1: Comparative diagram of the structure of mouse (A) and human (B) placenta. 
The main cell types found in each region are annotated in the left panel. The right panel 
shows a cross-section of the fetal-maternal interface. Figure adapted from (Rossant and 
Cross, 2001). 
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In the study presented in this chapter the MCT8 knockout mouse model produced 
by Dr H Heuer’s lab (Trajkovic et al., 2007) was used to investigate the effect of MCT8 
deficiency on fetoplacental development. For the generation of MCT8-deficient mice, a 
33 bp fragment of exon 2, corresponding to nucleotides 758-790 of the MCT8 cDNA 
clone, was replaced by an IRES-LacZ Neo Insert containing a polyadenylation signal at 
the 3’ end (Figure 6-2) (Trajkovic et al., 2007). The effects of MCT8 were assessed at 
gestational day 14.5 (E14.5), which is before the onset of fetal TH production in mice (De 
Felice et al., 2004), and at gestational day 18.5 (E18.5), which is after the onset of TH 
production and one day before delivery in mice. Fetal and placental weights and the 
morphology of the placenta were assessed in male MCT8 knockout and male wild-type 
fetuses in order to investigate the hypothesis that MCT8 influences placental 
development. 
 
Figure 6-2: Method used for the generation of MCT8 knockout mice. 
A fragment of exon 3 (33 bp) was replaced by an IRES-LacZ Neo 
insert. ATG: start codon; TGA: stop codon; pA: polyadenylation 
signal. Figure from (Trajkovic et al., 2007). 
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6.2 Materials and Methods 
Animal matings, euthanisation, dissection and genotyping were carried out during 
a visit to Dr H Heuer’s laboratory in the Leibniz Institute for Age Research/Fritz Lipmann 
Institute, Gena, Germany with approval by the Animal Welfare Committee of the 
Medizinische Hochschule Hannover, Germany. Further experiments were performed in 
the Institute of Biomedical Research, Birmingham, UK. 
6.2.1 Matings 
Heterozygous female carrier mice (MCT8+/-; n=6) were mated with male knockout 
mice (MCT8-/0) in order to generate male knockout (MCT8-/0), male wild-type (MCT8+/0), 
heterozygous female (MCT8+/-) and female knockout (MCT8-/-) offspring at ratios of 
1:1:1:1. Changes in fetoplacental weights and stereology of the placenta were compared 
between MCT8-/0 and MCT8+/0 fetuses. 
6.2.2 Euthanisation and dissection 
Two of the pregnant dams were euthanised at E14.5 and four were euthanised at 
E18.5. All pregnant dams were euthanised by CO2 administration and they were weighed. 
The abdominal cavity was dissected and the uterine horns were retrieved. Each fetus and 
placenta was dissected out separately in a Petri dish containing PBS. Fetuses were 
weighed and the tails were biopsied for genotyping in order to determine the sex and the 
MCT8 status of each fetus. Each placenta was cleared of any uterine muscle and yolk sac 
and was weighed. Half of the placenta was fixed overnight at 4°C in 
paraformaldehyde/PIPES fixative (pH 7.4) containing 4% (w/v) paraformaldehyde, 3% 
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(w/v) PIPES, 3% (w/v) PVP40 and 0.02% (w/v) CaCl2 for histological assessment. The 
other half was immediately frozen for RNA extraction. 
6.2.3 Genotyping 
6.2.3.1 DNA extraction 
DNA was extracted from the tails in order to determine the sex and MCT8 status 
of the fetuses by PCR. The tails were digested by incubating overnight at 55°C, with 
shaking at 1,000 rpm, in buffer (0.71 ml per sample) containing 50 mM Tris/HCl (pH 
8.0), 0.1 M EDTA (pH 8.0), 0.4% SDS and Proteinase K (0.53 mg/ml; Roth, Germany). 
Following digestion, 0.25 ml of 6 M NaCl were added to each sample and the samples 
were shaken (1,000 rpm) for 5 minutes at 55°C. The samples were centrifuged at 13,000 
rpm for 10 minutes and the supernatant, containing the DNA, was transferred to new 
tubes. Isopropanol (0.6 ml) was added to each sample, in order to precipitate the DNA, 
the solutions were mixed by inverting and were centrifuged at 13,000 rpm for 10 minutes. 
The supernatant was discarded and the pellet was washed with 1 ml 70% (v/v) ethanol by 
centrifugation at 13,000 rpm for 10 minutes. The pellet was air-dried and resuspended in 
100 µl Tris/HCl (10 mM; pH 8.0). The samples were shaken (1,000 rpm) at 55°C for 2 
hours and diluted 1:30 with molecular quality water. 
6.2.3.2 Sex determination 
The sex of each fetus was determined by PCR amplification of a 433 bp-long 
sequence in the sex-determining region of chromosome Y (SRY) using the primers shown 
in Table 6-1. A PCR product would only be present if the DNA originated from a male 
fetus, while absence of a product indicated that the DNA belonged to a female fetus. DNA 
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was amplified using the Taq PCR Core Kit (Qiagen). DNA (3 µl) was mixed with 3 
pmoles of each primer, dNTPs (2 nmoles of each), Buffer (1 µl), Q solution (2 µl) and 
Taq polymerase (1 unit) in a total volume of 10 µl. The samples were heated at 94°C for 3 
minutes followed by 35 cycles at 94°C for 90 seconds, 59°C for 60 seconds and 72°C for 
60 seconds. They were incubated at 72°C for 7 minutes before cooling at 10°C. 
Table 6-1: Primers for SRY genotyping 
Forward Primer Reverse Primer 
Amplicon 
length (bp) 
TGGTGAGAGGCACAAGTTGG CTGCTGGTGGTGGTTATGGA 433 
 
6.2.3.3 MCT8 genotyping 
Three primers were used to detect the targeted allele (containing the IRES-LacZ 
Neo Insert) and the wild-type allele (Table 6-2): two separate forward primers, 
recognising the wild-type allele or the targeted allele, and a common reverse primer that 
recognised both the wild-type and the targeted allele. The expected size of the PCR 
products was 450 bp for the wild-type allele and 680 bp for the targeted allele. DNA (2 
µl) was mixed with 5 pmoles of each primer, dNTPs (1 nmole of each), TEMPase buffer 
with 15 mM MgCl2 (1 µl) and 0.5 units of TEMPase polymerase (all from Ampliqon, 
Denmark) in a total volume of 10 µl. The samples were heated at 95°C for 15 minutes 
followed by 35 cycles at 95°C for 30 seconds, 60°C for 30 seconds and 72°C for 30 
seconds. They were incubated at 72°C for 5 minutes before cooling at 10°C. The SRY and 
MCT8 PCR products were electrophoresed through a 1% agarose gel and were visualised 
using a UV transilluminator. Representative gels for SRY and MCT8 genotyping are 
shown in Figure 6-3. The genotyping results for all litters are shown in Table 6-3. 
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Table 6-2: Primers for MCT8 genotyping  










Table 6-3: Genotyping of fetuses harvested at gestational days E14.5 and E18.5 
Dam ID Total N of 
fetuses 









769 12 1 2 1 8 
768 12 7 2 2 1 
E18.5 
756 11 3 4 4 0 
657 13 4 2 7 0 
679 9 2 1 2 4 
749 14 4 4 3 3 
Total 71 21 (29.6%) 15 (21.1%) 19 (26.8%) 16 (22.5%) 
 
Figure 6-3: Genotyping results for litter 769. (A) SRY genotyping: The presence of a 433 
bp long species indicated the presence of the Y chromosome. Samples in lanes 1, 2, 3 ,4 , 
5, 7, 8, 10 and 12 were identified as originating from male fetuses. Samples in lanes 6, 9 
and 11 were from females fetuses. (B) MCT8 genotyping: The presence of a band at 450 
bp indicated that the endogenous wild-type allele (E) was present, whilst the presence of a 
band at 680 bp indicated that the the target knockout allele (T) containing the 
lacZ/neomycin reporter casette was present. Samples in lanes 1, 3-10 and 12 were from 
MCT8 knockout fetuses. The sample in lane 2 was from a wild-type fetus and the sample 
in lane 11 was from a heterozygous fetus. 
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6.2.4 MCT8 mRNA expression assay 
RNA was extracted from frozen placental tissue harvested from male fetuses at 
E18.5 and reverse transcribed as described in sections 2.2.2 and 2.2.3. MCT8 mRNA 
expression was compared between placentae from MCT8-/0 (n = 6) and MCT8+/0 fetuses 
(n = 11) following the protocol described in section 2.2.5 using primer and probe 
sequences designed using the human MCT8 sequence and shown in Table 6-4. 
Table 6-4: Primer and probe sequences for relative quantification of mouse MCT8 
expression by TaqMan PCR. 







Sequences are given in the 5’-3’ direction. Underlined base pairs correspond to the 
boundary between exons 5 and 6. 
6.2.5 Stereo-histological assessment of the placenta 
Following overnight incubation in paraformaldehyde/PIPES, the placental halves 
were washed twice with PBS (15 minute washes). They were washed in 70% ethanol for 
30 minutes and were stored in 70% ethanol at 4°C until they were transported to 
Birmingham. The tissue was dehydrated by a 30-minute wash in 70% ethanol followed by 
three washes in 90% ethanol and three washes in 100% ethanol. The samples were 
incubated in histoclear overnight and then washed in fresh histoclear for another 60 
minutes. Before embedding, the tissues were incubated for 3 hours in paraffin at 58°C and 
during this incubation paraffin was replaced with fresh paraffin every hour. They were 
then embedded in fresh paraffin with the cut surface facing the bottom of the mould. 
Paraffin embedded placentae from two MCT8-/0 and two MCT8+/0 fetuses from the same 
litter (749) were exhaustively sectioned to 7 µm-thick sections and mounted onto slides. 
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Randomly selected sections ranging from the centre to the periphery of the 
placenta (20 sections per placenta) were stained with Harris Haematoxylin to visualise the 
nuclei and Eosin to stain the cytoplasm (H&E staining). The sections were incubated in 
xylene for 5 minutes followed by two 3-minute washes in industrial methylated spirits 
99% (IMS) and a 5-minute wash in tap water. They were stained in Haematoxylin for 3 
minutes followed by a 2-minute wash in tap water. After a 30-second incubation in acid 
alcohol (1%), the samples were washed in tap water for 2 minutes and incubated in 
Scott’s tap water for 30 seconds. The sections were stained in eosin for 2 minutes, washed 
in tap water for 2 minutes and washed twice in IMS for 2 minutes. Following a 2-minute 
incubation in xylene, the sections were mounted using DPX mountant (all from Surgipath, 
Peterborough, UK). The sections were photographed using a 2× objective lens and the 
volume fraction of the labyrinth zone and the junctional zone were estimated following 
the methodology described in Coan et al. (Coan et al., 2004). A grid was superimposed 
over each section and the total number of points falling on the labyrinth zone, the 
junctional zone and the whole placenta were counted. The volume fraction of each zone 
was estimated as the number of points falling on that zone divided by the number of 
points falling on the placenta. In order to calculate the absolute placental volume, the wet 
placental weight of each sample was multiplied by 1.05, which is the estimate of the 
specific gravity of the human placenta (Laga et al., 1973). This value was then multiplied 
by the volume fraction of each zone in order to get an estimate of the absolute volume of 
the labyrinth and junctional zone. 
6.2.6 Statistical analysis 
Differences between the MCT8-/0 group and the MCT8+/0 group were analysed by 
unpaired two-tailed Student’s t test using the Minitab® statistical software (version 15).  
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6.3 Results 
6.3.1 MCT8 mRNA expression in MCT8-/0 and MCT8+/0 placentae 
The knockdown of MCT8 mRNA expression in the placentae of MCT8-deficient 
fetuses at E18.5 was confirmed by quantitative TaqMan PCR. MCT8 mRNA expression 
was reduced by 84% in MCT8-/0 placentae compared with MCT8+/0 placentae (P<0.01; 
Figure 6-4). 
 
6.3.2 Fetoplacental weights 
Individual wet fetal and placental weights of MCT8+/0 and MCT8-/0 fetuses were 
compared. Due to the small number of litters (n = 2 for both gestational ages) that had 
fetuses of both MCT8+/0 and MCT8-/0 genotypes, it was not possible to compare the 
Figure 6-4: Relative mRNA expression of MCT8 in MCT8+/0 (n = 
11) and MCT8-/0 (n = 6) placentae disected at E18.5. Expression is 
compared to the mean MCT8 expression in MCT8+/0 placentae that 
was given the arbitrary value of one. Statistically significant 
differences between groups are indicated by ** (P < 0.01; t test). 
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average fetal and placental weights per litter, therefore the analysis was performed on 
pooled litters. 
At E14.5, the average fetal weight of MCT8+/0 fetuses was 308.1 mg ± 33.8 (n = 3; 
average ± SEM) and the average fetal weight of MCT8-/0 fetuses was 313.1 mg ± 4.7 (n = 
9; Figure 6-5A). However, at E18.5, MCT8-/0 fetuses (n = 7) were 9% lighter compared 
with MCT8+/0 fetuses (n = 16) (P < 0.05; Figure 6-5B; average fetal weight ± SEM: 1273 
mg ± 24.5 and 1397 ± 28.6 respectively). 
 
The placental weights of the two groups were also compared in order to assess 
whether placental growth was altered as a consequence of knocking down MCT8. The 
average weight of placentae from MCT8-/0 fetuses at E14.5 was 81.3 mg ± 3.8 (n = 9), 
whilst the average placenta weight from MCT8+/0 fetuses was 67.1 mg ± 5.7 (n = 3) (NS; 
Figure 6-6A). At E18.5 the average placenta weight of MCT8-/0 fetuses (n = 7) was 17% 
greater compared with the average placental weight from MCT8+/0 fetuses (n = 16) (P < 
Figure 6-5: Weights of MCT8+/0 and MCT8-/0 fetuses at gestational day 14.5 (A; E14.5) 
and at gestational day 18.5 (B; E18.5). Points represent weights of individual fetuses and 
the lines represent the mean fetal weight for each group. Statistically significant 
differences between groups are indicated by * (P<0.05; t test). 
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0.05; Figure 6-6B; average placental weight ± SEM: 90.3 mg ± 6.5 and 77.3 ± 2.8, 
respectively). 
 
Fetal to placental weight ratios in MCT8-/0 and MCT8+/0 fetuses were calculated to 
assess placental efficiency (Coan et al., 2008) and it was found that in MCT8-/0 fetuses the 
placenta supported less grams of fetus per gram of placenta compared with MCT8+/0 
fetuses, indicating that the MCT8-/0 placenta is less efficient than the MCT8+/0 placenta. 
The ratio of fetal to placental weight was decreased by 18% at E14.5 (NS; Figure 6-7A) 
and by 28% at E18.5 (P<0.01; Figure 6-7B) in MCT8-/0 fetuses compared with MCT8+/0 
fetuses. 
Figure 6-6: Weights of placentae from MCT8+/0 and MCT8-/0 fetuses at gestational day 
14.5 (A; E14.5) and at gestational day 18.5 (B; E18.5). Points represent weights of 
individual samples and the lines represent the mean placental weight for each group. 
Statistically significant differences between groups are indicated by * (P<0.05; t test). 
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6.3.3 Stereo-histological assessment of the placenta 
The stereology (Figure 6-8) of placentae from two MCT8+/0 and two MCT8-/0
fetuses obtained from the same litter (litter 749; E18.5) was assessed. The volume fraction 
of the junctional zone was increased whilst the volume fraction of the labyrinth zone was 
decreased in placentae from MCT8-/0 fetuses compared with placentae from MCT8+/0 
littermates (Figure 6-9). Furthermore, the calculated absolute volume of the junctional 
zone was 10% greater in the MCT8-/0 placentae, whilst the absolute volume of the 
labyrinth was smaller by 5% (Table 6-5). However, these results did not reach statistical 
significance in the limited sample number that was assessed. 
Figure 6-7: Ratios of fetal/placental weights for MCT8+/0 and MCT8-/0 fetuses at 
gestational day 14.5 (A; E14.5) and at gestational day 18.5 (B; E18.5). Bars represent 
average ratios for each group +SEM (E14.5: MCT8+/0 n = 3, MCT8-/0 n = 9; E18.5: 
MCT8+/0 n = 16, MCT8-/0 n = 7). Statistically significant differences between groups are 
indicated by ** (P<0.01; t test). 
 




Figure 6-8: Paraffin sections of E18.5 placentae. The sections were stained with 
Harris Hematoxylin and Eosin and were viewed under a 2× objective. (A) A grid 
was superimposed over each section and component densities of each zone relative 
to the placenta were measured by point counting. (B) Junctional (Jz) and labyrinth 
zones (Lz) in representative sections from one wild-type (MCT8+/0) and one 
knockout (MCT8-/0) placenta. 
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Table 6-5: Absolute volumes (cm3) of total placenta, Lz and Jz 
in the MCT8+/0 and the MCT8-/0 mouse placenta. 
 MCT8+/0 MCT8-/0 
Placenta 0.073 ± 0.003 0.076 ± 0.001 
Lz 0.046 ± 0.002 0.044 ± 0.003 
Jz 0.017 ± 0.003 0.019 ± 0.003 
Values are mean volumes obtained from two samples per group 
± SEM. Lz, Labyrinth zone; Jz, Junctional zone. 
Figure 6-9: Volume fractions of labyrinth (Lz) and junctional 
zones (Jz) of MCT8+/0 and MCT8-/0 placentae. Bars represent 
the average volume fractions of two samples for each group 
+SEM. 
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6.4 Discussion and conclusions 
6.4.1 Effect of knocking down MCT8 on murine placental development and fetal 
growth 
In this study, the MCT8 knockout mouse model developed by Dr H Heuer’s 
laboratory (Trajkovic et al., 2007) was used and preliminary results were obtained on the 
potential role of MCT8 in mouse placental development and fetal growth. At E18.5, 
which is one day before normal delivery, the growth of MCT8-/0 fetuses was impaired 
although placental weight was increased. The fetal to placental weight ratio of MCT8-/0 
animals was significantly reduced indicating that the MCT8-deficient placenta supports 
less grams of fetus per gram of placenta when compared with the placenta of normal 
fetuses and is thus less efficient at sustaining fetal growth (Coan et al., 2008). At E14.5, 
which is before the onset of fetal TH production (De Felice et al., 2004), there was no 
significant difference in the weights of MCT8-/0 and MCT8+/0 fetuses. However, similar 
trends to E18.5 were observed, with increased placental weight and decreased fetal to 
placental weight ratios in MCT8-deficient mice. These initial results suggest that although 
male MCT8-deficient mice have heavier placentae compared with male wild-type fetuses, 
their placentae are less efficient. This appears to result in impaired fetal growth at late 
gestation (E18.5). 
The effect of MCT8 knockdown on fetoplacental weights suggests that the lack of 
MCT8 may affect placental morphology and structure. There were no profound changes 
in the cellular structure of the placenta when comparing MCT8-/0 and MCT8+/0 placentae. 
However, quantification of the volume fractions of each zone revealed that whilst the 
volume fraction of the junctional zone was increased, the volume fraction of the labyrinth 
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zone was decreased in the MCT8-/0 compared with MCT8+/0 placentae. This observation 
persisted when absolute volumes were calculated, suggesting that the volume of the 
junctional zone is greater in the knockout placenta, whilst the labyrinth zone is smaller. 
These results were based on a small sample number and did not reach statistical 
significance, however, if confirmed in more samples, they suggest that MCT8 knockdown 
may alter the volumes of the placental components. The labyrinth zone of the placenta is 
the region responsible for maternofetal nutrient exchange (Watson and Cross, 2005). 
Therefore, a reduction in the volume of the labyrinth may be associated with reduced 
transport capacity of MCT8-/0 placenta and may contribute to impaired growth of MCT8-/0 
fetuses. It is possible that the increased weight of the placenta of knockout fetuses reflects 
an attempt to compensate for the reduced volume of the labyrinth zone. However, these 
initial results suggest that the even though the knockout placenta is larger compared with 
the wild-type, the volume of the labyrinth zone is smaller. 
6.4.2 Study limitations and future work 
This study provided important information about the potential role of MCT8 in 
mouse placental development. However, there are limitations to this work mostly due to 
the small sample number that was assessed. Future work needs to be carried out in order 
to confirm these results in larger sample groups. Assessment of placental and fetal 
weights from more litters will allow for analysis of the results per litter and can give a 
more accurate estimate on the effect of MCT8 knockout on placental and fetal weights. 
The results obtained from this sample cohort suggest that the growth of MCT8-null 
fetuses is significantly impaired at E18.5 but not at E14.5. It would be useful to assess 
placental and fetal weights across a broader range of gestational ages, including E16.5, in 
order to determine the gestational age at which fetal growth is most compromised. 
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Stereohistological assessment of the placenta can provide information about the 
placental zones that may be affected by the lack of MCT8 and thus identify 
developmental pathways that may be compromised. The initial assessment presented here 
suggests that the volume fraction of the labyrinth zone is reduced in MCT8-null placentae, 
however this study needs to be expanded in order to include more samples from E18.5 
and from earlier gestations, which could help to identify when placental architecture is 
first affected. Furthermore, it would be useful to analyse such sections further in order to 
determine the surface areas of the maternal blood spaces and the fetal capillaries and 
measure the thickness of the interhemal membrane, which constitutes the barrier between 
the maternal and the fetal circulation in the labyrinth zone of the mouse placenta (Coan et 
al., 2004). This information could be used in order to estimate and compare the theoretical 
diffusing capacity of the MCT8-/0 and the MCT8+/0 placenta (Coan et al., 2004). 
 Lack of MCT8 may result in impaired transplacental transport of THs. In the 
placenta, this could have implications for both placental development, that is known to be 
responsive to THs (Kilby et al., 2005), and for transplacental transport of maternal THs to 
the fetal circulation where they can reach TH-responsive fetal tissues, such as the 
developing brain (Chan and Kilby, 2000). In order to characterise transplacental transport 
of THs in MCT8-null mice, radioimmunoassays could be used to measure the 
concentrations of THs in the maternal circulation and in the fetus (Morreale de Escobar et 
al., 1985). Previous studies in MCT8-null mice have shown that TH availability varies 
between tissues depending on the tissue-specific expression of other TH transporters and 
on the activity of deiodinases. MCT8 knockout results in a hypothyroid state of the brain, 
where MCT8 appears to play a crucial role for TH uptake, whilst the liver and the kidneys 
are hyperthyroid (Dumitrescu et al., 2006, Trajkovic et al., 2007, Trajkovic-Arsic et al., 
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2009). Therefore, quantification and localisation of the expression of MCT8 and other TH 
transporters, and of deiodinase enzymes, in the mouse placenta across gestation would aid 
the understanding of the TH transport system in the mouse placenta. These further studies 
would greatly help to determine the importance of MCT8 for transplacental TH transport 
in mice and investigate the possibility that changes in the expression of other TH 
transporters and in the activity of deiodinase enzymes may partly compensate for the 
absence of MCT8. However, in vitro, MCT8 appears to affect human placental cells 
through both T3-dependent and T3-independent mechanisms, as discussed in Chapters 4 
and 5. It is therefore possible that the observed changes in the fetoplacental weights of 
MCT8-deficient fetuses are not associated with changes in transplacental transport of THs 
but with the transport of another compound important for development. 
6.4.3 Conclusions 
MCT8 knockout mouse models are useful tools to assess the role of MCT8 in 
placental development and fetal growth. The preliminary results presented here suggest 
that lack of MCT8 adversely affects fetoplacental growth. However, it is important to 
recognise that the mechanisms that regulate fetoplacental development may differ in mice 
from humans. This issue is highlighted by the absence of a severe neurological phenotype 
in MCT8-deficient mice in contrast with that observed in patients affected by MCT8 
mutations. Furthermore, TH transport is regulated by many TH transporters and the 
expression of these proteins in the mouse placenta has not yet been defined. Even though 
the extrapolation of results from animal studies to humans needs to be done with caution, 
such studies can help to elucidate the mechanisms that regulate TH transport across the 
placenta and may provide further insight on whether MCT8 transports compounds other 
than THs that may be important for fetoplacental development. 
Chapter 7: Final Discussion and Conclusions
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7.1 TH transporters in the human placenta and transplacental TH transport 
Transplacental transport of THs is of topical interest due to the importance of THs 
for fetal development (Haddow et al., 1999, Morreale de Escobar et al., 2004, Pop et al., 
2003). In this thesis, the ontogenic pattern of the TH transporters that have been reported 
in the human placenta was described. The expression of a range of TH transporters from 
early gestation is consistent with the hypothesis that transplacental transport of maternal 
THs can occur from early in pregnancy and until term. Furthermore, the expression of the 
TH transporters studied peaked towards term, suggesting that the supply of maternal THs 
may be necessary even after the onset of fetal TH production. 
Localisation of the TH transporters in specific human placental cells provided 
additional information on the TH transport capability of these cell types. The expression 
of TH transporters in the ST is particularly important, since these cells constitute the 
trophoblast layer that primarily regulates transplacental transport. It was previously shown 
that MCT8 is expressed in the ST throughout gestation (Chan et al., 2006). The 
LAT1/4F2hc complex and OATP4A1 were previously localised in the ST of third 
trimester placentae (Okamoto et al., 2002, Ritchie and Taylor, 2001, Sato et al., 2003). 
The results presented in this thesis demonstrate that MCT10, OATP1A2 and OATP4A1 
are also expressed in the ST of the placenta both in the first and in the third trimester. 
Taken together, these data demonstrate the presence of a range of TH transporters in the 
ST of the human placenta, where they can regulate transplacental TH transport, both in 
early and late pregnancy. In addition to the importance of the THs in fetal development, 
there is increasing evidence that THs play an important role in the development of the 
placenta (Barber et al., 2005, Laoag-Fernandez et al., 2004, Maruo et al., 1991, Oki et al., 
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2004). The expression of TH transporters in CTs and EVTs is consistent with a role for 
THs in the regulation of trophoblast differentiation and function. MCT8 (Chan et al., 
2006), MCT10 and OATP1A2 are found in CT cells, whilst EVTs express MCT8, 
MCT10, OATP1A2 and OATP4A1 (Loubière et al., 2010). 
Although the characterisation of TH transporter expression in human trophoblast 
cells across gestation is valuable for the understanding of the regulation of transplacental 
TH transport, this information is not sufficient to provide a full picture of TH transport 
through the placenta and into the fetal circulation. The TH transporters described have 
different affinities for THs and, with the exception of MCT8, are known to transport more 
substrates in addition to THs (see Table 1-1). Therefore, their contribution towards 
transplacental TH transport will depend on both their affinity for THs and on the 
circulating concentration of other substrates that may competitively inhibit TH transport. 
Future investigations of TH transport across the placenta are therefore necessary. Vesicles 
generated from the apical (microvillous; maternal facing) or the basal (fetal facing) 
plasma membranes of the ST would be a useful system to study transplacental TH 
transport (Glazier and Sibley, 2006). The contribution of each transporter to overall TH 
transport could be elucidated using inhibitors, such as tryptophan for MCT10 (Friesema et 
al., 2008, Kim et al., 2002), 2-amino-bicycloheptane-2-carboxylic acid for system L 
(Ritchie et al., 2003, Ritchie and Taylor, 2001) and bile acids or other amphipathic 
organic compounds for OATPs (Hagenbuch, 2007). 
It is currently unknown whether changes in transplacental transport of THs are 
associated with pregnancy complications, such as IUGR. The fetal circulating 
concentrations of free T4 and free T3 are reduced in severe, early onset IUGR pregnancies 
(Kilby et al., 1998). In the third trimester, THs in the fetal circulation are of both maternal 
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and fetal origin (see Figure 1-9). It is therefore difficult to speculate whether the reduced 
TH concentrations in fetuses affected by IUGR, are due to reduced transplacental 
transport of maternal THs or reduced fetal TH synthesis. However, the increased protein 
expression of MCT8 in the placenta in severe IUGR pregnancies suggest that 
transplacental TH transport may be altered in IUGR pregnancies. IUGR has been 
associated with reduced transplacental transport of amino acids (Sibley, 2009). Jansson et 
al. have demonstrated that the transport of leucine and lysine, which is facilitated by the 
system L is reduced in IUGR placentae (Jansson et al., 1998). It is therefore possible that 
the protein expression or activity of system L is altered with IUGR and this may impact 
on transplacental TH transport in addition to amino acid transport. 
In this thesis, primary cultures of CTs from third trimester placentae from normal 
pregnancies or non-severe IUGR pregnancies that syncytialised in vitro were used to 
assess transport of T3 and we found that there was increased intracellular accumulation of 
T3 within IUGR compared with normal CTs. This was accompanied by an increase in the 
expression of MCT8 in IUGR compared with normal CTs, whilst MCT10 expression was 
not affected in these samples. If these in vitro results are representative of the situation in 
the ST in vivo, they indicate that maternal T3 may be retained in the ST instead of being 
effluxed towards the fetal capillaries thus contributing to the decreased concentration of 
free T3 in the fetal circulation with IUGR. It is likely that a combination of factors, 
including increased expression of MCT8, increased individual volume of IUGR CTs due 
to increased syncytialisation (Crocker et al., 2004, Newhouse et al., 2007) and increased 
expression of intracellular T3-binding proteins, such as TRs (Kilby et al., 1998) contribute 
to the accumulation of T3 intracellularly in vitro. Furthermore, it is necessary to 
investigate the transport of T4 by normal and IUGR CTs and/or vesicle preparations, since 
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T4 is considered the TH hormone that is predominantly transported from the maternal to 
the fetal circulation (Chan et al., 2009). The investigation of TH transport in CTs from 
severe IUGR pregnancies is difficult due to the sparsity of gestationally-matched normal 
controls. However, assessment of TH transport in such samples would provide a picture 
of placental TH transport in pregnancies complicated by severe IUGR that are associated 
with increased risk for adverse fetal outcome (Gaffney et al., 1994, Kok et al., 1998). 
Our ex vivo results on the expression of MCT8 in placentae from normal and 
severe IUGR pregnancies were obtained using villous placental biopsies, which consist of 
different cell types. Therefore, they do not provide any information on the expression 
level of MCT8 in specific cell types i.e. CTs or ST. Furthermore, there is no information 
regarding the expression of TH transporters in the apical or basal membranes of the ST in 
normal and IUGR pregnancies. It has been previously reported that in many cases, 
changes in the activity of transporters in the ST in IUGR pregnancies are specific to either 
the apical or the basal ST membrane (Sibley, 2009). Such examples include system A that 
is decreased in the apical but not in the basal membrane with IUGR (Glazier et al., 1997, 
Jansson et al., 2002) and the lactate transporter that is decreased in the basal but not in the 
apical membrane as shown in experiments with preparations from the basal or the apical 
membrane of the ST (Settle et al., 2006). Nutrients, including THs have to cross both 
these membranes in order to reach the fetal capillaries. The identification of the 
transporters that facilitate the transport of THs across the basal and the apical membranes 
of the ST would therefore contribute to the understanding of the mechanisms that control 
transplacental TH transport. Vesicle preparations from the apical or the basal membranes 
from normal or IUGR placentae could be used to assess the activity of different TH 
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transporters and confirm whether the observed differences in expression affect 
transplacental transport. 
Although the results described here provide valuable information about 
transplacental TH transport in the third trimester in uncomplicated pregnancies and in 
pregnancies complicated by IUGR, there are no data available on the transport of THs in 
IUGR pregnancies early in gestation, which is a crucial period for both fetal and placental 
development. The realisation of such studies in the human placenta is hindered by the fact 
that IUGR is not diagnosed until later in gestation. However, animal studies could be 
performed to investigate transplacental TH transport early in pregnancy. IUGR animal 
models have been previously utilised to investigate fetoplacental growth (Vuguin, 2007). 
The advantage of such studies is that they would allow in vivo assessment of TH 
transport. However, the extrapolation of findings from animal models to humans is not 
always straightforward, especially because placentation differs between mammalian 
species. 
THs are necessary for normal development of both the fetus and the palcenta. 
Therefore, the supply of optimal TH levels from the maternal circulation to the placenta 
and the fetus is critical in pregnancy. IUGR is associated with increased risk for adverse 
fetal outcomes including increased risk for neurodevelopmental disorders (Kok et al., 
1998). Since THs are known to play a major role in the development of the CNS (Haddow 
et al., 1999, Pop et al., 2003, Pop et al., 1999), abnormal transplacental TH transport in 
IUGR pregnancies may contribute to the increased risk for neurodevelopmental delay. 
The results presented in this thesis provide evidence that transplacental TH transport may 
be altered in IUGR pregnancies. 
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7.2 T3-responsiveness of trophoblast cells 
In addition to their importance for fetal development, there is increasing evidence 
that THs affect the development of the placenta, particularly during early pregnancy. It 
has been previously reported that T3 increases invasion by EVTs (Oki et al., 2004). EVT 
invasion in the maternal endometrium and transformation of maternal spiral arteries by 
EVTs are important events that occur early in pregnancy and are essential for normal 
placentation and for the establishment of unobstructed blood flow from the maternal 
circulation to the placenta (Huppertz and Peeters, 2005). Due to difficulties in accessing 
placental tissue from early pregnancy, we have used the cell line SGHPL-4 as an EVT cell 
model and we have confirmed the promoting effect of T3 on invasion using this cell line. 
In addition, we found that T3 results in a mild rise in the proliferation of these cells but, 
unlike findings in primary EVTs (Laoag-Fernandez et al., 2004), does not affect 
apoptosis. Most of the effects of T3 are mediated via TRs that regulate gene expression. 
Many genes that are regulated by TRs have been identified in other cell types and they 
include Cx43, which encodes a gap junction protein that has a role in intercellular 
communication (Stock and Sies, 2000), and ME1, a cytosolic enzyme (Gonzalez-
Manchon et al., 1997). However, TR-mediated regulation of genes is cell type-dependent 
(Yen, 2001) and according to our findings, T3 does not affect the expression of either 
Cx43 or ME1 in SGHPL-4s. Further experiments are required to identify the genes that 
are regulated by T3 and result in increased SGHPL-4 invasion. Such a candidate could be 
furin, a protease that is upregulated by T3 as demonstrated in a hepatocellular carcinoma 
cell line (Chen et al., 2008b) and which promotes invasion by the EVT-like cell line, 
HTR8 (Zhou et al., 2009). 
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In contrast to EVT-like cells, we found that T3 had no effect on CTs from third 
trimester normal placentae, in terms of CT survival, apoptosis or syncytialisation assessed 
by hCG secretion. This is in accordance with previous data that have shown that whilst 
treatment with T3 promotes the endocrine activity of placental explants from early 
pregnancy, as demonstrated by increased secretion of progesterone, estradiol-17β, hCGα, 
hCGβ, hCG and hPL, it does not affect the endocrine activity of explants from term 
placenta (Maruo et al., 1991). Interestingly, we found that in contrast with CTs from 
normal placenta, IUGR CTs were responsive to T3 treatment, as demonstrated by 
decreased survival, and increased apoptosis in response to T3. IUGR has been associated 
with increased apoptosis (Endo et al., 2005, Ishihara et al., 2002, Smith et al., 1997) and 
increased syncytialisation (Crocker et al., 2004, Newhouse et al., 2007). However, the 
findings presented in this thesis demonstrate for the first time that T3 can adversely affect 
the survival and increase apoptosis of IUGR CTs and they raise the possibility that 
abnormally high levels of THs locally within the placenta may directly impact upon 
trophoblasts and contribute to the pathogenesis of IUGR in vulnerable pregnancies. 
The mechanisms that result in the differential T3 responsiveness of normal and 
IUGR CTs are unclear at present. Increased intracellular accumulation of T3 within IUGR 
CTs, compared with normal CTs is likely to contribute to the increased responsiveness of 
IUGR CTs to treatment with T3. Previously, it was reported that the protein, but not the 
mRNA, expression of the TR isoforms TRα1, TRα2 and TRβ1 was increased in sections 
obtained from IUGR placentae, compared with normal controls (Kilby et al., 1998). In the 
experiments with primary cultures of IUGR and normal CTs presented in this thesis, the 
mRNA expression of TRs was assessed and no differences were found between the IUGR 
and the normal group. However, the protein expression of TRs in these samples has not 
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been assessed and, similar to the previous study by our group (Kilby et al., 1998), mRNA 
expression may not correlate with protein expression. Increased accumulation of T3 within 
IUGR CTs, in conjunction with increased expression of TRs may cause increased 
activation of TH-responsive genes thus resulting in the altered responsiveness of IUGR 
CTs. In addition, the possibility that T3 affects IUGR CTs via non-genomic mechanisms 
has to be considered. It has been demonstrated that THs influence the proliferation of 
tumour cells via binding to a cell surface TR located on integrin αVβ3 (Davis et al., 
2008). Although T4 is the predominant ligand for this receptor, T3 can also bind to this TR 
(Davis et al., 2008). In addition, T3 can bind to TRs located in the cytoplasm (Davis et al., 
2008). T3 binding to extranuclear TRs initiates MAP kinase pathways that can in turn 
influence cell behaviour. Furthermore, T3 can bind to mitochondria-resident TRs and thus 
initiate the expression of mitochondrial genes (Wrutniak-Cabello et al., 2001). Unlike 
findings in CNS cell types (Bianco et al., 2002), treatment of term CTs with10 nM or less 
T3 does not alter the expression of the deiodinase enzymes, D2 and D3 (Chan et al., 
2003). Furthermore, no significant changes were observed in D2 and D3 mRNA 
expression and activity in biopsies from normal compared with IUGR placentae (Chan et 
al., 2003). Taken together these findings suggest that CTs cannot modulate intracellular 
T3 concentration through alterations in D2 and D3 activities, thus rendering IUGR CTs 
more vulnerable to the increased accumulation of T3 intracellularly that was demonstrated 
herein. 
Further experiments are necessary to elucidate the mechanisms that are involved in 
the responsiveness of IUGR, but not normal CTs, to T3. The present findings have 
demonstrated that increased accumulation of T3 intracellularly is associated with 
increased MCT8 protein expression, whilst the expression of MCT10 is not altered. 
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Assessment of the protein expression of the other TH transporters expressed in the human 
placenta: system L, OATP1A2 and OATP4A1 within CTs is necessary to better 
understand the mechanisms that result in increased net T3 uptake by IUGR CTs. The 
involvement of mechanisms in addition to increased MCT8 expression in the increased 
net T3 uptake in IUGR CTs is indicated by uptake studies in trophoblast cells transfected 
with human MCT8. These experiments demonstrated that although MCT8 overexpression 
increased initial T3 uptake, net T3 uptake after 30 minutes of incubation with [125I]-T3 was 
similar in cells transfected with MCT8 or VO, thus indicating that overexpression of 
MCT8 alone cannot explain the intracellular accumulation of T3 in IUGR CTs. In 
contrast, co-transfection with CRYM, a cytoplasmic protein that binds to T3 
intracellularly, resulted in increased net T3 uptake. It is therefore likely that increased 
expression of T3 binding proteins, such as TRs, may contribute to the intracellular 
accumulation of T3 within IUGR CTs. In order to conclude whether increased T3 binding 
to TRs is contributing to the increased accumulation of intracellular T3 and increased T3 
sensitivity of IUGR CTs, the previously reported increase in the expression of TRs in 
IUGR placental biopsies (Kilby et al., 1998), should be confirmed in the CT-culture 
model. Further assessment of the effects of T3 on IUGR CTs would involve the 
identification of the pathways that are activated in IUGR CTs in response to T3 treatment. 
One possible mechanism could be that T3 increases cell metabolism and therefore oxygen 
consumption (Yen, 2001). Although oxygen consumption is essential for energy 
expenditure and cell metabolism, it also results in the generation of reactive oxygen 
intermediates and free radicals, which are associated with oxidative stress and cell 
damage. Oxidative stress is associated with IUGR and it is likely that IUGR CTs are more 
sensitive to oxidative damage than normal CTs thus resulting in decreased cell survival 
and increased apoptosis of IUGR CTs in response to T3. However, it is currently difficult 
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to speculate whether the altered responsiveness of IUGR CTs to T3 is a contributing factor 
or an effect of the pathology associated with these pregnancies. 
The impact of THs on trophoblast cells is of great clinical interest, especially 
because abnormal maternal TH status is a risk factor for pregnancy complications 
associated with malplacentation, such as IUGR. Assessment of the impact that changes in 
TH availability have on trophoblast cells in vitro would aid the understanding of the 
effects of abnormal maternal TH status on placental development in vivo and could supply 
important information relevant to the clinical debate on the screening of maternal thyroid 
function during pregnancy and even more so in women who previously had pregnancies 
complicated by IUGR. 
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7.3 The role of MCT8 in trophoblast cells 
The expression of MCT8 in EVTs, CTs and ST of the human placenta throughout 
gestation indicates that MCT8 may play a role in the development of the placenta (Chan 
et al., 2006). Furthermore, the finding that MCT8 expression is increased in placentae 
from IUGR pregnancies suggests that MCT8 may be associated with the malplacentation 
associated with IUGR. In order to investigate the role of MCT8 in different trophoblast 
types, MCT8 expression was silenced or upregulated in the invasive EVT-like cell line, 
SGHPL-4 and in primary cultures of CTs from term placentae that spontaneously 
syncytialise in vitro. 
As discussed in the previous section, T3 promotes invasion by primary EVTs (Oki 
et al., 2004) in vitro. In SGHPL-4s, T3 treatment results in an increasing trend in invasion, 
which was not statistically significant. However, when SGHPL-4s were transfected with 
MCT8 T3 had a statistically significant pro-invasive effect on these cells, consistent with a 
role for MCT8 in the facilitation of the effects of T3 on trophoblast cells. This finding 
indicates that TH transporters, and particularly MCT8, are likely to regulate the effect of 
T3 on EVT invasion. The mechanisms that are involved in the T3-mediated effect on EVT 
invasion in vitro are not completely understood. However, they may include upregulation 
of the activity of MMPs, degradative enzymes that are associated with EVT invasion in 
the maternal decidua, as demonstrated in a study by Oki et al., where T3 increased the 
expression of MMP-2 and MMP-3 in primary EVTs (Oki et al., 2004). 
In addition, it has been demonstrated that T3 may affect EVT invasion indirectly 
by reducing EVT apoptosis (Laoag-Fernandez et al., 2004). We therefore investigated the 
possibility that the MCT8-facilitated effect of T3 on SGHPL-4 invasion may be mediated 
Chapter 7     Final discussion 
241 
indirectly via changes in cell proliferation, apoptosis or necrosis and thus cell number. In 
contrast to previous results in the choriocarcinoma cell line JEG-3 (James et al., 2009), 
MCT8 did not have an effect on SGHPL-4 cell number, indicating that the increase in 
SGHPL-4 invasion following MCT8 transfection in the presence of T3 was not mediated 
via changes in cell number. However, when the endogenous expression of MCT8 was 
silenced, we did observe a mild decrease of caspase 3/7 activity with no overall effect on 
cell number as assessed by the MTT assay. In other cell types, such as JEG-3 and N-Tera2 
cells, MCT8 did not affect cell apoptosis (James et al., 2009). Similar to the previous 
report on the effect of MCT8 on cell proliferation (James et al., 2009), the decrease of 
caspase 3/7 activity following MCT8 silencing in SGHPL-4s was independent of T3 
treatment, suggesting that MCT8 may facilitate the transport of another substrate that 
mediates this effect. The physiological significance of these findings is unclear, however 
it should be noted that in contrast to JEG-3 choriocarcinoma-derived cell lines that have a 
high proliferation rate, SGHPL-4s are derived from EVTs that are cells with an invasive 
phenotype and with reduced proliferative capacity. The differences in the phenotype of 
these cells, are likely responsible for the different effects of MCT8 on JEG-3 and SGHPL-
4 proliferation. 
In contrast to its effects on first trimester trophoblasts, T3 does not affect the 
endocrine activity (Maruo et al., 1991) or the cell viability (Barber et al., 2005) of 
trophoblasts from term placentae. This was confirmed in our experiments with primary 
CTs from normal term placentae. However, the expression of MCT8 in the human 
placenta increased with advancing gestation and reached a peak towards term. Although 
this change may be associated with increased fetal demand for THs, MCT8 may in 
addition play a role in the regulation of trophoblast behaviour and function in the third 
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trimester. Modulation of the expression of MCT8 in primary CTs from term placentae 
demonstrated that MCT8 adversely affects the survival of CTs as assessed by MTT. 
However, this effect was not mediated via increased activation of the apoptotic caspase 
cascade or via increased cell necrosis, indicating that MCT8 may affect cell viability or 
cell metabolic activity via another pathway. In our laboratory, we have recently confirmed 
that MCT8 affects CT survival by counting the number of nuclei in CT cultures. 
Similar to the effect observed previously on JEG-3 proliferation (James et al., 
2009), the effect of MCT8 on CT viability was observed both in the absence and in the 
presence of T3 indicating that it is not mediated via changes in T3 transport. The finding 
that MCT8 has T3-independect actions in multiple cell types that has been presented both 
in this thesis and in a study by James et al. (James et al., 2009) raises the possibility that 
MCT8 transports another compound responsible for the observed effects on cell viability 
and proliferation, which has to be investigated further. Alternatively, MCT8 may affect 
the pathways that regulate cell survival and proliferation independently of its transporter 
function. One such possibility could be that even though MCT8 does not transport amino 
acids, as demonstrated by Friesema et al. (Friesema et al., 2003), it may function as an 
amino acid transceptor, a receptor that is structurally related to a transporter. Amino acid 
transceptors have a role in sensing extracellular and/or intracellular amino acid 
availability and activating intracellular pathways as a response. In cases of amino acid 
deficiency, transceptors are thought to play a role in upregulating proteins that are 
involved in the transport of deficient amino acids (Goberdhan et al., 2009, Taylor, 2009). 
Furthermore, signalling by amino acid transceptors may be one of the mechanisms 
leading to the activation of the mammalian target of rapamycin (mTOR), a key regulator 
of energy homeostasis, cell physiology and growth (Goberdhan et al., 2009). So far, 
Chapter 7     Final discussion 
243 
SNAT2, a member of the sodium-coupled amino acid transporter (SNAT) family, (Taylor, 
2009) and PATH, a member of the proton-assisted amino acid transporter (PAT) family, 
(Goberdhan et al., 2009) have been identified as amino acid transceptors. It would 
therefore be useful to address the possibility that MCT8 may function as a transceptor in 
future studies. 
Although the mechanisms that mediate the effect of MCT8 on CT survival are 
unclear at present, reduced cell survival may adversely affect placental development and 
growth. As discussed in the previous section, IUGR is associated with increased 
expression of MCT8 in the placenta. We can therefore speculate that the increased 
expression of MCT8 may reduce CT viability in vivo and thus contribute to the smaller 
placental size observed in IUGR pregnancies. In contrast, the lack of a change in the 
secretion of hCG following changes in MCT8 expression suggests that MCT8 is not 
implicated in the regulation of syncytialisation of term CTs. 
Assessment of T3 uptake in SGHPL-4s or primary CTs following silencing or 
upregulation of MCT8 expression revealed similar results in both cell types. Silencing of 
endogenous MCT8 expression decreased T3 uptake, thus highlighting the TH transport 
activity of MCT8 in trophoblasts. However, there was significant residual T3 transport 
activity even after MCT8 silencing indicating the activity of other TH transporters in 
addition to MCT8 in these cells. Even though there was significant residual T3 uptake in 
trophoblasts following silencing of endogenous MCT8, accumulation of T3 in these cells 
was significantly lower than that in control cells even after the longest incubation period 
tested (30 minutes). Intracellular T3 accumulation in SGHPL-4s transfected with MCT8 
siRNA was lower compared with controls even after co-transfection with CRYM, a 
cytoplasmic protein that binds to T3 intracellularly and thus prevents its efflux. These 
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findings highlight the importance of MCT8 for T3 transport in these cells and indicate that 
the other TH transporters present in these cells cannot compensate for the lack of MCT8. 
Upregulation of MCT8 expression resulted in increased initial T3 uptake, however it did 
not affect the net T3 uptake observed following a 30-minute incubation period with [125I]-
T3. Prevention of T3 efflux by co-transfection with CRYM in SGHPL-4s resulted in 
increased accumulation of T3 intracellularly that was maintained after a 30-minute 
incubation period. These findings suggest that increased T3 efflux may compensate for the 
initial increase in T3 uptake in cells overexpressing MCT8 and may thus maintain the 
basal intracellular T3 concentration in the absence of unoccupied intracellular T3-binding 
sites. 
The importance of MCT8 for the development of the placenta is further 
highlighted by initial results on the fetal and placental growth of MCT8-deficient mice. 
According to our findings, MCT8-null fetuses are lighter than their wild-type littermates, 
whilst their placentae are heavier. This results in decreased fetal to placental weight ratios, 
indicating that the MCT8-deficient placenta can support less grams of fetus and thus 
placental efficiency is reduced. The expression of MCT8 in the mouse placenta has not 
been characterised to date. It is therefore difficult to speculate about the cell types that 
may be affected by the lack of MCT8. However, initial assessment of the volumes of 
placental components suggests that the volume of the labyrinth zone, which is responsible 
for transplacental transport, is reduced in MCT8-null fetuses compared with wild-type 
littermates, whilst the volume of the junctional zone is increased. A reduction in the 
volume of the labyrinth zone may therefore reduce nutrient transfer from the maternal to 
the fetal circulation and thus result in fetal growth restriction in MCT8 knockout mice. 
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However, it has to be noted that, in humans, MCT8 mutations have not been associated 
with reduced birth weight. 
The results presented in this thesis demonstrate that MCT8 has a role in both 
transplacental transport of THs and in placental development. Further studies are 
necessary to better define the role of MCT8 in trophoblasts. The adverse effect of MCT8 
on the viability of term CTs suggests that MCT8 may have a role in the regulation of 
trophoblast cell number and therefore placental size. It would therefore be interesting to 
assess the role of MCT8 in primary CTs from first trimester placentae, which are the 
proliferative cells of the placenta that differentiate to EVTs or fuse with the ST depending 
on the chemical and hormonal signals they receive (Lunghi et al., 2007). An adverse 
effect of MCT8 on the viability of first trimester CTs would provide further evidence that 
increased MCT8 expression may be implicated in the reduced placental size in IUGR 
pregnancies. Furthermore, additional studies are required to elucidate the mechanisms that 
are involved in mediating the adverse effect of MCT8 on CT viability and particularly to 
investigate the possibility raised from the results presented in this thesis and from 
previous results (James et al., 2009) that MCT8 transports another compound in addition 
to T3. Furthermore, the MCT8-null mouse model provides a useful tool for further 
investigations of the role of MCT8 in the transplacental transport of THs and possibly 
other compounds and in the development of the placenta. 
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7.4 Conclusions 
The findings presented in this thesis indicate the presence of a range of TH 
transporters in the human placenta throughout gestation thus composing an efficient 
system for transplacental TH transport that ensures adequate supply of maternal THs to 
both the developing fetus and the placenta. Our findings suggest that IUGR, a pregnancy 
complication with increased risk of adverse fetal outcome, is associated with changes in 
both TH transport and TH action within trophoblast cells. These observations provide 
further insight into the factors that are involved in the malplacentation associated with 
IUGR. Furthermore, they are highly relevant to the clinical debate concerning the 
advantage of universal screening for thyroid dysfunction in women during pregnancy. In 
this thesis, the role of the TH transporter MCT8 in transplacental TH transport and in the 
modulation of trophoblast behaviour was further investigated. It was demonstrated that 
even though there is a range of TH transporters expressed in trophoblast cells, MCT8 
plays an essential role in TH transport by trophoblasts. Furthermore, the findings 
presented here indicate that MCT8 affects the behaviour and survival of trophoblast cells 
via both T3-dependent and T3-independent mechanisms thus suggesting that MCT8 has 
another function in addition to TH transport. Further investigation of the role of MCT8 in 
placental development is warranted, particularly in light of the finding that the expression 
of MCT8 is increased in placentae from pregnancies complicated by IUGR. 
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